Citation Report
List of articles citing

Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma

DOI: 10.1038/25931
Nature, 1998, 395, 137-43.

#	Paper	IF	Citations
1719	Structure-based analysis of the ultraspiracle protein and docking studies of putative ligands. **2002**, 2, 25		10
1718	Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. **1998**, 12, 3357-68		491
1717	Structure and specificity of nuclear receptor-coactivator interactions. **1998**, 12, 3343-56		747
1716	Les hormones corticostéroïdes : mécanismes impliqués dans la reconnaissance de l'aldostérone par le récepteur aux minéralocorticoïdes. **1999**, 193, 355-360		
1715	Characterization of receptor-interacting protein 140 in retinoid receptor activities. **1999**, 274, 31320-6		53
1714	Effect of ligand and DNA binding on the interaction between human transcription intermediary factor 1alpha and estrogen receptors. **1999**, 13, 2137-50		17
1713	Constitutive activation of transcription and binding of coactivator by estrogen-related receptors 1 and 2. **1999**, 13, 2151-62		125
1712	Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. **1999**, 13, 1912-23		118
1711	P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. **1999**, 96, 5382-7		154
1710	Hormone-independent transcriptional activation and coactivator binding by novel orphan nuclear receptor ERR3. **1999**, 274, 22618-26		218
1709	Identification of ARA70 as a ligand-enhanced coactivator for the peroxisome proliferator-activated receptor gamma. **1999**, 274, 16147-52		102
1708	Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. **1999**, 23, 255-75		276
1707	L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding. **1999**, 274, 7913-22		91
1706	Nuclear receptor coregulators: cellular and molecular biology. **1999**, 20, 321-44		1380
1705	Activity of the Nurr1 carboxyl-terminal domain depends on cell type and integrity of the activation function 2. **1999**, 274, 37483-90		59
1704	Nuclear receptor coactivators. **2000**, 47, 89-112		82
1703	A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation. **1999**, 96, 6102-6		301

1702	Mouse steroid receptor coactivator-1 is not essential for peroxisome proliferator-activated receptor alpha-regulated gene expression. **1999**, 96, 1585-90		71
1701	Competition between thyroid hormone receptor-associated protein (TRAP) 220 and transcriptional intermediary factor (TIF) 2 for binding to nuclear receptors. Implications for the recruitment of TRAP and p160 coactivator complexes. **1999**, 274, 6667-77		68
1700	Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. **1999**, 274, 37219-25		264
1699	The alpha-helical FXXPhiPhi motif in p53: TAF interaction and discrimination by MDM2. **1999**, 96, 14801-6		122
1698	20-Epi analogues of 1,25-dihydroxyvitamin D3 are highly potent inducers of DRIP coactivator complex binding to the vitamin D3 receptor. **1999**, 274, 16838-45		75
1697	Identification of nuclear receptor corepressor as a peroxisome proliferator-activated receptor alpha interacting protein. **1999**, 274, 15901-7		103
1696	Ligand-dependent activation of transcription in vitro by retinoic acid receptor alpha/retinoid X receptor alpha heterodimers that mimics transactivation by retinoids in vivo. **1999**, 96, 1995-2000		44
1695	Structural basis for engineering of retinoic acid receptor isotype-selective agonists and antagonists. **1999**, 6, 519-29		73
1694	Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. **1999**, 10, 564-70		168
1693	Ligand-binding domain of estrogen receptors. **1999**, 10, 550-6		36
1692	Three-dimensional structure-function relationship of vitamin D: side chain location and various activities. **1999**, 9, 1041-6		27
1691	Three-dimensional quantitative structure activity relationships (3-D-QSAR) of antihyperglycemic agents. **1999**, 7, 1475-85		31
1690	Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. *Nature*, **1999**, 400, 378-82	50.4	754
1689	The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. *Nature*, **1999**, 402, 93-6	50.4	542
1688	Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. *Nature*, **1999**, 402, 880-3	50.4	1129
1687	Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. **1999**, 18, 4608-18		727
1686	Steroid and nuclear receptors. Villefranche-sur-Mer, France, May 25-27, 1999. **1999**, 18, 6201-10		63
1685	Role of the essential yeast protein PSU1 in p6anscriptional enhancement by the ligand-dependent activation function AF-2 of nuclear receptors. **1999**, 18, 2229-40		32

1684	PPARgamma, the ultimate thrifty gene. **1999**, 42, 1033-49	534
1683	Leukemia: the sophisticated subversion of hematopoiesis by nuclear receptor oncoproteins. **1999**, 1423, F15-33	4
1682	Combinatorial gene regulation by eukaryotic transcription factors. **1999**, 9, 48-55	61
1681	Steroid hormone receptors: evolution, ligands, and molecular basis of biologic function. **1999**, Suppl 32-33, 110-22	122
1680	Three-dimensional model of the ligand binding domain of the nuclear receptor for 1,25-dihydroxy-vitamin D3. **1999**, 74, 323-333	39
1679	Peroxisome proliferator-activated receptors: nuclear control of metabolism. **1999**, 20, 649-88	2239
1678	Orphan nuclear receptors: shifting endocrinology into reverse. **1999**, 284, 757-60	427
1677	Orphan nuclear receptors: from gene to function. **1999**, 20, 689-725	564
1676	Coactivator and corepressor complexes in nuclear receptor function. **1999**, 9, 140-7	813
1675	Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. **1999**, 3, 397-403	963
1674	Loss-of-function mutations in PPAR gamma associated with human colon cancer. **1999**, 3, 799-804	438
1673	The HDQVH-motif in domain E of the estradiol receptor alpha is responsible for zinc-binding and zinc-induced hormone release. **1999**, 153, 71-8	5
1672	Steroid-induced conformational changes of rat glucocorticoid receptor cause altered trypsin cleavage of the putative helix 6 in the ligand binding domain. **1999**, 155, 85-100	7
1671	Functional analysis of R651 mutations in the putative helix 6 of rat glucocorticoid receptors. **1999**, 158, 117-30	5
1670	The structure of the nuclear hormone receptors. **1999**, 64, 310-9	312
1669	Substitution of a conserved amino acid residue alters the ligand binding properties of peroxisome proliferator activated receptors. **1999**, 463, 205-10	7
1668	Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. **1999**, 98, 675-86	593
1667	Cysteine 530 of the human estrogen receptor alpha is the main covalent attachment site of 11beta-(aziridinylalkoxyphenyl)estradiols. **1999**, 38, 14752-62	10

1666	Nuclear-receptor ligands and ligand-binding domains. **1999**, 68, 559-81	301
1665	The role of coactivators in steroid hormone action. **1999**, 253, 349-56	54
1664	Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. **1999**, 293, 321-31	2343
1663	P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. **1999**, 369, 11-23	638
1662	Versatile copurification procedure for rapid isolation of homogeneous RAR-RXR heterodimers. **1999**, 16, 308-14	4
1661	Activation of PPARgamma coactivator-1 through transcription factor docking. **1999**, 286, 1368-71	483
1660	Importance of oestrogen, xenoestrogen and phytoestrogen metabolism in breast cancer risk. **1999**, 27, 299-304	5
1659	Molecular mechanisms of cytochrome P-450 induction by xenobiotics: An expanded role for nuclear hormone receptors. **1999**, 56, 851-7	97
1658	The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function. **1999**, 66, 733-9	244
1657	Chapter 32. Pharmacogenomics and its Impact on Drug Design and Optimisation. **1999**, 339-348	2
1656	Dominant activity of activation function 1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor alpha-beta heterodimeric complex. **1999**, 19, 1919-27	119
1655	Molecular determinants of the estrogen receptor-coactivator interface. **1999**, 19, 3895-903	156
1654	Human TAF(II)55 interacts with the vitamin D(3) and thyroid hormone receptors and with derivatives of the retinoid X receptor that have altered transactivation properties. **1999**, 19, 5486-94	45
1653	Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. **1999**, 19, 6164-73	219
1652	Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: discovery of peptide antagonists of estrogen receptors alpha and beta. **1999**, 19, 8226-39	336
1651	The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. **1999**, 19, 8383-92	329
1650	Allosteric regulation of the discriminative responsiveness of retinoic acid receptor to natural and synthetic ligands by retinoid X receptor and DNA. **1999**, 19, 3073-85	41
1649	Transcriptional activation by NF-kappaB requires multiple coactivators. **1999**, 19, 6367-78	393

1648	Modulation of transcriptional activation and coactivator interaction by a splicing variation in the F domain of nuclear receptor hepatocyte nuclear factor 4alpha1. **1999**, 19, 6509-22	117
1647	NRIF3 is a novel coactivator mediating functional specificity of nuclear hormone receptors. **1999**, 19, 7191-202	53
1646	A novel role for helix 12 of retinoid X receptor in regulating repression. **1999**, 19, 6448-57	95
1645	The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. **1999**, 19, 6085-97	226
1644	Chromatin-remodeling complexes involved in gene activation by the glucocorticoid receptor. **2000**, 60, 75-122	8
1643	Regulation of cytochrome P450 (CYP) genes by nuclear receptors. **2000**, 347, 321-37	227
1642	Transcriptional repression by nuclear receptors: mechanisms and role in disease. **2000**, 28, 390	7
1641	Transcriptional repression by nuclear receptors: mechanisms and role in disease. **2000**, 28, 390-396	14
1640	Regulation of cytochrome P450 (CYP) genes by nuclear receptors. **2000**, 347, 321-337	358
1639	Ligand binding and nuclear receptor evolution. **2000**, 22, 717-27	201
1638	Prediction of interaction partners for orphan nuclear receptors by prior-based protein sequence profiles. **2000**, 13, 117-26	
1637	Fatty acids as regulators of lipid metabolism. **2000**, 102, 746-762	21
1636	Mechanistic aspects of mineralocorticoid receptor activation. **2000**, 57, 1250-5	49
1635	Novel oximes having 5-benzyl-2,4-thiazolidinedione as antihyperglycemic agents: synthesis and structure-activity relationship. **2000**, 10, 373-5	41
1634	Structure and lipid transport mechanism of a StAR-related domain. **2000**, 7, 408-14	403
1633	Structural basis of dimerization, coactivator recognition and MODY3 mutations in HNF-1alpha. **2000**, 7, 744-8	32
1632	Peroxisome proliferator-activated receptors in the cardiovascular system. **2000**, 129, 823-34	272
1631	Potentiation of calcium levels by extracellular arachidonic acid in nuclei isolated from macrophages stimulated with receptor-recognized forms of alpha(2)-macroglobulin. **2000**, 12, 99-104	6

1630	Nuclear receptors arose from pre-existing protein modules during evolution. **2000**, 25, 227-8	38
1629	PPAR signaling in the control of cardiac energy metabolism. **2000**, 10, 238-45	383
1628	Troglitazone has a reducing effect on thromboxane production. **2000**, 62, 135-43	14
1627	15-deoxy-Delta(12,14)PGJ(2) induces diverse biological responses via PPARgamma activation in cancer cells. **2000**, 62, 23-32	33
1626	Peroxisome proliferator-activated receptors: insight into multiple cellular functions. **2000**, 448, 121-38	357
1625	The role of coactivators and corepressors in the biology and mechanism of action of steroid hormone receptors. **2000**, 5, 307-24	100
1624	A new model for 20-hydroxyecdysone and dibenzoylhydrazine binding: a homology modeling and docking approach. **2000**, 9, 1073-84	68
1623	Synergy between estrogen receptor alpha activation functions AF1 and AF2 mediated by transcription intermediary factor TIF2. **2000**, 1, 151-7	123
1622	Crystal structure of the human RXRalpha ligand-binding domain bound to its natural ligand: 9-cis retinoic acid. **2000**, 19, 2592-601	265
1621	FHL2, a novel tissue-specific coactivator of the androgen receptor. **2000**, 19, 359-69	257
1620	Activation of orphan receptor-mediated transcription by Ca(2+)/calmodulin-dependent protein kinase IV. **2000**, 19, 691-701	67
1619	Structural studies on nuclear receptors. **2000**, 57, 1748-69	180
1618	Modulation of metabolism through transcriptional control has created new treatment opportunities for type 2 diabetes. **2000**, 1, 63-71	4
1617	Fatty acids and immune responses--a new perspective in searching for clues to mechanism. **2000**, 20, 431-56	163
1616	Central role of peroxisome proliferator-activated receptors in the actions of peroxisome proliferators. **2000**, 40, 491-518	285
1615	DAF-16 recruits the CREB-binding protein coactivator complex to the insulin-like growth factor binding protein 1 promoter in HepG2 cells. **2000**, 97, 10412-7	146
1614	Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B. **2000**, 275, 32681-7	274
1613	Dimerization interfaces of v-erbA homodimers and heterodimers with retinoid X receptor alpha. **2000**, 275, 41018-27	12

1612	N-terminal transcriptional activation domain of LZIP comprises two LxxLL motifs and the host cell factor-1 binding motif. **2000**, 97, 10757-62	30
1611	Rational discovery of novel nuclear hormone receptor antagonists. **2000**, 97, 1008-13	104
1610	The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. **2000**, 20, 2951-8	367
1609	The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. **2000**, 20, 1868-76	928
1608	Coactivator-vitamin D receptor interactions mediate inhibition of the atrial natriuretic peptide promoter. **2000**, 275, 15039-48	23
1607	Both coactivator LXXLL motif-dependent and -independent interactions are required for peroxisome proliferator-activated receptor gamma (PPARgamma) function. **2000**, 275, 3733-6	40
1606	Three-dimensional modeling of and ligand docking to vitamin D receptor ligand binding domain. **2000**, 97, 1467-72	66
1605	Aspartate 351 of estrogen receptor alpha is not crucial for the antagonist activity of antiestrogens. **2000**, 275, 20867-72	28
1604	Degradation of the peroxisome proliferator-activated receptor gamma is linked to ligand-dependent activation. **2000**, 275, 18527-33	293
1603	Specific recognition of androgens by their nuclear receptor. A structure-function study. **2000**, 275, 24022-31	87
1602	DAX-1 functions as an LXXLL-containing corepressor for activated estrogen receptors. **2000**, 275, 39855-9	126
1601	Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. **2000**, 275, 26164-71	438
1600	Differential mechanisms of nuclear receptor regulation by receptor-associated coactivator 3. **2000**, 275, 5976-82	28
1599	Nuclear receptors in metabolic diseases. **2000**, 4, 377-396	4
1598	Functional probing of the human glucocorticoid receptor steroid-interacting surface by site-directed mutagenesis. Gln-642 plays an important role in steroid recognition and binding. **2000**, 275, 19041-9	26
1597	Residues in the ligand binding domain that confer progestin or glucocorticoid specificity and modulate the receptor transactivation capacity. **2000**, 14, 1028-37	30
1596	Insulin sensitiser drugs. **2000**, 9, 1347-61	7
1595	Temporal formation of distinct thyroid hormone receptor coactivator complexes in HeLa cells. **2000**, 14, 2001-9	32

1594	Nuclear hormone receptor coregulators in action: diversity for shared tasks. **2000**, 14, 329-47	330
1593	Structure-function analysis of the Rev-erbA and RVR ligand-binding domains reveals a large hydrophobic surface that mediates corepressor binding and a ligand cavity occupied by side chains. **2000**, 14, 700-17	56
1592	Alteration of a single amino acid in peroxisome proliferator-activated receptor-alpha (PPAR alpha) generates a PPAR delta phenotype. **2000**, 14, 733-40	68
1591	Dissecting the molecular mechanism of nuclear receptor action: transcription coactivators and corepressors. **2000**, 32, 53-60	4
1590	Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene. **2000**, 20, 4699-707	334
1589	Human androgen receptor mutation disrupts ternary interactions between ligand, receptor domains, and the coactivator TIF2 (transcription intermediary factor 2). **2000**, 14, 1187-97	34
1588	Crucial role of the H11-H12 loop in stabilizing the active conformation of the human mineralocorticoid receptor. **2000**, 14, 1210-21	43
1587	A new thiazolidinedione, NC-2100, which is a weak PPAR-gamma activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. **2000**, 49, 759-67	139
1586	A tissue-specific coactivator of steroid receptors, identified in a functional genetic screen. **2000**, 20, 2411-22	250
1585	The orphan nuclear receptor SHP inhibits hepatocyte nuclear factor 4 and retinoid X receptor transactivation: two mechanisms for repression. **2000**, 20, 187-95	273
1584	Specific structural motifs determine TRAP220 interactions with nuclear hormone receptors. **2000**, 20, 5433-46	101
1583	The DRIP complex and SRC-1/p160 coactivators share similar nuclear receptor binding determinants but constitute functionally distinct complexes. **2000**, 20, 2718-26	176
1582	Recruitment of nuclear receptor corepressor and coactivator to the retinoic acid receptor by retinoid ligands. Influence of DNA-heterodimer interactions. **2000**, 275, 19401-8	31
1581	Discrete roles for peroxisome proliferator-activated receptor gamma and retinoid X receptor in recruiting nuclear receptor coactivators. **2000**, 20, 8008-17	108
1580	Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators. **2000**, 275, 33201-4	152
1579	A new family of nuclear receptor coregulators that integrate nuclear receptor signaling through CREB-binding protein. **2000**, 20, 5048-63	96
1578	Isolation of a novel family of C(2)H(2) zinc finger proteins implicated in transcriptional repression mediated by chicken ovalbumin upstream promoter transcription factor (COUP-TF) orphan nuclear receptors. **2000**, 275, 10315-22	156
1577	Receptor-interacting protein 140 directly recruits histone deacetylases for gene silencing. **2000**, 275, 40782-7	119

1576	Cytoplasmic catalytic subunit of protein kinase A mediates cross-repression by NF-kappa B and the glucocorticoid receptor. **2000**, 97, 11893-8	108
1575	Structural basis for autorepression of retinoid X receptor by tetramer formation and the AF-2 helix. **2000**, 14, 2229-41	106
1574	Ligand-dependent interactions of coactivators steroid receptor coactivator-1 and peroxisome proliferator-activated receptor binding protein with nuclear hormone receptors can be imaged in live cells and are required for transcription. **2000**, 97, 4363-8	133
1573	The orphan nuclear receptor SHP utilizes conserved LXXLL-related motifs for interactions with ligand-activated estrogen receptors. **2000**, 20, 1124-33	134
1572	The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. **2000**, 14, 27-39	565
1571	The orphan nuclear receptor Ear-2 is a negative coregulator for thyroid hormone nuclear receptor function. **2000**, 20, 2604-18	35
1570	A 12(S)-hydroxyeicosatetraenoic acid receptor interacts with steroid receptor coactivator-1. **2000**, 97, 5779-83	16
1569	A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. **2000**, 275, 5754-9	222
1568	FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. **2000**, 275, 22986-94	332
1567	Activation of different lipoxygenase isozymes induces apoptosis in human erythroleukemia and neuroblastoma cells. **2000**, 272, 345-50	25
1566	nhr-25, the Caenorhabditis elegans ortholog of ftz-f1, is required for epidermal and somatic gonad development. **2000**, 221, 259-72	116
1565	Ligand-induced stabilization of PPARgamma monitored by NMR spectroscopy: implications for nuclear receptor activation. **2000**, 298, 187-94	140
1564	Analysis of protein dimerization and ligand binding of orphan receptor HNF4alpha. **2000**, 302, 831-51	97
1563	The SRC family of nuclear receptor coactivators. **2000**, 245, 1-11	442
1562	Mechanisms of gene regulation by vitamin D(3) receptor: a network of coactivator interactions. **2000**, 246, 9-21	261
1561	Multiple variants of the peroxisome proliferator-activated receptor (PPAR) gamma are expressed in the liver of atlantic salmon (Salmo salar). **2000**, 255, 411-8	78
1560	Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. **2000**, 21, 381-8	381
1559	PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. **2000**, 21, 469-74	327

1558	A PPARgamma mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus. **2000**, 162, 57-67	34
1557	Resistance to thyroid hormone (RTH) syndrome reveals novel determinants regulating interaction of T3 receptor with corepressor. **2000**, 159, 109-24	29
1556	Differential effects of PPARalpha activators on induction of ectopic expression of tissue-specific fatty acid binding protein genes in the mouse liver. **2000**, 32, 1085-92	46
1555	Differential interaction of steroid hormone receptors with LXXLL motifs in SRC-1a depends on residues flanking the motif. **2000**, 72, 35-46	73
1554	A structural biologist's view of the oestrogen receptor. **2000**, 74, 261-8	126
1553	Considerations on the structural evidence of a ligand-binding function of ultraspiracle, an insect homolog of vertebrate RXR. **2000**, 30, 671-9	44
1552	Gene regulation by thyroid hormone. **2000**, 11, 207-11	178
1551	Transcriptional repression by nuclear hormone receptors. **2000**, 11, 6-10	242
1550	Dynamic stabilization of nuclear receptor ligand binding domains by hormone or corepressor binding. **2000**, 6, 245-53	86
1549	The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. **2000**, 5, 173-9	695
1548	Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. **2000**, 5, 289-98	362
1547	Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. **2000**, 5, 545-55	503
1546	Estrogen receptor interaction with co-activators and co-repressors. **2000**, 65, 227-51	364
1545	Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. **2000**, 102, 731-44	1383
1544	Thiazolidinediones: an update. **2000**, 355, 1008-10	174
1543	Cloning of a mouse glucocorticoid modulatory element binding protein, a new member of the KDWK family. **2000**, 468, 203-10	14
1542	Ligand-protein interactions in nuclear receptors of hormones. **2000**, 476, 62-7	74
1541	The important role of residue F268 in ligand binding by LXRbeta. **2000**, 484, 159-63	12

1540	Estrogen receptor transcription and transactivation: Structure-function relationship in DNA- and ligand-binding domains of estrogen receptors. **2000**, 2, 353-9	91
1539	Ligand selectivity by nuclear hormone receptors. **2000**, 17 Suppl 1, 17-21	1
1538	Structure-function analysis of vitamin D and VDR model. **2000**, 6, 733-48	23
1537	On the role of the carboxyl-terminal helix of RXR in the interactions of the receptor with ligand. **2000**, 39, 4090-5	6
1536	Steroidal affinity labels of the estrogen receptor alpha. 4. Electrophilic 11beta-aryl derivatives of estradiol. **2000**, 43, 613-28	16
1535	Molecular modeling, affinity labeling, and site-directed mutagenesis define the key points of interaction between the ligand-binding domain of the vitamin D nuclear receptor and 1 alpha,25-dihydroxyvitamin D3. **2000**, 39, 12162-71	26
1534	The mechanism of action of thyroid hormones. **2000**, 62, 439-66	552
1533	The PPARs: from orphan receptors to drug discovery. **2000**, 43, 527-50	1561
1532	Steroid/nuclear receptor coactivators. **2000**, 58, 391-448	44
1531	Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgen receptor ligand binding domain bound to testosterone and nonsteroidal ligands. **2001**, 44, 1729-40	82
1530	Binding of ligands and activation of transcription by nuclear receptors. **2001**, 30, 329-59	169
1529	Peroxisome proliferator-activated receptor gamma and metabolic disease. **2001**, 70, 341-67	515
1528	Stabilization of peroxisome proliferator-activated receptor alpha by the ligand. **2001**, 288, 106-10	29
1527	The human estrogen receptor alpha dimer binds a single SRC-1 coactivator molecule with an affinity dictated by agonist structure. **2001**, 306, 433-42	65
1526	Regulated assembly of transcription factors and control of transcription initiation. **2001**, 314, 335-52	47
1525	The nuclear receptor Ftz-F1 and homeodomain protein Ftz interact through evolutionarily conserved protein domains. **2001**, 107, 39-53	47
1524	Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. **2001**, 22, 937-44	154
1523	Peroxisome proliferator-activated receptor (PPAR) gamma agonists for diabetes. **2001**, 56, 181-212	31

1522	Prospects for prevention and treatment of cancer with selective PPARgamma modulators (SPARMs). **2001**, 7, 395-400	126
1521	Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands. **2001**, 1, 803-12	88
1520	New insights into receptor ligand binding domains from a novel assembly assay. **2001**, 76, 3-7	7
1519	The TRAP/SMCC/Mediator complex and thyroid hormone receptor function. **2001**, 12, 127-34	226
1518	Nuclear receptors, coactivators and chromatin: new approaches, new insights. **2001**, 12, 191-7	59
1517	A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. **2001**, 8, 737-47	264
1516	Why do we need a three-dimensional architecture of the ligand-binding domain of the nuclear 1alpha,25-dihydroxyvitamin D(3) receptor?. **2001**, 66, 189-201	7
1515	Vitamin D receptor and nuclear receptor coactivators: crucial interactions in vitamin D-mediated transcription. **2001**, 66, 171-6	68
1514	Preventing estrogen receptor action with dimer-interface peptides. **2001**, 66, 549-58	14
1513	Structure-function evaluation of ER alpha and beta interplay with SRC family coactivators. ER selective ligands. **2001**, 40, 6756-65	95
1512	An inhibitor of the interaction of thyroid hormone receptor beta and glucocorticoid interacting protein 1. **2001**, 123, 1525-6	37
1511	Solution structure determination and mutational analysis of the papillomavirus E6 interacting peptide of E6AP. **2001**, 40, 1293-9	54
1510	Pharmacophore analysis of the nuclear oxysterol receptor LXRalpha. **2001**, 44, 886-97	109
1509	The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. **2001**, 292, 2329-33	675
1508	Nuclear hormone receptors and gene expression. **2001**, 81, 1269-304	1167
1507	Mechanisms of estrogen action. **2001**, 81, 1535-65	1475
1506	Protein coregulators that mediate estrogen receptor function. **2001**, 13, 221-9	11
1505	Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. **2001**, 12, 245-54	161

1504	Peroxisome proliferator-activated receptors in endothelial cell biology. **2001**, 12, 511-8	40
1503	Fatty-acyl-CoA thioesters inhibit recruitment of steroid receptor co-activator 1 to alpha and gamma isoforms of peroxisome-proliferator-activated receptors by competing with agonists. **2001**, 353, 231-8	29
1502	Peroxisomal bifunctional enzyme binds and activates the activation function-1 region of the peroxisome proliferator-activated receptor alpha. **2001**, 353, 253-8	12
1501	The activation function-1 of hepatocyte nuclear factor-4 is an acidic activator that mediates interactions through bulky hydrophobic residues. **2001**, 356, 635-42	9
1500	Fatty-acyl-CoA thioesters inhibit recruitment of steroid receptor co-activator 1 to □and □isoforms of peroxisome-proliferator-activated receptors by competing with agonists. **2001**, 353, 231-238	35
1499	Peroxisomal bifunctional enzyme binds and activates the activationfunction-1 region of the peroxisome proliferator-activated receptor □**2001**, 353, 253-258	20
1498	The activation function-1 of hepatocyte nuclear factor-4 is an acidic activator that mediates interactions through bulky hydrophobic residues. **2001**, 356, 635-642	17
1497	[Physiological and pharmacological function of PPARs]. **2001**, 117, 319-27	2
1496	Drug discovery and the intracellular receptor family. **2001**, 62, 253-80	3
1495	Molecular Basis for Designing Selective Modulators of Retinoic Acid Receptor Transcriptional Activities. **2001**, 1, 153-164	3
1494	Transcriptional coregulators of the nuclear receptor superfamily: coactivators and corepressors. **2001**, 58, 289-97	102
1493	The pleiotropic functions of peroxisome proliferator-activated receptor gamma. **2001**, 79, 30-47	175
1492	New pharmacologic agents for diabetes. **2001**, 1, 119-26	11
1491	Ligand recognition by the vitamin D receptor. **2001**, 9, 1721-30	37
1490	Interaction between peroxisome proliferator-activated receptor gamma and its agonists: docking study of oximes having 5-benzyl-2,4-thiazolidinedione. **2001**, 19, 536-42, 598-600	18
1489	Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. **2001**, 21, 185-210	520
1488	Different ligands-different receptor conformations: modeling of the hER alpha LBD in complex with agonists and antagonists. **2001**, 21, 523-39	31
1487	Peroxisome proliferator-activated receptor (PPAR) modulators: diabetes and beyond. **2001**, 21, 540-52	63

1486	Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres. **2001**, 44, 326-37		52
1485	Genetic lesions and perturbation of chromatin architecture: a road to cell transformation. **2001**, 82, 310-25		17
1484	X-ray structure of the orphan nuclear receptor RORbeta ligand-binding domain in the active conformation. **2001**, 20, 5822-31		99
1483	A role for coactivators and histone acetylation in estrogen receptor alpha-mediated transcription initiation. **2001**, 20, 6084-94		86
1482	FTZ-Factor1 and Fushi tarazu interact via conserved nuclear receptor and coactivator motifs. **2001**, 20, 510-9		48
1481	Autonomic healing of polymer composites. *Nature*, **2001**, 409, 794-7	50.4	3147
1480	Structural insights into the mode of action of a pure antiestrogen. **2001**, 9, 145-53		294
1479	Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. **2001**, 9, 699-706		273
1478	Crystal structure of a mutant hERalpha ligand-binding domain reveals key structural features for the mechanism of partial agonism. **2001**, 276, 15059-65		106
1477	Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region. **2001**, 276, 7493-9		57
1476	Role of retinoid receptor coactivator pockets in cofactor recruitment and transcriptional regulation. **2001**, 276, 23127-34		11
1475	Tip60 is a co-activator specific for class I nuclear hormone receptors. **2001**, 276, 46841-8		74
1474	Ternary complexes and cooperative interplay between NCoA-62/Ski-interacting protein and steroid receptor coactivators in vitamin D receptor-mediated transcription. **2001**, 276, 40614-20		57
1473	Self-association of CIITA and its transactivation potential. **2001**, 21, 4919-28		39
1472	Domain structure of the NRIF3 family of coregulators suggests potential dual roles in transcriptional regulation. **2001**, 21, 8371-84		23
1471	Site-specific molecular design and its relevance to pharmacogenomics and chemical biology. **2001**, 1, 38-47		4
1470	Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. **2001**, 98, 4904-9		402
1469	Androgen-induced NH2- and COOH-terminal Interaction Inhibits p160 coactivator recruitment by activation function 2. **2001**, 276, 42293-301		105

1468	Dioxin-inducible transactivation in a chromosomal setting. Analysis of the acidic domain of the Ah receptor. **2001**, 276, 25037-42	13
1467	Analysis of the steroid receptor coactivator 1 (SRC1)-CREB binding protein interaction interface and its importance for the function of SRC1. **2001**, 21, 39-50	93
1466	Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists. **2001**, 276, 16015-23	209
1465	Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity. **2001**, 276, 22177-82	114
1464	Coregulator codes of transcriptional regulation by nuclear receptors. **2001**, 276, 36865-8	376
1463	Crystal structure of the ligand-binding domain of the ultraspiracle protein USP, the ortholog of retinoid X receptors in insects. **2001**, 276, 7465-74	143
1462	The tamoxifen-responsive estrogen receptor alpha mutant D351Y shows reduced tamoxifen-dependent interaction with corepressor complexes. **2001**, 276, 42684-91	40
1461	Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities. **2001**, 276, 1089-98	280
1460	Distinct retinoid X receptor activation function-2 residues mediate transactivation in homodimeric and vitamin D receptor heterodimeric contexts. **2001**, 27, 211-27	57
1459	Ligand-dependent formation of retinoid receptors, receptor-interacting protein 140 (RIP140), and histone deacetylase complex is mediated by a novel receptor-interacting motif of RIP140. **2001**, 276, 16107-12	40
1458	DNA binding-independent transcriptional activation by the androgen receptor through triggering of coactivators. **2001**, 276, 31030-6	15
1457	Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors. **2001**, 276, 6695-702	122
1456	Ligand-dependent degradation of retinoid X receptors does not require transcriptional activity or coactivator interactions. **2001**, 21, 4909-18	43
1455	PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth. **2001**, 276, 37731-4	903
1454	Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. **2001**, 21, 3057-70	149
1453	The modified human DNA repair enzyme O(6)-methylguanine-DNA methyltransferase is a negative regulator of estrogen receptor-mediated transcription upon alkylation DNA damage. **2001**, 21, 7105-14	52
1452	Acyl-CoA esters antagonize the effects of ligands on peroxisome proliferator-activated receptor alpha conformation, DNA binding, and interaction with Co-factors. **2001**, 276, 21410-6	37
1451	The structure of the ultraspiracle ligand-binding domain reveals a nuclear receptor locked in an inactive conformation. **2001**, 98, 1549-1554	135

1450	Definition of the surface in the thyroid hormone receptor ligand binding domain for association as homodimers and heterodimers with retinoid X receptor. **2001**, 276, 14987-95	43
1449	Oct-1 preferentially interacts with androgen receptor in a DNA-dependent manner that facilitates recruitment of SRC-1. **2001**, 276, 6420-8	32
1448	Use of suppressor mutants to probe the function of estrogen receptor-p160 coactivator interactions. **2001**, 21, 4379-90	13
1447	Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. **2001**, 98, 13919-24	461
1446	Determinants of CoRNR-dependent repression complex assembly on nuclear hormone receptors. **2001**, 21, 1747-58	117
1445	The peptide near the C terminus regulates receptor CAR nuclear translocation induced by xenochemicals in mouse liver. **2001**, 21, 2838-46	142
1444	Large scale production of nuclear receptor ligand-binding domains. **2001**, 176, 81-90	3
1443	Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes. **2001** , 15, 909-22	104
1442	Isoform-specific transcriptional regulation by thyroid hormone receptors: hormone-independent activation operates through a steroid receptor mode of co-activator interaction. **2001**, 15, 1170-85	28
1441	Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. **2001**, 15, 1720-8	255
1440	Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation. **2001**, 15, 1729-38	80
1439	Hormone selectivity in thyroid hormone receptors. **2001**, 15, 398-410	137
1438	Cloning and characterization of human WDR10, a novel gene located at 3q21 encoding a WD-repeat protein that is highly expressed in pituitary and testis. **2001**, 20, 41-52	14
1437	Segmentation gene product Fushi tarazu is an LXXLL motif-dependent coactivator for orphan receptor FTZ-F1. **2001**, 98, 12403-8	30
1436	Synthetic retinoids dissociate coactivator binding from corepressor release. **2002**, 22, 31-61	11
1435	A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. **2002**, 25, 708-11	207
1434	The FXXLF motif mediates androgen receptor-specific interactions with coregulators. **2002**, 277, 10226-35	153
1433	Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. **2002**, 277, 38087-94	222

1432	PGC-1 functions as a transcriptional coactivator for the retinoid X receptors. **2002**, 277, 3913-7	73
1431	Molecular biology of the androgen receptor. **2002**, 20, 3001-15	729
1430	Androgen receptor (AR) coregulators: an overview. **2002**, 23, 175-200	680
1429	The PGC-1-related protein PERC is a selective coactivator of estrogen receptor alpha. **2002**, 277, 13918-25	175
1428	NRC-interacting factor 1 is a novel cotransducer that interacts with and regulates the activity of the nuclear hormone receptor coactivator NRC. **2002**, 22, 6883-94	30
1427	Functional evidence for retinoid X receptor (RXR) as a nonsilent partner in the thyroid hormone receptor/RXR heterodimer. **2002**, 22, 5782-92	59
1426	Peroxisome proliferator-activated receptor gamma coactivator 1beta (PGC-1beta), a novel PGC-1-related transcription coactivator associated with host cell factor. **2002**, 277, 1645-8	414
1425	T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. **2002**, 277, 19649-57	226
1424	Peroxisome proliferator-activated receptor coactivator-1alpha (PGC-1alpha) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor-alpha and -gamma. Identification of novel leucine-rich interaction motif within PGC-1alpha. **2002**, 277, 40265-74	373
1423	Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha. **2002**, 277, 21862-8	137
1422	Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction. **2002**, 277, 25631-9	125
1421	The BmE75 nuclear receptors function as dominant repressors of the nuclear receptor BmHR3A. **2002**, 277, 41637-44	37
1420	Microtubule-dependent subcellular redistribution of the transcriptional coactivator p/CIP. **2002**, 22, 6611-26	37
1419	The amino acid residues asparagine 354 and isoleucine 372 of human farnesoid X receptor confer the receptor with high sensitivity to chenodeoxycholate. **2002**, 277, 25963-9	29
1418	Insights from a three-dimensional model into ligand binding to constitutive active receptor. **2002**, 30, 951-6	31
1417	Characterization of the two coactivator-interacting surfaces of the androgen receptor and their relative role in transcriptional control. **2002**, 277, 49230-7	55
1416	Genomics versus orphan nuclear receptors--a half-time report. **2002**, 16, 1135-44	64
1415	Peroxisome proliferators compete and ameliorate Hcy-mediated endocardial endothelial cell activation. **2002**, 283, C1073-9	43

1414	Novel insulin sensitizers: pharmacogenomic aspects. **2002**, 3, 99-116	31
1413	Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. **2002**, 143, 517-24	43
1412	Characterization of the retinoid orphan-related receptor-alpha coactivator binding interface: a structural basis for ligand-independent transcription. **2002**, 16, 998-1012	27
1411	Real-time analysis of molecular interaction of retinoid receptors and receptor-interacting protein 140 (RIP140). **2002**, 16, 2528-37	18
1410	Selective intranuclear redistribution of PPAR isoforms by RXR alpha. **2002**, 16, 707-21	40
1409	Androgen receptor mutations causing human androgen insensitivity syndromes show a key role of residue M807 in Helix 8-Helix 10 interactions and in receptor ligand-binding domain stability. **2002**, 8, 101-8	21
1408	Novel mechanism of nuclear receptor corepressor interaction dictated by activation function 2 helix determinants. **2002**, 22, 6831-41	82
1407	A structural model of the constitutive androstane receptor defines novel interactions that mediate ligand-independent activity. **2002**, 22, 5270-80	99
1406	The structural basis for the specificity of retinoid-X receptor-selective agonists: new insights into the role of helix H12. **2002**, 277, 11385-91	59
1405	Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. **2002**, 143, 2376-84	346
1404	A coregulatory role for the TRAP-mediator complex in androgen receptor-mediated gene expression. **2002**, 277, 42852-8	85
1403	PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy. **2002**, 51, 3586-90	217
1402	Repression of glucagon gene transcription by peroxisome proliferator-activated receptor gamma through inhibition of Pax6 transcriptional activity. **2002**, 277, 1941-8	21
1401	Isolation and characterization of mammalian HDAC10, a novel histone deacetylase. **2002**, 277, 187-93	136
1400	Role of peroxisome proliferator-activated receptor-gamma in hematologic malignancies. **2002**, 9, 294-302	29
1399	Steroid hormone receptors and dietary ligands: a selected review. **2002**, 61, 105-22	68
1398	Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor delta-mediated transactivation. **2002**, 363, 157-65	53
1397	Mass-spectrometric analysis of agonist-induced retinoic acid receptor conformational change. **2002**, 362, 173-181	7

1396	Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor mediated transactivation. **2002**, 363, 157-165	83
1395	Fluorinated vitamin D analogs to probe the conformation of vitamin D in its receptor complex: 19F-NMR studies and biological activity. **2002**, 50, 475-83	13
1394	Use of in vitro pregnane X receptor assays to assess CYP3A4 induction potential of drug candidates. **2002**, 357, 161-70	13
1393	Fluorescence-based ligand-binding assays for peroxisome proliferator-activated receptors. **2002**, 357, 188-97	3
1392	PPAR(gamma) and glucose homeostasis. **2002**, 22, 167-97	358
1391	Lipoxygenase activity in altered gravity. **2002**, 8, 1-17	
1390	Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. **2002**, 41, 6640-50	462
1389	Molecular recognition of agonist ligands by RXRs. **2002**, 16, 987-97	142
1388	The proline 12 alanine substitution in the peroxisome proliferator--activated receptor-gamma2 gene is associated with lower lipoprotein lipase activity in vivo. **2002**, 51, 867-70	40
1387	Structure-based analysis of the ultraspiracle protein and docking studies of putative ligands. **2002**, 2, 1-11	30
1386	Interactions of RXR with coactivators are differentially mediated by helix 11 of the receptor's ligand binding domain. **2002**, 41, 2500-8	9
1385	Domain interactions between coregulator ARA(70) and the androgen receptor (AR). **2002**, 16, 287-300	42
1384	Interactions that determine the assembly of a retinoid X receptor/corepressor complex. **2002**, 99, 5842-7	39
1383	Combinatorial control of gene expression by nuclear receptors and coregulators. **2002**, 108, 465-74	1245
1382	Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. **2002**, 110, 93-105	662
1381	Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. **2002**, 45, 789-804	136
1380	The NH(2)-terminal and carboxyl-terminal interaction in the human androgen receptor. **2002**, 75, 293-8	78
1379	Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor 3. **2002**, 9, 303-13	238

1378	Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. **2002**, 22, 1-23	168
1377	PPAR and immune system--what do we know?. **2002**, 2, 1029-44	84
1376	Acetylation in hormone signaling and the cell cycle. **2002**, 13, 259-76	35
1375	Molecular modelling of the peroxisome proliferator-activated receptor alpha (PPAR alpha) from human, rat and mouse, based on homology with the human PPAR gamma crystal structure. **2002**, 16, 275-80	14
1374	The AF2 domain of the orphan nuclear receptor TEC is essential for the transcriptional activity of the oncogenic fusion protein EWS/TEC. **2002**, 183, 87-94	17
1373	The mechanisms of action of PPARs. **2002**, 53, 409-35	1974
1372	Crystal structure of the HNF4 alpha ligand binding domain in complex with endogenous fatty acid ligand. **2002**, 277, 37973-6	216
1371	Ligand binding. **2002**, 37-41	
1370	Linking dioxins to diabetes: epidemiology and biologic plausibility. **2002**, 110, 853-8	157
1369	Molecular mechanisms of transcriptional regulation. **2002**, 42-61	
1368	PPAR. **2002**, 141-158	
1367	General organization of nuclear receptors. **2002**, 3-21	
1366	Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis. **2002**, 95, 47-62	83
1365	Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus. **2002**, 54, 1173-97	55
1364	Structure-Based Androgen Receptor Gene Mutation Database: A Tool to Link Molecular Location and Receptor Function. **2002**, 3, 76-91	
1363	Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids. **2002**, 10, 1225-34	247
1362	X-ray structure of the hRORalpha LBD at 1.63 A: structural and functional data that cholesterol or a cholesterol derivative is the natural ligand of RORalpha. **2002**, 10, 1697-707	252
1361	Roles of peroxisome proliferator-activated receptor gamma in cardiovascular disease. **2002**, 16, 108-14	20

1360	Multiplexed microsphere-based flow cytometric assays. **2002**, 30, 1227-37		243
1359	Structural Studies of Insect Nuclear Receptors. 177-192		
1358	Peroxisome proliferator-activated receptor gamma agonists: potential use for treating chronic inflammatory diseases. **2002**, 46, 598-605		29
1357	Development of a homogeneous, fluorescence resonance energy transfer-based in vitro recruitment assay for peroxisome proliferator-activated receptor delta via selection of active LXXLL coactivator peptides. **2002**, 304, 63-9		8
1356	Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. **2002**, 100, 309-17		110
1355	PPARs: transcriptional effectors of fatty acids and their derivatives. **2002**, 59, 790-8		263
1354	Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor (PPAR) activators: novel human PPARalpha-selective activators. **2002**, 12, 77-80		40
1353	Enantio-dependent binding and transactivation of optically active phenylpropanoic acid derivatives at human peroxisome proliferator-activated receptor alpha. **2002**, 12, 333-5		23
1352	Synthesis and pharmacological evaluation of a new class of peroxisome proliferator-activated receptor modulators. **2002**, 12, 3565-7		18
1351	Identification of residues in the PXR ligand binding domain critical for species specific and constitutive activation. **2002**, 269, 4896-904		32
1350	Amino acids 3-13 and amino acids in and flanking the 23FxxLF27 motif modulate the interaction between the N-terminal and ligand-binding domain of the androgen receptor. **2002**, 269, 5780-91		31
1349	Activation of transcription through the ligand-binding pocket of the orphan nuclear receptor ultraspiracle. **2002**, 269, 6026-36		65
1348	Quantitative structure--activity relationships for inducers of cytochromes P450 and nuclear receptor ligands involved in P450 regulation within the CYP1, CYP2, CYP3 and CYP4 families. **2002**, 176, 51-7		43
1347	Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators. *Nature*, **2002**, 415, 549-53	50.4	373
1346	Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. *Nature*, **2002**, 415, 813-7	50.4	528
1345	Correction: Autonomic healing of polymer composites. *Nature*, **2002**, 415, 817-817	50.4	52
1344	Chaperones and transcriptional regulation by nuclear receptors. **2002**, 9, 640-2		15
1343	Folding and stability of the ligand-binding domain of the glucocorticoid receptor. **2002**, 11, 1926-36		19

1342	Peroxisome proliferator-activated receptors target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis. **2003**, 17, 785-96	19
1341	Crystal structure of the heterodimeric complex of LXRalpha and RXRbeta ligand-binding domains in a fully agonistic conformation. **2003**, 22, 4625-33	212
1340	Role of nitric oxide in matrix remodeling in diabetes and heart failure. **2003**, 8, 23-8	26
1339	Nuclear receptors and the control of metabolism. **2003**, 65, 261-311	500
1338	A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells. **2003**, 46, 365-77	37
1337	Nuclear receptors: integration of multiple signalling pathways through phosphorylation. **2003**, 15, 355-66	249
1336	A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth. **2003**, 466, 225-34	38
1335	Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. **2003**, 89, 38-47	51
1334	Structure-function relationships of vitamin D including ligand recognition by the vitamin D receptor. **2003**, 23, 89-115	78
1333	An assessment of protein-ligand binding site polarizability. **2003**, 70, 201-11	8
1332	R□gulation de l□expression g□nique par les acides gras. **2003**, 17, 80-88	1
1331	Finding specificity within a conserved interaction site. **2003**, 10, 675-6	8
1330	Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR). **2003**, 13, 1865-8	22
1329	Analysis of the critical structural determinant(s) of species-selective peroxisome proliferator-activated receptor alpha (PPAR alpha)-activation by phenylpropanoic acid-type PPAR alpha agonists. **2003**, 13, 3145-9	21
1328	Synthesis of a high-affinity fluorescent PPARgamma ligand for high-throughput fluorescence polarization assays. **2003**, 11, 4325-32	18
1327	Agonist□PPAR□interactions: Molecular modeling study with docking approach. **2003**, 93, 405-410	8
1326	Apoptosis antagonizing transcription factor AATF is a novel coactivator of nuclear hormone receptors. **2003**, 3, 17-25	14
1325	A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease. **2003**, 10, 136-40	134

1324	All-trans retinoic acid is a ligand for the orphan nuclear receptor ROR beta. **2003**, 10, 820-5		180
1323	Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. *Nature*, **2003**, 423, 555-60	50.4	461
1322	Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. **2003**, 22, 3888-900		89
1321	Ascochlorin derivatives as ligands for nuclear hormone receptors. **2003**, 46, 4113-23		30
1320	The use of phage display technique for the isolation of androgen receptor interacting peptides with (F/W)XXL(F/W) and FXXLY new signature motifs. **2003**, 278, 23691-8		70
1319	Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators. **2003**, 46, 3581-99		73
1318	Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. **2003**, 46, 1306-17		104
1317	Inhibition of peroxisome proliferator-activated receptor alpha signaling by vitamin D receptor. **2003**, 312, 513-9		17
1316	Drug-activated nuclear receptors CAR and PXR. **2003**, 35, 172-82		142
1315	Ligands differentially modulate the protein interactions of the human estrogen receptors alpha and beta. **2003**, 326, 77-92		77
1314	Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. **2003**, 331, 815-28		191
1313	The Drosophila orphan nuclear receptor DHR38 mediates an atypical ecdysteroid signaling pathway. **2003**, 113, 731-42		203
1312	2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. **2003**, 42, 1430-8		280
1311	Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms. **2003**, 11, 139-50		209
1310	Structural basis for bile acid binding and activation of the nuclear receptor FXR. **2003**, 11, 1093-100		232
1309	Nuclear receptor ligands and cofactor recruitment: is there a coactivator "on deck"?. **2003**, 11, 850-1		15
1308	Structural basis for ligand-independent activation of the orphan nuclear receptor LRH-1. **2003**, 11, 1575-85		136
1307	Homology modelling of the nuclear receptors: human oestrogen receptorbeta (hERbeta), the human pregnane-X-receptor (PXR), the Ah receptor (AhR) and the constitutive androstane receptor (CAR) ligand binding domains from the human oestrogen receptor alpha (hERalpha) crystal structure, and the human peroxisome proliferator activated receptor alpha (PPARalpha) ligand binding domain from the human PPARgamma crystal structure. **2003**, 84, 117-32		57

1306	Oestrogen and progestin responses in human endometrium. **2003**, 84, 393-410	49
1305	The roles of protein-protein interactions and protein methylation in transcriptional activation by nuclear receptors and their coactivators. **2003**, 85, 139-45	99
1304	Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo. **2003**, 46, 4883-94	29
1303	Vanadyl-thiazolidinedione combination agents for diabetes therapy. **2003**, 14, 212-21	37
1302	Endocrine mechanisms of disease: Expression and degradation of androgen receptor: mechanism and clinical implication. **2003**, 88, 4043-54	125
1301	Subtype specific effects of peroxisome proliferator-activated receptor ligands on corepressor affinity. **2003**, 42, 9278-87	39
1300	PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic. **2003**, 306, 763-71	59
1299	Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs. **2003**, 23, 2135-50	87
1298	Comparative analysis of docking motifs in MAP-kinases and nuclear receptors. **2003**, 20, 623-34	5
1297	Peroxisome proliferator-activated receptor (PPAR)-beta as a target for wound healing drugs: what is possible?. **2003**, 4, 523-30	30
1296	Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. **2003**, 100, 11273-8	198
1295	Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. **2003**, 100, 131-6	476
1294	Structure-function analysis reveals the molecular determinants of the impaired biological function of DAX-1 mutants in AHC patients. **2003**, 12, 1063-72	37
1293	Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor gamma in vascular smooth muscle cells. **2003**, 93, e38-47	74
1292	Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor. **2003** , 278, 20420-8	70
1291	T:G mismatch-specific thymine-DNA glycosylase potentiates transcription of estrogen-regulated genes through direct interaction with estrogen receptor alpha. **2003**, 278, 38586-92	92
1290	Isotype-restricted corepressor recruitment: a constitutively closed helix 12 conformation in retinoic acid receptors beta and gamma interferes with corepressor recruitment and prevents transcriptional repression. **2003**, 23, 2844-58	54
1289	Development of a versatile platform for nuclear receptor screening using AlphaScreen. **2003**, 8, 191-7	27

1288	A Gly482Ser missense mutation in the peroxisome proliferator-activated receptor gamma coactivator-1 is associated with altered lipid oxidation and early insulin secretion in Pima Indians. **2003**, 52, 895-8	130
1287	NMR structure of a complex containing the TFIIF subunit RAP74 and the RNA polymerase II carboxyl-terminal domain phosphatase FCP1. **2003**, 100, 5688-93	36
1286	X-ray crystal structure of the liver X receptor beta ligand binding domain: regulation by a histidine-tryptophan switch. **2003**, 278, 27138-43	173
1285	The three-dimensional structure of the liver X receptor beta reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands. **2003**, 278, 38821-8	130
1284	Nuclear coactivator-62 kDa/Ski-interacting protein is a nuclear matrix-associated coactivator that may couple vitamin D receptor-mediated transcription and RNA splicing. **2003**, 278, 35325-36	127
1283	Molecular determinants of the balance between co-repressor and co-activator recruitment to the retinoic acid receptor. **2003**, 278, 43797-806	24
1282	Basis of a high-throughput method for nuclear receptor ligands. **2003**, 133, 791-7	34
1281	LXXLL-related motifs in Dax-1 have target specificity for the orphan nuclear receptors Ad4BP/SF-1 and LRH-1. **2003**, 23, 238-49	120
1280	Chapter 8. Modulators of peroxisome proliferator-activated receptors (PPARs). **2003**, 38, 71-80	19
1279	Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. **2003**, 23, 1674-87	150
1278	Therapeutic potential of thiazolidinediones as anticancer agents. **2003**, 12, 1925-37	68
1277	Cell-free ligand binding assays for nuclear receptors. **2003**, 364, 53-71	4
1276	Co-repressor release but not ligand binding is a prerequisite for transcription activation by human retinoid acid receptor alpha ligand-binding domain. **2003**, 278, 7366-73	10
1275	An extended LXXLL motif sequence determines the nuclear receptor binding specificity of TRAP220. **2003**, 278, 10942-51	46
1274	Progesterone and glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. **2003**, 23, 3763-73	204
1273	Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1. **2003**, 278, 12335-43	112
1272	Vitamin D receptor. **2003**, 6, 50-68	11
1271	Hierarchical affinities and a bipartite interaction model for estrogen receptor isoforms and full-length steroid receptor coactivator (SRC/p160) family members. **2003**, 278, 13271-7	31

1270	Peroxisome proliferator-activated receptor gamma-mediated differentiation: a mutation in colon cancer cells reveals divergent and cell type-specific mechanisms. **2003**, 278, 22669-77	44
1269	Ligand and coactivator identity determines the requirement of the charge clamp for coactivation of the peroxisome proliferator-activated receptor gamma. **2003**, 278, 8637-44	53
1268	Transcription activation by the ecdysone receptor (EcR/USP): identification of activation functions. **2003**, 17, 716-31	146
1267	Inhibition of interleukin-4 production in CD4+ T cells by peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: involvement of physical association between PPAR-gamma and the nuclear factor of activated T cells transcription factor. **2003**, 64, 1169-79	60
1266	Nuclear receptor superfamily: Principles of signaling. **2003**, 75, 1619-1664	37
1265	Recent advances in peroxisome proliferator-activated receptor science. **2003**, 10, 267-80	89
1264	Cloning and characterization of a novel zinc finger protein that modulates the transcriptional activity of nuclear receptors. **2003**, 17, 2303-19	10
1263	Activation functions 1 and 2 of nuclear receptors: molecular strategies for transcriptional activation. **2003**, 17, 1901-9	202
1262	Dynamic inhibition of nuclear receptor activation by corepressor binding. **2003**, 17, 366-72	36
1261	Transactivation functions of the N-terminal domains of nuclear hormone receptors: protein folding and coactivator interactions. **2003**, 17, 1-10	158
1260	Peroxisome proliferator-activated receptor gamma inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells. **2003**, 17, 1005-18	30
1259	Role of the LXXLL-motif and activation function 2 domain in subcellular localization of Dax-1 (dosage-sensitive sex reversal-adrenal hypoplasia congenita critical region on the X chromosome, gene 1). **2003**, 17, 994-1004	38
1258	A homogeneous in vitro functional assay for estrogen receptors: coactivator recruitment. **2003**, 17, 346-55	49
1257	Identification of a novel glucocorticoid receptor mutation in budesonide-resistant human bronchial epithelial cells. **2003**, 17, 2566-82	12
1256	Design and synthesis of receptor ligands. **2003**, 364, 71-91	5
1255	Interactions of exogenous endocrine active substances with nuclear receptors. **2003**, 75, 1797-1817	17
1254	A neuronal-specific differentiation protein that directly modulates retinoid receptor transcriptional activation. **2003**, 1, 7	6
1253	Cross-Talk between Intracellular Lipid Binding Proteins and Ligand Activated Nuclear Receptors A Signaling Pathway for Fatty Acids. 267-283	1

1252	SDP1 is a peroxisome-proliferator-activated receptor gamma 2 co-activator that binds through its SCAN domain. **2003**, 370, 719-27	15
1251	Structure and mechanism of the oestrogen receptor. **2003**, 31, 56-9	57
1250	. **2003**,	2
1249	Structure and Function of PPARs and Their Molecular Recognition of Fatty Acids. 173-189	
1248	Structural insights into regulation of nuclear receptors by ligands. **2003**, 1, e004	10
1247	Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia. **2003**, 284, L333-41	23
1246	Review: peroxisome proliferator-activated receptor-gamma and its role in the development and treatment of diabetes. **2004**, 5, 99-109	16
1245	Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor. **2004**, 18, 2132-50	94
1244	Recent advances in the mechanisms of action and physiological functions of the retinoid-related orphan receptors (RORs). **2004**, 3, 395-412	60
1243	Hormone resistance: it's SMRT to fight repression. **2004**, 145, 1525-6	1
1242	Retinoic acid receptor-alpha is stabilized in a repressive state by its C-terminal, isotype-specific F domain. **2004**, 18, 2839-53	27
1241	Structure and function of the glucocorticoid receptor ligand binding domain. **2004**, 68, 49-91	47
1240	Pharmacology of nuclear receptor-coregulator recognition. **2004**, 68, 145-83	23
1239	Identification of a novel co-regulator interaction surface on the ligand binding domain of Nurr1 using NMR footprinting. **2004**, 279, 53338-45	48
1238	Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma. **2004**, 145, 1527-38	51
1237	Repression of p65 transcriptional activation by the glucocorticoid receptor in the absence of receptor-coactivator interactions. **2004**, 18, 53-62	27
1236	Single-chain estrogen receptors (ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways. **2004**, 24, 7681-94	111
1235	Bifunctional properties of peroxisome proliferator-activated receptor gamma1 in KDR gene regulation mediated via interaction with both Sp1 and Sp3. **2004**, 53, 1222-9	52

1234	Structural basis for HNF-4alpha activation by ligand and coactivator binding. **2004**, 279, 23311-6	54
1233	Peroxisome proliferator-activated receptor gamma: implications for cardiovascular disease. **2004**, 43, 297-305	124
1232	A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. **2004**, 279, 41124-30	58
1231	Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. **2004**, 18, 2388-401	71
1230	Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. **2004**, 24, 230-9	129
1229	The nuclear hormone receptor coactivator NRC is a pleiotropic modulator affecting growth, development, apoptosis, reproduction, and wound repair. **2004**, 24, 4994-5004	42
1228	Structural and functional organization of TRAP220, the TRAP/mediator subunit that is targeted by nuclear receptors. **2004**, 24, 8244-54	80
1227	Developmentally essential protein flightless I is a nuclear receptor coactivator with actin binding activity. **2004**, 24, 2103-17	113
1226	Nuclear receptors: the evolution of diversity. **2004**, 2004, pe4	20
1225	Laminar flow activates peroxisome proliferator-activated receptor-gamma in vascular endothelial cells. **2004**, 110, 1128-33	65
1224	Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. **2004**, 43, 993-1002	928
1223	Identification of an alternative ligand-binding pocket in the nuclear vitamin D receptor and its functional importance in 1alpha,25(OH)2-vitamin D3 signaling. **2004**, 101, 12876-81	137
1222	Tip110, the human immunodeficiency virus type 1 (HIV-1) Tat-interacting protein of 110 kDa as a negative regulator of androgen receptor (AR) transcriptional activation. **2004**, 279, 21766-73	22
1221	1. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands and their therapeutic utility. **2004**, 42, 1-53	19
1220	A novel nuclear receptor/coregulator complex controls C. elegans lipid metabolism, larval development, and aging. **2004**, 18, 2120-33	101
1219	The coactivator LXXLL nuclear receptor recognition motif. **2004**, 63, 207-12	193
1218	The novel synthetic oleanane triterpenoid CDDO (2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid) induces apoptosis in Mycosis fungoides/S□ary syndrome cells. **2004**, 123, 380-7	24
1217	Retinoid X receptors: X-ploring their (patho)physiological functions. **2004**, 11 Suppl 2, S126-43	192

1216	Control of peroxisome proliferator-activated receptor gamma2 stability and activity by SUMOylation. **2004**, 12, 921-8	56
1215	PPAR gamma ligands, 15-deoxy-delta12,14-prostaglandin J2 and rosiglitazone regulate human cultured airway smooth muscle proliferation through different mechanisms. **2004**, 141, 517-25	51
1214	Digging deep into the pockets of orphan nuclear receptors: insights from structural studies. **2004**, 14, 369-76	70
1213	Mechanism of the nuclear receptor molecular switch. **2004**, 29, 317-24	318
1212	Partial androgen insensitivity with phenotypic variation caused by androgen receptor mutations that disrupt activation function 2 and the NH(2)- and carboxyl-terminal interaction. **2004**, 125, 683-95	52
1211	Discovery of novel nuclear receptor modulating ligands: an integral role for peptide interaction profiling. **2004**, 9, 741-51	27
1210	Pharmacological characterization of a human-specific peroxisome proliferater-activated receptor alpha (PPARalpha) agonist in dogs. **2004**, 67, 2057-69	24
1209	Eigenvalue analysis of peroxisome proliferator-activated receptor gamma agonists. **2004**, 44, 230-8	12
1208	3D QSAR studies on peroxisome proliferator-activated receptor gamma agonists using CoMFA and CoMSIA. **2004**, 10, 165-77	22
1207	Molecular characterization of three peroxisome proliferator-activated receptors from the sea bass (Dicentrarchus labrax). **2004**, 39, 1085-92	64
1206	Rational discovery of a novel interface for a coactivator in the peroxisome proliferator-activated receptor gamma: theoretical implications of impairment in type 2 diabetes mellitus. **2005**, 58, 418-25	6
1205	Receptor-based 3D QSAR Studies on PPAR□Agonists using CoMFA and CoMSIA Approaches. **2004**, 23, 637-649	13
1204	Binding analyses between Human PPARgamma-LBD and ligands. **2004**, 271, 386-97	49
1203	Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. **2004**, 20, 455-80	243
1202	Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. **2004**, 279, 7119-30	162
1201	SitePrint: three-dimensional pharmacophore descriptors derived from protein binding sites for family based active site analysis, classification, and drug design. **2004**, 44, 2190-8	10
1200	Different ways to regulate the PPAR$alpha; stability. **2004**, 319, 663-663	
1199	Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. **2004**, 279, 36093-102	143

1198	Structure-based design of potent retinoid X receptor alpha agonists. **2004**, 47, 2010-29	43
1197	The role of corepressors in transcriptional regulation by nuclear hormone receptors. **2004**, 66, 315-60	270
1196	Molecular structure of the rat vitamin D receptor ligand binding domain complexed with 2-carbon-substituted vitamin D3 hormone analogues and a LXXLL-containing coactivator peptide. **2004**, 43, 4101-10	166
1195	Glutathione S-transferases (GSTs) inhibit transcriptional activation by the peroxisomal proliferator-activated receptor gamma (PPAR gamma) ligand, 15-deoxy-delta 12,14prostaglandin J2 (15-d-PGJ2). **2004**, 43, 2345-52	61
1194	Packing, specificity, and mutability at the binding interface between the p160 coactivator and CREB-binding protein. **2004**, 13, 203-10	59
1193	Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis. **2004**, 64 Suppl 2, 19-41	52
1192	Genetic basis of type 2 diabetes mellitus: implications for therapy. **2004**, 3, 257-67	14
1191	Isoxazolyl-serine-based agonists of peroxisome proliferator-activated receptor: design, synthesis, and effects on cardiomyocyte differentiation. **2004**, 126, 16714-5	34
1190	Selective LXXLL peptides antagonize transcriptional activation by the retinoid-related orphan receptor RORgamma. **2004**, 315, 919-27	41
1189	17Beta-estradiol induces nuclear translocation of CrkL at the window of embryo implantation. **2004** , 318, 103-12	16
1188	Different ways to regulate the PPARalpha stability. **2004**, 319, 663-70	28
1187	Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. **2004**, 16, 425-38	246
1186	The nuclear xenobiotic receptor CAR: structural determinants of constitutive activation and heterodimerization. **2004**, 16, 893-905	87
1185	Structure of the murine constitutive androstane receptor complexed to androstenol: a molecular basis for inverse agonism. **2004**, 16, 907-17	49
1184	Towards selectively modulating mineralocorticoid receptor function: lessons from other systems. **2004**, 217, 151-65	29
1183	Role of residues 143 and 278 of the human nuclear Vitamin D receptor in the full-length and Delta165-215 deletion mutant. **2004**, 89-90, 83-7	4
1182	Emerging insights into the coactivator role of NCoA62/SKIP in Vitamin D-mediated transcription. **2004**, 89-90, 179-86	30
1181	Functional analyses of an LXXLL motif in nuclear receptor corepressor (N-CoR). **2004**, 91, 191-6	9

1180	Structure of the NCoA-1/SRC-1 PAS-B domain bound to the LXXLL motif of the STAT6 transactivation domain. **2004**, 336, 319-29	62
1179	Solution structure of the KIX domain of CBP bound to the transactivation domain of c-Myb. **2004**, 337, 521-34	154
1178	A family-based approach reveals the function of residues in the nuclear receptor ligand-binding domain. **2004**, 341, 321-35	27
1177	Rapid Racemization in Thiazolidinediones: A Quantum Chemical Study. **2004**, 108, 3784-3788	27
1176	Allosteric control of ligand selectivity between estrogen receptors alpha and beta: implications for other nuclear receptors. **2004**, 13, 317-27	94
1175	The jensen symposium; a tribute to a pioneer in the field of nuclear receptor biology. **2004**, 13, 459-67	2
1174	Selective recognition of distinct classes of coactivators by a ligand-inducible activation domain. **2004**, 13, 725-38	53
1173	Sphingosine 1-phosphate and lysophosphatidic acid receptors: agonist and antagonist binding and progress toward development of receptor-specific ligands. **2004**, 15, 467-76	37
1172	Control of gene expression by fatty acids. **2004**, 134, 2444S-2449S	176
1171	Troglitazone inhibits the progression of chronic pancreatitis and the profibrogenic activity of pancreatic stellate cells via a PPARgamma-independent mechanism. **2004**, 29, 67-74	35
1170	Unique functional properties of a member of the Fushi Tarazu-Factor 1 family from Schistosoma mansoni. **2004**, 382, 337-51	13
1169	[Design and synthesis of subtype- and species-selective peroxisome proliferator-activated receptor (PPAR) alpha ligands]. **2004**, 124, 803-13	3
1168	Role of Nitric Oxide in Matrix Remodeling in Diabetes and Heart Failure. **2004**, 195-200	
1167	Activation of the nuclear receptor FXR induces fibrinogen expression: a new role for bile acid signaling. **2005**, 46, 458-68	26
1166	Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. **2005**, 23, 393-9	120
1165	Recent Advances in Peroxisome Proliferator- Activated Receptor Science. **2005**, 2, 233-251	
1164	Structural characteristics of lysophosphatidic acid biological targets. **2005**, 33, 1366-1369	13
1163	Structural characteristics of lysophosphatidic acid biological targets. **2005**, 33, 1366-9	14

1162	Thr176 regulates the activity of the mouse nuclear receptor CAR and is conserved in the NR1I subfamily members PXR and VDR. **2005**, 388, 623-30	14
1161	Nuclear receptor antagonists designed based on the helix-folding inhibition hypothesis. **2005**, 13, 5080-93	63
1160	Assay development and data analysis of receptor-ligand binding based on scintillation proximity assay. **2005**, 7, 38-44	19
1159	Selective PPARgamma modulators with improved pharmacological profiles. **2005**, 15, 2437-40	59
1158	6-Aryl-4-methylsulfanyl-2H-pyran-2-one-3-carbonitriles as PPAR-gamma activators. **2005**, 15, 3356-60	7
1157	Molecular recognition of 15-deoxy-delta(12,14)-prostaglandin J2 by nuclear factor-kappa B and other cellular proteins. **2005**, 15, 4057-63	37
1156	Additivity of molecular fields: CoMFA study on dual activators of PPARalpha and PPARgamma. **2005**, 48, 3015-25	49
1155	Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. **2005**, 54, 3442-52	248
1154	A new mechanism of action for skin whitening agents: binding to the peroxisome proliferator-activated receptor. **2005**, 27, 123-32	27
1153	Controlling nuclear receptors: the circular logic of cofactor cycles. **2005**, 6, 542-54	393
1152	PPARgamma: a critical determinant of body fat distribution in humans and mice. **2005**, 15, 81-5	49
1151	The LxxLL motif: a multifunctional binding sequence in transcriptional regulation. **2005**, 30, 66-9	159
1150	Orphan nuclear receptors adopted by crystallography. **2005**, 15, 708-15	60
1149	Potent inhibitors of LXXLL-based protein-protein interactions. **2005**, 6, 1991-8	72
1148	Identification of putative metabolites of docosahexaenoic acid as potent PPARgamma agonists and antidiabetic agents. **2005**, 15, 517-22	78
1147	Molecular dynamics simulations of the human CAR ligand-binding domain: deciphering the molecular basis for constitutive activity. **2005**, 11, 69-79	22
1146	Nuclear Vitamin D Receptor: Structure-Function, Molecular Control of Gene Transcription, and Novel Bioactions. **2005**, 219-261	16
1145	Structure and function of the human nuclear xenobiotic receptor PXR. **2005**, 6, 357-67	76

1144	Homocysteine-dependent cardiac remodeling and endothelial-myocyte coupling in a 2 kidney, 1 clip Goldblatt hypertension mouse model. **2005**, 83, 583-94	16
1143	Anti-Atherogenic Role of Peroxisome Proliferator-Activated Receptor Ligands. **2005**, 1, 89-102	2
1142	Structural basis for the cell-specific activities of the NGFI-B and the Nurr1 ligand-binding domain. **2005**, 280, 19250-8	95
1141	Coactivator recruitment is essential for liganded thyroid hormone receptor to initiate amphibian metamorphosis. **2005**, 25, 5712-24	62
1140	Structural and biochemical basis for selective repression of the orphan nuclear receptor liver receptor homolog 1 by small heterodimer partner. **2005**, 102, 9505-10	86
1139	Ligand-binding pocket of the ecdysone receptor. **2005**, 73, 101-29	31
1138	RORgammat recruits steroid receptor coactivators to ensure thymocyte survival. **2005**, 175, 3800-9	49
1137	Development of peptide antagonists for the androgen receptor using combinatorial peptide phage display. **2005**, 19, 2478-90	63
1136	Coactivator proteins as determinants of estrogen receptor structure and function: spectroscopic evidence for a novel coactivator-stabilized receptor conformation. **2005**, 19, 1516-28	42
1135	Evolution of the pregnane x receptor: adaptation to cross-species differences in biliary bile salts. **2005**, 19, 1720-39	87
1134	Selective expression of a dominant-negative form of peroxisome proliferator-activated receptor in keratinocytes leads to impaired epidermal healing. **2005**, 19, 2335-48	29
1133	Cloning, genomic organization, and expression analysis of zebrafish nuclear receptor coactivator, TIF2. **2005**, 2, 33-46	2
1132	Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. **2005**, 201, 1205-15	361
1131	Ligand control of coregulator recruitment to nuclear receptors. **2005**, 67, 309-33	212
1130	Hyperhomocysteinemic diabetic cardiomyopathy: oxidative stress, remodeling, and endothelial-myocyte uncoupling. **2005**, 10, 1-10	44
1129	The crystal structures of human steroidogenic factor-1 and liver receptor homologue-1. **2005**, 102, 7505-10	120
1128	Alpha,beta-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor gamma. **2005**, 280, 14145-53	176
1127	Characterization of the interaction between retinoic acid receptor/retinoid X receptor (RAR/RXR) heterodimers and transcriptional coactivators through structural and fluorescence anisotropy studies. **2005**, 280, 1625-33	104

1126	Delineation of a unique protein-protein interaction site on the surface of the estrogen receptor. **2005**, 102, 3593-8	54
1125	Structural determinants of the agonist-independent association of human peroxisome proliferator-activated receptors with coactivators. **2005**, 280, 26543-56	51
1124	Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. **2005**, 280, 23653-9	81
1123	Biochemical and NMR mapping of the interface between CREB-binding protein and ligand binding domains of nuclear receptor: beyond the LXXLL motif. **2005**, 280, 5682-92	15
1122	Three peroxisome proliferator-activated receptor isotypes from each of two species of marine fish. **2005**, 146, 3150-62	164
1121	T:G mismatch-specific thymine-DNA glycosylase (TDG) as a coregulator of transcription interacts with SRC1 family members through a novel tyrosine repeat motif. **2005**, 33, 6393-404	41
1120	Nuclear hormone receptor coregulator: role in hormone action, metabolism, growth, and development. **2005**, 26, 583-97	65
1119	Role of nuclear receptors in lung tumourigenesis. **2005**, 41, 2561-8	29
1118	Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity. **2005**, 48, 4457-68	71
1117	Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities. **2005**, 48, 8194-208	76
1116	Vitamin D Nuclear Receptor Ligand-Binding Domain Crystal Structures. **2005**, 279-289	1
1115	Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping. **2005**, 44, 1193-209	55
1114	The nuclear receptor coactivator PGC-1alpha exhibits modes of interaction with the estrogen receptor distinct from those of SRC-1. **2005**, 347, 921-34	42
1113	Crystal structure of the human LRH-1 DBD-DNA complex reveals Ftz-F1 domain positioning is required for receptor activity. **2005**, 354, 1091-102	40
1112	Crystallographic identification and functional characterization of phospholipids as ligands for the orphan nuclear receptor steroidogenic factor-1. **2005**, 17, 491-502	186
1111	A novel PPAR response element in the murine iNOS promoter. **2005**, 42, 1303-10	37
1110	Effect of 25-hydroxyl group orientation on biological activity and binding to the 1alpha,25-dihydroxy vitamin D3 receptor. **2005**, 94, 279-88	8
1109	Conformational adaptation of nuclear receptor ligand binding domains to agonists: potential for novel approaches to ligand design. **2005**, 93, 127-37	43

1108	5-(3,5-Di-tert-butyl-4-hydroxybenzylidene) thiazolidine-2,4-dione modulates peroxisome proliferators-activated receptor gamma in 3T3-L1 adipocytes: roles as a PPARgamma ligand. **2005**, 242, 96-102	8
1107	The Drosophila nuclear receptor e75 contains heme and is gas responsive. **2005**, 122, 195-207	213
1106	The conserved residue Phe273(282) of PPARalpha(gamma), beyond the ligand-binding site, functions in binding affinity through solvation effect. **2005**, 87, 539-50	12
1105	The effect of PPARgamma ligands on the adipose tissue in insulin resistance. **2005**, 73, 65-75	94
1104	Effects of the peroxisome proliferator-activated receptor-gamma co-activator-1 Gly482Ser variant on features of the metabolic syndrome. **2005**, 86, 300-6	23
1103	Applications of the Vitamin D sterol-Vitamin D receptor (VDR) conformational ensemble model. **2005**, 70, 464-71	19
1102	Androgen receptor-cofactor interactions as targets for new drug discovery. **2005**, 26, 225-8	70
1101	Molecular dynamics simulations reveal multiple pathways of ligand dissociation from thyroid hormone receptors. **2005**, 89, 2011-23	61
1100	A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor. **2005**, 280, 31283-93	159
1099	Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity. **2005**, 48, 5509-19	52
1098	The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics. **2005**, 6, 2577-91	12
1097	Probing protein ligand interactions by automated hydrogen/deuterium exchange mass spectrometry. **2006**, 78, 1005-14	250
1096	Platelets as a novel target for PPARgamma ligands : implications for inflammation, diabetes, and cardiovascular disease. **2006**, 20, 231-41	35
1095	Photoprotection, Photoinhibition, Gene Regulation, and Environment. **2006**,	42
1094	Thiazolidinediones: potential as therapeutics for psoriasis and perhaps other hyperproliferative skin disease. **2006**, 15, 1453-68	11
1093	Overview of nomenclature of nuclear receptors. **2006**, 58, 685-704	473
1092	Control of peroxisome proliferator-activated receptor fate by the ubiquitinproteasome system. **2006**, 26, 679-92	20
1091	Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists. **2006**, 49, 6421-4	26

1090	Human PXR forms a tryptophan zipper-mediated homodimer. **2006**, 45, 8579-89	46
1089	Recombinant human PPAR-beta/delta ligand-binding domain is locked in an activated conformation by endogenous fatty acids. **2006**, 356, 1005-13	73
1088	Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes. **2006**, 35, 561-74, ix	22
1087	Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities. **2006**, 49, 2703-12	90
1086	Screening drug-like compounds by docking to homology models: a systematic study. **2006**, 46, 365-79	75
1085	Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. **2006**, 49, 4781-4	93
1084	Design and synthesis of the first generation of dithiolane thiazolidinedione- and phenylacetic acid-based PPARgamma agonists. **2006**, 49, 4072-84	38
1083	QSAR Studies on Thiazolidines: A Biologically Privileged Scaffold. 161-249	37
1082	Lessons learnt from structural studies of the oestrogen receptor. **2006**, 20, 1-14	97
1081	Computational screening of phthalate monoesters for binding to PPARgamma. **2006**, 19, 999-1009	26
1080	Bioassay for the identification of natural product-based activators of peroxisome proliferator-activated receptor-gamma (PPARgamma): the marine sponge metabolite psammaplin A activates PPARgamma and induces apoptosis in human breast tumor cells. **2006**, 69, 547-52	39
1079	Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. **2006**, 124, 615-29	219
1078	The region of CQQQKPQRRP of PGC-1alpha interacts with the DNA-binding complex of FXR/RXRalpha. **2006**, 342, 734-43	1
1077	PPARs and other nuclear receptors in inflammation. **2006**, 6, 421-7	108
1076	Cloning and expression pattern of peroxisome proliferator-activated receptor alpha in the thicklip grey mullet Chelon labrosus. **2006**, 62 Suppl, S113-7	24
1075	The pleiotropic function of PPAR gamma in the placenta. **2006**, 249, 10-5	80
1074	Structural rearrangements in the thyroid hormone receptor hinge domain and their putative role in the receptor function. **2006**, 360, 586-98	97
1073	Reevaluation of the PPAR-beta/delta ligand binding domain model reveals why it exhibits the activated form. **2006**, 21, 1-2	50

1072	From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. **2006**, 45, 120-59	564
1071	Peroxisome proliferator-activated receptors and shock state. **2006**, 6, 1770-82	8
1070	. **2006**,	4
1069	Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor gamma. **2006**, 29, 423-9	24
1068	Physiological ligands of PPARs in inflammation and lipid homeostasis. **2006**, 1, 191-201	6
1067	Spectroscopic analyses of the binding kinetics of 15d-PGJ2 to the PPARgamma ligand-binding domain by multi-wavelength global fitting. **2006**, 393, 749-55	18
1066	The Ftz-F1 family: Orphan nuclear receptors regulated by novel protein□protein interactions. **2006**, 16, 255-296	11
1065	New molecular targeted therapies in thyroid cancer. **2006**, 17, 869-79	17
1064	Role of the mediator complex in nuclear hormone receptor signaling. **2006**, 156, 23-43	61
1063	Nuclear Receptors and the Control of Gene Expression by Fatty Acids. **2006**, 74-91	2
1062	Nuclear Receptors and Disease. **2006**,	1
1061	Regulation of lipoprotein lipase expression by effect of hawthorn flavonoids on peroxisome proliferator response element pathway. **2006**, 100, 51-8	39
1060	Identifying off-target effects and hidden phenotypes of drugs in human cells. **2006**, 2, 329-37	261
1059	Combinatorial roles of nuclear receptors in inflammation and immunity. **2006**, 6, 44-55	336
1058	15d-Prostaglandin J2 activates peroxisome proliferator-activated receptor-gamma, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats. **2006**, 26, 811-20	201
1057	Novel 1,3-dicarbonyl compounds having 2(3H)-benzazolonic heterocycles as PPARgamma agonists. **2006**, 14, 7377-91	15
1056	Diphenylmethane skeleton as a multi-template for nuclear receptor ligands: preparation of FXR and PPAR ligands. **2006**, 16, 3213-8	38
1055	Design and synthesis of novel N-sulfonyl-2-indole carboxamides as potent PPAR-gamma binding agents with potential application to the treatment of osteoporosis. **2006**, 16, 5659-63	40

1054	Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands. **2006**, 16, 6328-33	3
1053	Peroxisome proliferator-activated receptor alpha antagonism inhibits hepatitis C virus replication. **2006**, 13, 23-30	72
1052	Synthesis of docosahexaenoic acid derivatives designed as novel PPARgamma agonists and antidiabetic agents. **2006**, 14, 98-108	42
1051	2D QSAR of PPARgamma agonist binding and transactivation. **2006**, 14, 5178-95	25
1050	Structure-based de novo design, synthesis, and biological evaluation of the indole-based PPARgamma ligands (I). **2006**, 16, 5913-6	11
1049	Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. **2006**, 57, 313-29	184
1048	In silico Studies on PPAR Agonistic Heterocyclic Systems. 149-180	6
1047	Hydrogen/deuterium-exchange (H/D-Ex) of PPARgamma LBD in the presence of various modulators. **2006**, 15, 1883-92	97
1046	Molecular mechanisms of cross-talk between thyroid hormone and peroxisome proliferator activated receptors: focus on the heart. **2006**, 20, 463-9	18
1045	Imposex in marine gastropods may be caused by binding of organotins to retinoid X receptor. **2006**, 149, 117-124	28
1044	Vascular effects of TZDs: new implications. **2006**, 45, 3-18	42
1043	Can PPARgamma agonists have a role in the management of obesity-related hypertension?. **2006**, 45, 46-53	20
1042	Neuronal expression of peroxisome proliferator-activated receptor-gamma (PPARgamma) and 15d-prostaglandin J2--mediated protection of brain after experimental cerebral ischemia in rat. **2006**, 1096, 196-203	71
1041	In vitro screening of 200 pesticides for agonistic activity via mouse peroxisome proliferator-activated receptor (PPAR)alpha and PPARgamma and quantitative analysis of in vivo induction pathway. **2006**, 217, 235-44	69
1040	Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance. **2006**, 111, 145-73	87
1039	The dipeptide H-Trp-Glu-OH shows highly antagonistic activity against PPARgamma: bioassay with molecular modeling simulation. **2006**, 7, 74-82	34
1038	Highly potent vitamin D receptor antagonists: design, synthesis, and biological evaluation. **2006**, 7, 1479-90	27
1037	A fluorescent indicator to visualize activities of the androgen receptor ligands in single living cells. **2006**, 45, 2707-12	26

1036	The nuclear receptor superfamily and drug discovery. **2006**, 1, 504-23	121
1035	Virtual screening for PPAR modulators using a probabilistic neural network. **2006**, 1, 1346-50	17
1034	A Fluorescent Indicator To Visualize Activities of the Androgen Receptor Ligands in Single Living Cells. **2006**, 118, 2773-2778	3
1033	Coactivator-associated arginine methyltransferase-1 enhances nuclear factor-kappaB-mediated gene transcription through methylation of histone H3 at arginine 17. **2006**, 20, 1562-73	65
1032	Isolation and characterization of a transcriptional cofactor and its novel isoform that bind the deoxyribonucleic acid-binding domain of peroxisome proliferator-activated receptor-gamma. **2006**, 147, 377-88	38
1031	PPARgamma activity in the vessel wall: anti-atherogenic properties. **2006**, 13, 3227-38	21
1030	Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. **2006**, 7, 349-65	114
1029	Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus. **2006**, 291, F694-701	38
1028	Recent results on A-ring modification of 1alpha,25-dihydroxyvitamin D3: design and synthesis of VDR-agonists and antagonists with high biological activity. **2006**, 6, 1273-88	23
1027	Detailed molecular understanding of agonistic and antagonistic vitamin D receptor ligands. **2006**, 6, 1243-53	32
1026	Clinical thiazolidinediones as PPARgamma ligands with the potential for the prevention of cardiovascular disease in diabetes. **2006**, 2, 227-39	3
1025	Retinoid-related Orphan Receptors (RORs): Roles in Cellular Differentiation and Development. **2006**, 16, 313-355	61
1024	Pioglitazone prevents cardiac remodeling in high-fat, high-calorie-induced Type 2 diabetes mellitus. **2006**, 291, H81-7	20
1023	Ligand binding domain of vitamin D receptors. **2006**, 6, 1229-41	32
1022	Modelling interaction sites in protein domains with interaction profile hidden Markov models. **2006** , 22, 2851-7	33
1021	Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer. **2006**, 27, 2201-8	47
1020	Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity. **2006**, 15, 921-31	18
1019	Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma. **2006**, 281, 3398-407	71

1018	The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). **2006**, 90, 269-95	217
1017	Peroxisome proliferator-activated receptor subtype- and cell-type-specific activation of genomic target genes upon adenoviral transgene delivery. **2006**, 26, 5698-714	70
1016	Phosphorylation of the hinge domain of the nuclear hormone receptor LRH-1 stimulates transactivation. **2006**, 281, 7850-5	64
1015	The acute myeloid leukemia fusion protein AML1-ETO targets E proteins via a paired amphipathic helix-like TBP-associated factor homology domain. **2006**, 103, 10242-10247	35
1014	A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. **2006**, 20, 809-30	137
1013	Characterization of the Nurr1 ligand-binding domain co-activator interaction surface. **2006**, 37, 317-26	29
1012	A second binding site for hydroxytamoxifen within the coactivator-binding groove of estrogen receptor beta. **2006**, 103, 9908-11	97
1011	Examination of Ligand-Dependent Coactivator Recruitment by Peroxisome Proliferator-Activated Receptor-alpha (PPARalpha). **2006**, 2006, 69612	17
1010	Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. **2006**, 20, 1405-28	728
1009	Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. **2006**, 103, 13162-7	292
1008	Structure of FitAB from Neisseria gonorrhoeae bound to DNA reveals a tetramer of toxin-antitoxin heterodimers containing pin domains and ribbon-helix-helix motifs. **2006**, 281, 37942-51	107
1007	Cytochrome P450 and xenobiotic receptor humanized mice. **2006**, 46, 41-64	129
1006	International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. **2006**, 58, 726-41	749
1005	Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin. **2006**, 26, 5827-37	189
1004	Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. **2006**, 103, 3100-5	66
1003	The endocrine disruptor monoethyl-hexyl-phthalate is a selective peroxisome proliferator-activated receptor gamma modulator that promotes adipogenesis. **2007**, 282, 19152-66	249
1002	Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor gamma. **2007**, 282, 18625-18633	49
1001	Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis. **2007**, 178, 2940-9	138

1000	Peroxisome proliferator-activated receptor-gamma ligands as investigational modulators of angiogenesis. **2007**, 16, 1561-72	26
999	Hydrogen/deuterium exchange-mass spectrometry: a powerful tool for probing protein structure, dynamics and interactions. **2007**, 14, 2344-58	86
998	PPAR-gamma knockout in pancreatic epithelial cells abolishes the inhibitory effect of rosiglitazone on caerulein-induced acute pancreatitis. **2007**, 293, G319-26	20
997	Selective Modulators of PPAR-gamma Activity: Molecular Aspects Related to Obesity and Side-Effects. **2007**, 2007, 32696	81
996	Definition of the molecular basis for estrogen receptor-related receptor-alpha-cofactor interactions. **2007**, 21, 62-76	44
995	Nuclear Hormone Receptors. **2007**, 993-1036	
994	Peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease. **2007**, 2007, 14983	34
993	Metabolic Functions of Peroxisome Proliferator-Activated Receptor beta/delta in Skeletal Muscle. **2007**, 2007, 86394	10
992	MAPK kinases as nucleo-cytoplasmic shuttles for PPARgamma. **2007**, 6, 1539-48	112
991	Impaired peroxisome proliferator-activated receptor gamma function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy. **2007**, 21, 1049-65	35
990	The nuclear receptor-coactivator interaction surface as a target for peptide antagonists of the peroxisome proliferator-activated receptors. **2007**, 21, 2361-77	36
989	Chemistory of Fibrates. **2007**, 1, 311-316	
988	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. **2007**, 148, 903-11	114
987	Pharmacogenetics of the PPAR genes and cardiovascular disease. **2007**, 8, 1581-95	7
986	Constitutive coactivator of peroxisome proliferator-activated receptor (PPARgamma), a novel coactivator of PPARgamma that promotes adipogenesis. **2007**, 21, 2320-33	32
985	Combined simulation and mutagenesis analyses reveal the involvement of key residues for peroxisome proliferator-activated receptor alpha helix 12 dynamic behavior. **2007**, 282, 9666-9677	31
984	Identification of a novel prostaglandin reductase reveals the involvement of prostaglandin E2 catabolism in regulation of peroxisome proliferator-activated receptor gamma activation. **2007**, 282, 18162-18172	73
983	PPARgamma1 attenuates cytosol to membrane translocation of PKCalpha to desensitize monocytes/macrophages. **2007**, 176, 681-94	69

982	Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands. **2007**, 282, 17314-24	93
981	Treating insulin resistance: future prospects. **2007**, 4, 20-31	30
980	Structural development studies of nuclear receptor ligands. **2007**, 79, 615-626	9
979	[Application of the human hepatoblastoma cell lines inducibly expressing peroxisome proliferator-activated receptors (PPARs)]. **2007**, 127, 1223-9	1
978	Crystal structure of the vitamin D nuclear receptor ligand binding domain in complex with a locked side chain analog of calcitriol. **2007**, 460, 172-6	35
977	Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. **2007**, 1771, 915-25	228
976	Regulatory functions of PPARbeta in metabolism: implications for the treatment of metabolic syndrome. **2007**, 1771, 983-90	43
975	PPARs and molecular mechanisms of transrepression. **2007**, 1771, 926-35	369
974	Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes. **2007**, 1771, 1094-107	62
973	Adaptability of the Vitamin D nuclear receptor to the synthetic ligand Gemini: remodelling the LBP with one side chain rotation. **2007**, 103, 235-42	74
972	Residues of the human nuclear vitamin D receptor that form hydrogen bonding interactions with the three hydroxyl groups of 1alpha,25-dihydroxyvitamin D3. **2007**, 103, 347-51	6
971	Structural insight into the constitutive repression function of the nuclear receptor Rev-erbbeta. **2007**, 373, 735-44	44
970	A novel 165-kDa Golgin protein induced by brain ischemia and phosphorylated by Akt protects against apoptosis. **2007**, 36, 392-407	6
969	Conformational dynamics of the estrogen receptor alpha: molecular dynamics simulations of the influence of binding site structure on protein dynamics. **2007**, 46, 1743-58	76
968	Ab initio fragment molecular orbital study of molecular interactions between liganded retinoid X receptor and its coactivator: roles of helix 12 in the coactivator binding mechanism. **2007**, 111, 3525-33	32
967	Nutrigenomics: concepts and applications to pharmacogenomics and clinical medicine. **2007**, 8, 369-90	32
966	Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats. **2007**, 80, 177-84	26
965	Nuclear Hormone Receptors: Insights for Drug Design from Structure and Modeling. **2007**, 725-747	1

964	Cardiac synchronous and dys-synchronous remodeling in diabetes mellitus. **2007**, 9, 971-8	2
963	Macrophage peroxisome proliferator activated receptor gamma as a therapeutic target to combat Type 2 diabetes. **2007**, 11, 1503-20	10
962	A consideration of PPAR-gamma ligands with respect to lipophilicity: current trends and perspectives. **2007**, 16, 413-7	15
961	High-throughput system for analyzing ligand-induced cofactor recruitment by vitamin D receptor. **2007**, 18, 614-20	10
960	Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor gamma activity: a combined virtual screening and biological assay approach. **2007**, 71, 398-406	42
959	Peroxisome proliferator-activated receptor-gamma ligands as bone turnover modulators. **2007**, 16, 195-207	9
958	Thermodynamic characterization of the interaction between CAR-RXR and SRC-1 peptide by isothermal titration calorimetry. **2007**, 46, 862-70	20
957	The use of in vitro peptide binding profiles and in silico ligand-receptor interaction profiles to describe ligand-induced conformations of the retinoid X receptor alpha ligand-binding domain. **2007**, 21, 30-48	13
956	Crystal Structures of Toxicology Targets. 469-519	1
955	Low-resolution structures of thyroid hormone receptor dimers and tetramers in solution. **2007**, 46, 1273-83	10
954	Is PPARbeta/delta a Retinoid Receptor?. **2007**, 2007, 73256	24
953	Reversal of systemic hypertension-associated cardiac remodeling in chronic pressure overload myocardium by ciglitazone. **2007**, 3, 385-92	31
952	. **2007**,	19
951	Imaging of selective nuclear receptor modulator-induced conformational changes in the nuclear receptor to allow interaction with coactivator and corepressor proteins in living cells. **2007**, 8, 737-43	11
950	Silicon analogues of the retinoid agonists TTNPB and 3-methyl-TTNPB, disila-TTNPB and disila-3-methyl-TTNPB: chemistry and biology. **2007**, 8, 1688-99	34
949	RIF-1, a novel nuclear receptor corepressor that associates with the nuclear matrix. **2007**, 102, 1021-35	16
948	Peroxisome proliferator-activated receptor-gamma protects against hepatic ischemia/reperfusion injury in mice. **2008**, 47, 215-24	62
947	Synthesis, biological evaluation, and molecular modeling investigation of chiral phenoxyacetic acid analogues with PPARalpha and PPARgamma agonist activity. **2007**, 2, 641-54	26

946	A fluorescent indicator to visualize ligand-induced receptor/coactivator interactions for screening of peroxisome proliferator-activated receptor gamma ligands in living cells. **2007**, 22, 2564-9	12
945	Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism. **2007**, 15, 2156-66	104
944	Synthesis and in vivo antihyperglycemic activity of nature-mimicking furanyl-2-pyranones in STZ-S model. **2007**, 17, 2425-9	12
943	Design and synthesis of 6-methyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid derivatives as PPARgamma activators. **2007**, 17, 4613-8	19
942	Synthesis, biological evaluation and molecular modeling studies of arylidene-thiazolidinediones with potential hypoglycemic and hypolipidemic activities. **2007**, 42, 1263-71	38
941	Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. **2007**, 17, 3957-61	36
940	Comparison of homology models and X-ray structures of the nuclear receptor CAR: assessing the structural basis of constitutive activity. **2007**, 25, 644-57	18
939	Vitamin A regulation of gene expression: molecular mechanism of a prototype gene. **2007**, 18, 497-508	86
938	Investigation of the lipophilic behaviour of some thiazolidinediones. Relationships with PPAR-gamma activity. **2007**, 857, 181-7	23
937	Design of selective nuclear receptor modulators: RAR and RXR as a case study. **2007**, 6, 811-20	210
936	Structural insights into the transcriptional and translational roles of Ebp1. **2007**, 26, 3936-44	80
935	Tom20 recognizes mitochondrial presequences through dynamic equilibrium among multiple bound states. **2007**, 26, 4777-87	118
934	Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. **2007**, 21, 231-44	42
933	Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study. **2008**, 71, 57-70	89
932	Structure-based drug design of a novel family of chalcones as PPARalpha agonists: virtual screening, synthesis, and biological activities in vitro. **2007**, 28, 2040-52	11
931	Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line. **2007**, 7, 216	11
930	Panning for SNuRMs: using cofactor profiling for the rational discovery of selective nuclear receptor modulators. **2007**, 12, 860-9	22
929	PPARs and the placenta. **2007**, 28, 65-76	102

928	The platelet as a therapeutic target for treating vascular diseases and the role of eicosanoid and synthetic PPARgamma ligands. **2007**, 82, 68-76	17
927	Partial agonists activate PPARgamma using a helix 12 independent mechanism. **2007**, 15, 1258-71	271
926	Estrogen receptors: how do they signal and what are their targets. **2007**, 87, 905-31	1266
925	Peroxisome proliferator-activated receptors as sensors of fatty acids and derivatives. **2007**, 64, 2459-64	61
924	Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patients' survival. **2007**, 52, 2305-11	35
923	Peroxisome proliferator-activated receptor gamma (PPARgamma) and colorectal carcinogenesis. **2007**, 133, 917-28	33
922	Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma. **2008**, 56, 331-45	80
921	Peroxisome proliferator activated receptor gamma and oxidized docosahexaenoic acids as new class of ligand. **2008**, 377, 541-7	38
920	Detecting mitochondrial RNA and other cellular events in living cells. **2008**, 391, 1591-8	1
919	Ligand-escape pathways from the ligand-binding domain of PPARgamma receptor as probed by molecular dynamics simulations. **2008**, 37, 369-79	39
918	Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?. **2008**, 7, 6	32
917	Metformin and glitazones: does similarity in biomolecular mechanism originate from tautomerism in these drugs?. **2008**, 21, 30-33	14
916	Neuroprotective effects of prostaglandin A(1) in rat models of permanent focal cerebral ischemia are associated with nuclear factor-kappaB inhibition and peroxisome proliferator-activated receptor-gamma up-regulation. **2008**, 86, 1132-41	35
915	Thalidomide as a multi-template for development of biologically active compounds. **2008**, 341, 536-47	62
914	Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha. **2008**, 27, 217-24	44
913	CoMFA analysis of dual/multiple PPAR activators. **2008**, 43, 2784-91	10
912	Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. **2008**, 43, 2699-716	12
911	Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARalpha/gamma dual agonists, and X-ray crystallographic studies. **2008**, 16, 4883-907	27

910	Synthesis, biological evaluation, and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPARalpha and PPARgamma agonist activity. **2008**, 16, 9498-510		18
909	New PPARgamma ligands based on 2-hydroxy-1,4-naphthoquinone: computer-aided design, synthesis, and receptor-binding studies. **2008**, 18, 3192-5		17
908	New PPARgamma ligands based on barbituric acid: virtual screening, synthesis and receptor binding studies. **2008**, 18, 4959-62		26
907	Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design. **2008**, 51, 7768-76		80
906	Ligand-induced stabilization and activation of peroxisome proliferator-activated receptor gamma. **2008**, 72, 50-7		8
905	Quantitative structure-activity relationships for PPAR-gamma binding and gene transactivation of tyrosine-based agonists using multivariate statistics. **2008**, 72, 257-64		13
904	Interference of pollutants with PPARs: endocrine disruption meets metabolism. **2008**, 32 Suppl 6, S53-61		104
903	Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA. *Nature*, **2008**, 456, 350-6	50.4	575
902	Epoxygenases and peroxisome proliferator-activated receptors in mammalian vascular biology. **2008**, 93, 148-54		46
901	Structural basis for the activation of PPARgamma by oxidized fatty acids. **2008**, 15, 924-31		321
900	Insights into PPARgamma from structures with endogenous and covalently bound ligands. **2008**, 15, 893-5		28
899	How does Plasmodium falciparum stick to CSA? Let's see in the crystal. **2008**, 15, 895-7		5
898	Cytosporone B is an agonist for nuclear orphan receptor Nur77. **2008**, 4, 548-56		232
897	PPAR: a therapeutic target in Parkinson's disease. **2008**, 106, 506-18		129
896	Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis. **2008**, 10, 617-25		14
895	An amphioxus orthologue of the estrogen receptor that does not bind estradiol: insights into estrogen receptor evolution. **2008**, 8, 219		58
894	Deoxyelephantopin inhibits cancer cell proliferation and functions as a selective partial agonist against PPARgamma. **2008**, 75, 1381-92		33
893	Sulindac derivatives that activate the peroxisome proliferator-activated receptor gamma but lack cyclooxygenase inhibition. **2008**, 51, 4911-9		26

892	Molecular dynamics simulations of human LRH-1: the impact of ligand binding in a constitutively active nuclear receptor. **2008**, 47, 5205-15	12
891	Conserved themes in target recognition by the PAH1 and PAH2 domains of the Sin3 transcriptional corepressor. **2008**, 375, 1444-56	43
890	Nuclear receptors, mitochondria and lipid metabolism. **2008**, 8, 329-37	101
889	Pigment epithelium-derived factor induces THP-1 macrophage apoptosis and necrosis by the induction of the peroxisome proliferator-activated receptor gamma. **2008**, 45, 898-909	33
888	Corepressor interaction differentiates the permissive and non-permissive retinoid X receptor heterodimers. **2008**, 472, 105-14	18
887	Effect of heterodimer partner RXRalpha on PPARgamma activation function-2 helix in solution. **2008**, 365, 42-6	13
886	The RXRalpha C-terminus T462 is a NMR sensor for coactivator peptide binding. **2008**, 366, 932-7	6
885	Cloning of peroxisome proliferators activated receptors in the cobia (Rachycentron canadum) and their expression at different life-cycle stages under cage aquaculture. **2008**, 425, 69-78	38
884	The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control. **2008**, 82, 127-31	31
883	Construction and characterization of a fully active PXR/SRC-1 tethered protein with increased stability. **2008**, 21, 425-33	39
882	Modulaci□ del PPAR□por agentes farmacol□gicos y naturales y sus implicaciones metab□icas. **2008**, 20, 259-289	1
881	PPARgamma and Proline Oxidase in Cancer. **2008**, 2008, 542694	20
880	The conjugate addition-Peterson olefination reaction for the preparation of cross-conjugated cyclopentenone, PPAR-gamma ligands. **2008**, 6, 4649-61	34
879	PPAR-gamma signaling pathway in placental development and function: a potential therapeutic target in the treatment of gestational diseases. **2008**, 12, 1049-63	16
878	Intrinsic disorder in nuclear hormone receptors. **2008**, 7, 4359-72	63
877	Xenobiotic-activated receptors: from transcription to drug metabolism to disease. **2008**, 21, 1651-71	67
876	Multiscale Monte Carlo Sampling of Protein Sidechains: Application to Binding Pocket Flexibility. **2008**, 4, 835-846	12
875	Only subtle protein conformational adaptations are required for ligand binding to thyroid hormone receptors: simulations using a novel multipoint steered molecular dynamics approach. **2008**, 112, 10741-51	48

874	Ab initio fragment molecular orbital study of molecular interactions between liganded retinoid X receptor and its coactivator; part II: influence of mutations in transcriptional activation function 2 activating domain core on the molecular interactions. **2008**, 112, 1986-98	37
873	NMR structure of DREAM: Implications for Ca(2+)-dependent DNA binding and protein dimerization. **2008**, 47, 2252-64	40
872	Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation. **2008**, 105, 5337-42	76
871	Protein polarization is critical to stabilizing AF-2 and helix-2' domains in ligand binding to PPAR-gamma. **2008**, 130, 17129-33	67
870	Lipoxygenases, Apoptosis, and the Role of Antioxidants. **2008**, 321-332	3
869	Ligand dissociation from estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations. **2008**, 22, 1565-78	49
868	Transcriptional Control of Vascular Smooth Muscle Cell Proliferation by Peroxisome Proliferator-Activated Receptor-gamma: Therapeutic Implications for Cardiovascular Diseases. **2008**, 2008, 429123	21
867	Regulation of Lymphocyte Function by PPARgamma: Relevance to Thyroid Eye Disease-Related Inflammation. **2008**, 2008, 895901	21
866	Ligand-dependent and -independent regulation of PPAR gamma and orphan nuclear receptors. **2008**, 1, pe52	25
865	Is rosiglitazone a promising treatment for ulcerative colitis?. **2008**, 5, 486-7	2
864	Transcriptional control of the expression of MUC1. **2008**, 3, 463-471	6
863	Mitochondrial respiratory enzyme complexes in rostral ventrolateral medulla as cellular targets of nitric oxide and superoxide interaction in the antagonism of antihypertensive action of eNOS transgene. **2008**, 74, 1319-32	14
862	Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes. **2008**, 28, 188-200	158
861	A peroxisome proliferator-activated receptor gamma-retinoid X receptor heterodimer physically interacts with the transcriptional activator PAX6 to inhibit glucagon gene transcription. **2008**, 73, 509-17	19
860	Sumoylation of peroxisome proliferator-activated receptor gamma by apoptotic cells prevents lipopolysaccharide-induced NCoR removal from kappaB binding sites mediating transrepression of proinflammatory cytokines. **2008**, 181, 5646-52	103
859	Targeted inactivation of MLL3 histone H3-Lys-4 methyltransferase activity in the mouse reveals vital roles for MLL3 in adipogenesis. **2008**, 105, 19229-34	142
858	A functional peroxisome proliferator-activated receptor-gamma ligand-binding domain is not required for adipogenesis. **2008**, 283, 24290-4	45
857	The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities. **2008**, 73, 62-74	63

856	Identification of COUP-TFII orphan nuclear receptor as a retinoic acid-activated receptor. **2008**, 6, e227	151
855	Peroxisome proliferator activated receptors and lipoprotein metabolism. **2008**, 2008, 132960	85
854	PPAR Genomics and Pharmacogenomics: Implications for Cardiovascular Disease. **2008**, 2008, 374549	9
853	P160/SRC/NCoA coactivators form complexes via specific interaction of their PAS-B domain with the CID/AD1 domain. **2008**, 36, 1847-60	12
852	Rescue of neurons from ischemic injury by peroxisome proliferator-activated receptor-gamma requires a novel essential cofactor LMO4. **2008**, 28, 12433-44	37
851	Vitamin D-dependent recruitment of corepressors to vitamin D/retinoid X receptor heterodimers. **2008**, 28, 3817-29	45
850	HRASLS3 is a PPARgamma-selective target gene that promotes adipocyte differentiation. **2008**, 49, 2535-44	21
849	The adipogenic acetyltransferase Tip60 targets activation function 1 of peroxisome proliferator-activated receptor gamma. **2008**, 149, 1840-9	54
848	Oral Hypoglycemics: A Review of Chemicals Used to Treat Type 2 Diabetes. **2008**, 4, 68-85	3
847	Targeting PPAR as a therapy to treat multiple sclerosis. **2008**, 12, 1565-75	17
846	T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties. **2008**, 283, 9168-76	59
845	Structure-based design and synthesis of fluorescent PPARalpha/delta co-agonist and its application as a probe for fluorescent polarization assay of PPARdelta ligands. **2008**, 56, 1357-9	15
844	RXR heterodimerization allosterically activates LXR binding to the second NR box of activating signal co-integrator-2. **2008**, 410, 319-30	17
843	Peroxisome Proliferator-Activated Receptor Modulation for the Treatment of Type 2 Diabetes. **2008**, 367-387	
842	NR4A Subfamily of Receptors and their Modulators. **2008**, 431-451	1
841	PPAR Regulation of Inflammatory Signaling in CNS Diseases. **2008**, 2008, 658520	85
840	Nuclear Receptors as Drug Targets: A Historical Perspective of Modern Drug Discovery. **2008**, 1-23	5
839	PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors?. **2008**, 8, 728-49	79

838	Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: novel pharmacological agents in the treatment of ischemia reperfusion injury. **2008**, 8, 562-79	36
837	. **2008**,	14
836	PPARgamma: The Portrait of a Target Ally to Cancer Chemopreventive Agents. **2008**, 2008, 436489	6
835	Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies. **2008**, 2008, 834612	19
834	Peroxisome Proliferator-Activated Receptor Delta: A Conserved Director of Lipid Homeostasis through Regulation of the Oxidative Capacity of Muscle. **2008**, 2008, 172676	30
833	PPARgamma and PPARdelta as Modulators of Neoplasia and Cell Fate. **2008**, 2008, 247379	16
832	PPARgamma and MEK Interactions in Cancer. **2008**, 2008, 309469	42
831	Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. **2008**, 2008, 679137	59
830	The Development of INT131 as a Selective PPARgamma Modulator: Approach to a Safer Insulin Sensitizer. **2008**, 2008, 936906	55
829	Nuclear receptor coactivator/coregulator NCoA6(NRC) is a pleiotropic coregulator involved in transcription, cell survival, growth and development. **2008**, 6, e002	37
828	Docosahexaenoic acid regulates adipogenic genes in myoblasts via porcine peroxisome proliferator-activated receptor gamma. **2008**, 86, 3385-92	22
827	. **2009**,	7
826	Cross-Talk between PPARgamma and Insulin Signaling and Modulation of Insulin Sensitivity. **2009**, 2009, 818945	116
825	Multiple myeloma cells undergo differentiation upon exposure to rosiglitazone and all-trans retinoic acid. **2009**, 50, 966-73	5
824	The p160 coactivator PAS-B motif stabilizes nuclear receptor binding and contributes to isoform-specific regulation by thyroid hormone receptors. **2009**, 284, 19554-63	16
823	Multiple binding modes between HNF4alpha and the LXXLL motifs of PGC-1alpha lead to full activation. **2009**, 284, 35165-76	24
822	Cross-Talk between PPARs and the Partners of RXR: A Molecular Perspective. **2009**, 2009, 925309	39
821	Differential modulation of farnesoid X receptor signaling pathway by the thiazolidinediones. **2009**, 330, 125-34	38

820	The vitamin D sterol-vitamin D receptor ensemble model offers unique insights into both genomic and rapid-response signaling. **2009**, 2, re4	106
819	The multiple endocrine neoplasia type 1 (MEN1) tumor suppressor regulates peroxisome proliferator-activated receptor gamma-dependent adipocyte differentiation. **2009**, 29, 5060-9	45
818	The physiology of vitamin D receptor activation. **2009**, 163, 206-212	21
817	Structural basis for the design of PPAR-gamma ligands: a survey on quantitative structure- activity relationships. **2009**, 9, 1075-83	8
816	MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. **2009**, 23, 975-88	71
815	Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor delta. **2009**, 61, 373-93	169
814	Current understanding of the role of PPAR□n gastrointestinal cancers. **2009**, 2009, 816957	8
813	Roles of histone H3-lysine 4 methyltransferase complexes in NR-mediated gene transcription. **2009**, 87, 343-82	29
812	The retinoid X receptor binding to the thyroid hormone receptor: relationship with cofactor binding and transcriptional activity. **2009**, 42, 415-28	8
811	Molecular characterization of novel and selective peroxisome proliferator-activated receptor alpha agonists with robust hypolipidemic activity in vivo. **2009**, 75, 296-306	17
810	A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. **2009**, 150, 862-70	29
809	Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. **2009**, 106, 262-7	115
808	Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. **2009**, 122, 246-63	113
807	Cadmium--a metallohormone?. **2009**, 238, 266-71	131
806	Eicosapentaenoic acid increases cytochrome P-450 2J2 gene expression and epoxyeicosatrienoic acid production via peroxisome proliferator-activated receptor □n endothelial cells. **2009**, 54, 368-74	20
805	Molecular cloning and characterization of olive flounder (Paralichthys olivaceus) peroxisome proliferator-activated receptor gamma. **2009**, 163, 251-8	20
804	All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells. **2009**, 83, 191-202	10
803	Atomic structure of mutant PPARgamma LBD complexed with 15d-PGJ2: novel modulation mechanism of PPARgamma/RXRalpha function by covalently bound ligands. **2009**, 583, 320-4	37

802	Convergence of nitric oxide and lipid signaling: anti-inflammatory nitro-fatty acids. **2009**, 46, 989-1003	94
801	Interaction of a Biological Response Modifier with Proteins. 149-168	
800	From molecular shape to potent bioactive agents I: bioisosteric replacement of molecular fragments. **2009**, 4, 41-4	18
799	Role of melatonin in the epigenetic regulation of breast cancer. **2009**, 115, 13-27	61
798	Molecular recognition of long chain fatty acids by peroxisome proliferator-activated receptor □ **2009**, 18, 8-19	4
797	Ligand unbinding pathways from the vitamin D receptor studied by molecular dynamics simulations. **2009**, 38, 185-98	50
796	Ligand unbinding from the estrogen receptor: a computational study of pathways and ligand specificity. **2009**, 77, 842-56	25
795	Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures. **2009**, 65, 786-95	43
794	Review article: nuclear receptors and liver disease--current understanding and new therapeutic implications. **2009**, 30, 816-25	12
793	Genistein induces adipogenesis but inhibits leptin induction in human synovial fibroblasts. **2009**, 89, 811-22	39
792	Posttranslational modifications of PPAR-gamma: fine-tuning the metabolic master regulator. **2009**, 17, 213-9	116
791	Altering PPARgamma ligand selectivity impairs adipogenesis by thiazolidinediones but not hormonal inducers. **2009**, 17, 965-72	11
790	Quantitative structure-activity relationship models with receptor-dependent descriptors for predicting peroxisome proliferator-activated receptor activities of thiazolidinedione and oxazolidinedione derivatives. **2009**, 73, 428-41	4
789	Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons. **2009**, 109, 1800-11	60
788	Cloning and expression pattern of peroxisome proliferator-activated receptors, estrogen receptor alpha and retinoid X receptor alpha in the thicklip grey mullet Chelon labrosus. **2009**, 149, 26-35	10
787	Differential action on coregulator interaction defines inverse retinoid agonists and neutral antagonists. **2009**, 16, 479-89	90
786	'Sum of activities' as dependent parameter: a new CoMFA-based approach for the design of pan PPAR agonists. **2009**, 44, 42-53	22
785	Important pharmacophoric features of pan PPAR agonists: common chemical feature analysis and virtual screening. **2009**, 44, 3488-95	15

784	Discovery of novel dual functional agent as PPARgamma agonist and 11beta-HSD1 inhibitor for the treatment of diabetes. **2009**, 17, 5722-32	29
783	Synthesis and evaluation of novel alpha-heteroaryl-phenylpropanoic acid derivatives as PPARalpha/gamma dual agonists. **2009**, 17, 7113-25	20
782	Selective, potent PPARgamma agonists with cyclopentenone core structure. **2009**, 19, 1883-6	8
781	5,6-Diarylanthranilo-1,3-dinitriles as a new class of antihyperglycemic agents. **2009**, 19, 2158-61	33
780	The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. **2009**, 28, 515-9	28
779	Quantification of the vitamin D receptor-coregulator interaction. **2009**, 48, 1454-61	53
778	C/EBPalpha and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor gamma agonists. **2009**, 29, 4714-28	151
777	Dietary modulation of peroxisome proliferator-activated receptor gamma. **2009**, 58, 586-93	73
776	A pan-PPAR ligand induces hepatic fatty acid oxidation in PPARalpha-/- mice possibly through PGC-1 mediated PPARdelta coactivation. **2009**, 1791, 1076-83	13
775	Molecular determinants of the interactions between LXR/RXR heterodimers and TRAP220. **2009**, 384, 389-93	13
774	Functional implications of genetic variation in human PPARgamma. **2009**, 20, 380-7	80
773	Role for PPARgamma in IL-2 inhibition in T cells by Echinacea-derived undeca-2E-ene-8,10-diynoic acid isobutylamide. **2009**, 9, 1260-4	26
772	Structural changes of vitamin D receptor induced by 20-epi-1alpha,25-(OH)2D3: an insight from a computational analysis. **2009**, 113, 253-8	7
771	Oxysterol signaling links cholesterol metabolism and inflammation via the liver X receptor in macrophages. **2009**, 30, 134-52	61
770	Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. **2009**, 30, 297-343	207
769	PPAR-mediated activity of phthalates: A link to the obesity epidemic?. **2009**, 304, 43-8	224
768	Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids. **2009**, 385, 188-99	118
767	INT131: a selective modulator of PPAR gamma. **2009**, 386, 1301-11	88

766	Resveratrol inhibits MMP-9 expression by up-regulating PPAR alpha expression in an oxygen glucose deprivation-exposed neuron model. **2009**, 451, 105-8	52
765	Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands as potential therapeutic agents to treat arthritis. **2009**, 60, 160-9	50
764	Cloning and transcription of nuclear receptors and other toxicologically relevant genes, and exposure biomarkers in European hake (Merluccius merluccius) after the Prestige oil spill. **2009**, 2, 201-13	9
763	Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists. **2009**, 52, 2618-22	17
762	PPAR and Pain. **2009**, 85, 165-77	23
761	Nuclear receptors: one big family. **2009**, 505, 3-18	93
760	Cow's milk increases the activities of human nuclear receptors peroxisome proliferator-activated receptors alpha and delta and retinoid X receptor alpha involved in the regulation of energy homeostasis, obesity, and inflammation. **2009**, 92, 4180-7	9
759	Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. **2009**, 7, e003	455
758	Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity. **2009**, 113, 3558-67	30
757	Nuclear Receptor-Mediated Gene Regulation in Drug Metabolism. 449-478	1
756	Pregnane X receptor and its potential role in drug resistance in cancer treatment. **2009**, 4, 19-27	27
755	PPAR polymorphisms and cancer risk: A meta-analysis involving 32,138 subjects. **2010**, 24,	11
754	Structural and functional insights into nuclear receptor signaling. **2010**, 62, 1218-26	60
753	Dynamic correlation networks in human peroxisome proliferator-activated receptor- nuclear receptor protein. **2010**, 39, 1503-12	14
752	Activation of PPAR promotes mitochondrial energy metabolism and decreases basal insulin secretion in palmitate-treated cells. **2010**, 343, 249-56	14
751	Orphan nuclear receptors as targets for drug development. **2010**, 27, 1439-68	27
750	PPAR transcriptional activator complex polymorphisms and the promise of individualized therapy for heart failure. **2010**, 15, 197-207	10
749	Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists. **2010**, 5, 1707-16	7

748	An interpretation of positional displacement of the helix12 in nuclear receptors: preexistent swing-up motion triggered by ligand binding. **2010**, 1804, 1832-40		13
747	Synthesis and biological activities of novel indole derivatives as potent and selective PPARgamma modulators. **2010**, 20, 1399-404		41
746	LXXLL peptide mimetics as inhibitors of the interaction of vitamin D receptor with coactivators. **2010**, 20, 1712-7		30
745	Discovery of a novel selective PPARgamma modulator from (-)-Cercosporamide derivatives. **2010**, 20, 2095-8		15
744	Flexible ligand recognition of peroxisome proliferator-activated receptor-gamma (PPARgamma). **2010**, 20, 3344-7		21
743	Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol. **2010**, 9, 49		50
742	Expression and regulation of soluble epoxide hydrolase in adipose tissue. **2010**, 18, 489-98		73
741	The nuclear receptor PPAR□individually responds to serotonin- and fatty acid-metabolites. **2010**, 29, 3395-407		117
740	Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. *Nature*, **2010**, 466, 451-6	50.4	654
739	Structural basis for the activation of peroxisome proliferator-activated receptor-gamma by telmisartan. **2010**,		
738	De novo Based Ligand generation and Docking studies of PPAR□Agonists: Correlations between Predicted Biological activity vs. Biopharmaceutical Descriptors. **2010**, 10, 74-86		
737	Peroxisome Proliferator-Activated Receptors. **2010**, 145-167		1
736	Modulation of Soluble Receptor Signaling by Coregulators. **2010**, 183-206		
735	Human transcriptional coactivator with PDZ-binding motif (TAZ) is downregulated during decidualization. **2010**, 82, 1112-8		16
734	Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. **2010**, 91, 267S-272S		118
733	Thyroid hormone receptors regulate adipogenesis and carcinogenesis via crosstalk signaling with peroxisome proliferator-activated receptors. **2010**, 44, 143-54		48
732	Virtual Screening as a Technique for PPAR Modulator Discovery. **2010**, 2010, 861238		23
731	Prevention of diet-induced obesity by safflower oil: insights at the levels of PPARalpha, orexin, and ghrelin gene expression of adipocytes in mice. **2010**, 42, 202-8		18

730	Structural insights into the YAP and TEAD complex. **2010**, 24, 235-40	237
729	Drug Management of Prostate Cancer. **2010**,	3
728	Transcriptional switches: chemical approaches to gene regulation. **2010**, 285, 11033-8	35
727	A chromatin perspective of adipogenesis. **2010**, 6, 15-23	28
726	Molecular Mechanisms and Genome-Wide Aspects of PPAR Subtype Specific Transactivation. **2010**, 2010,	45
725	PPARs: Nuclear Receptors Controlled by, and Controlling, Nutrient Handling through Nuclear and Cytosolic Signaling. **2010**, 2010,	36
724	Human ADA3 regulates RARalpha transcriptional activity through direct contact between LxxLL motifs and the receptor coactivator pocket. **2010**, 38, 5291-303	12
723	PPAR-gamma Signaling Crosstalk in Mesenchymal Stem Cells. **2010**, 2010,	32
722	PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors. **2010**, 2010, 427401	9
721	Endogenous ligands for nuclear receptors: digging deeper. **2010**, 285, 40409-15	123
720	Cytotoxic flavonoids as agonists of peroxisome proliferator-activated receptor gamma on human cervical and prostate cancer cells. **2010**, 73, 1261-5	15
719	Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone. **2010**,	17
718	Structural insight into peroxisome proliferator-activated receptor gamma binding of two ureidofibrate-like enantiomers by molecular dynamics, cofactor interaction analysis, and site-directed mutagenesis. **2010**, 53, 4354-66	39
717	Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome. **2010**, 53, 1076-85	28
716	Proline metabolism and microenvironmental stress. **2010**, 30, 441-63	185
715	Binding of reduced nicotinamide adenine dinucleotide phosphate destabilizes the iron-sulfur clusters of human mitoNEET. **2010**, 49, 9604-12	27
714	Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. **2010**, 37, 1822-7	90
713	PPARs: Important Regulators in Metabolism and Inflammation. **2010**, 259-285	1

712	Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPARgamma by cyclic phosphatidic acid. **2010**, 39, 421-32	100
711	X-ray structures of the LXRalpha LBD in its homodimeric form and implications for heterodimer signaling. **2010**, 399, 120-32	38
710	Structural requirement for PPARgamma binding revealed by a meta analysis of holo-crystal structures. **2010**, 92, 499-506	4
709	Complete androgen insensitivity syndrome is frequently due to premature stop codons in exon 1 of the androgen receptor gene: an international collaborative report of 13 new mutations. **2010**, 94, 472-6	29
708	Nuclear receptors, inflammation, and neurodegenerative diseases. **2010**, 106, 21-59	27
707	On the denaturation mechanisms of the ligand binding domain of thyroid hormone receptors. **2010** , 114, 1529-40	7
706	Nuclear Hormone Receptor Medicinal Chemistry. **2010**, 77-188	
705	Peroxisome proliferator-activated receptor a master regulator of metabolic pathways in skeletal muscle. **2010**, 4, 565-73	3
704	Bacterial expression, refolding, functional characterization, and mass spectrometric identification of full-length human PPAR-gamma. **2010**, 74, 1173-80	1
703	Targeting the peroxisome proliferator-activated receptors (PPARs) in spinal cord injury. **2011**, 15, 943-59	30
702	Synthesis of novel PPAR dual agonists as potential drugs for the treatment of the metabolic syndrome and diabetes type II designed using a new de novo design program PROTOBUILD. **2011**, 9, 1169-88	17
701	Design and structure of stapled peptides binding to estrogen receptors. **2011**, 133, 9696-9	199
700	Structure, energetics, and dynamics of binding coactivator peptide to the human retinoid X receptor ligand binding domain complex with 9-cis-retinoic acid. **2011**, 50, 93-105	18
699	Ligand-specific structural changes in the vitamin D receptor in solution. **2011**, 50, 11025-33	40
698	Postprocessing of docked protein-ligand complexes using implicit solvation models. **2011**, 51, 267-82	39
697	Design, synthesis, and structural analysis of phenylpropanoic acid-type PPAR selective agonists: discovery of reversed stereochemistry-activity relationship. **2011**, 54, 331-41	19
696	Identification of diaryl ether-based ligands for estrogen-related receptor as potential antidiabetic agents. **2011**, 54, 788-808	90
695	Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor- **2011**, 54, 4219-33	43

694	Cloning, identification and accurate normalization expression analysis of PPAR gene by GeNorm in Megalobrama amblycephala. **2011**, 31, 462-8		57
693	Pigment epithelium-derived factor (PEDF) promotes tumor cell death by inducing macrophage membrane tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). **2011**, 286, 35943-35954		28
692	The acidic transcription activator Gcn4 binds the mediator subunit Gal11/Med15 using a simple protein interface forming a fuzzy complex. **2011**, 44, 942-53		120
691	HL005--a new selective PPAR antagonist specifically inhibits the proliferation of MCF-7. **2011**, 124, 112-20		19
690	Endocrine disrupting chemicals and disease susceptibility. **2011**, 127, 204-15		705
689	Helix 12 dynamics and thyroid hormone receptor activity: experimental and molecular dynamics studies of Ile280 mutants. **2011**, 412, 882-93		14
688	Production of protein complexes via co-expression. **2011**, 75, 1-14		44
687	Mediator-dependent nuclear receptor function. **2011**, 22, 749-58		79
686	PPARs and lipid ligands in inflammation and metabolism. **2011**, 111, 6321-40		111
685	Antidiabetic actions of a non-agonist PPAR ligand blocking Cdk5-mediated phosphorylation. *Nature*, **2011**, 477, 477-81	50.4	404
684	12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice. **2011**, 118, 6909-19		53
683	Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor (PPAR) modulators. **2011**, 54, 8541-54		39
682	Nuclear Vitamin D Receptor: Natural Ligands, Molecular Structure Function, and Transcriptional Control of Vital Genes. **2011**, 137-170		10
681	Synthetic Thiazolidinediones: Potential Antidiabetic Compounds. **2011**, 15, 108-127		9
680	Analysis of rate-limiting long-range contacts in the folding rate of three-state and two-state Proteins. **2011**, 18, 1042-52		6
679	Structural insight into the crucial role of ligand chirality in the activation of PPARs by crystallographic methods. **2011**, 11, 819-39		8
678	The DLK gene is a transcriptional target of PPAR **2011**, 438, 93-101		8
677	Pharmacology and in vitro profiling of a novel peroxisome proliferator-activated receptor ligand, Cerco-A. **2011**, 34, 1094-104		13

676	Role of peroxisome proliferator-activated receptor-γ in atherosclerosis: an update. **2011**, 75, 528-35	55
675	DNA binding alters coactivator interaction surfaces of the intact VDR-RXR complex. **2011**, 18, 556-63	154
674	Common architecture of nuclear receptor heterodimers on DNA direct repeat elements with different spacings. **2011**, 18, 564-70	148
673	CIDEA interacts with liver X receptors in white fat cells. **2011**, 585, 744-8	9
672	Epigenetic codes of PPARγ in metabolic disease. **2011**, 585, 2121-8	77
671	Ligand entry pathways in the ligand binding domain of PPARγ receptor. **2011**, 585, 2599-603	18
670	Evaluation of in vitro PXR-based assays and in silico modeling approaches for understanding the binding of a structurally diverse set of drugs to PXR. **2011**, 81, 669-79	28
669	Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR-γ pathway. **2011**, 82, 464-75	149
668	Structure-based design of a new series of D-glutamic acid based inhibitors of bacterial UDP-N-acetylmuramoyl-L-alanine:D-glutamate ligase (MurD). **2011**, 54, 4600-10	56
667	Novel PPARγ partial agonists with weak activity and no cytotoxicity; identified by a simple PPARγ ligand screening system. **2011**, 358, 75-83	18
666	Ligand-based in silico 3D-QSAR study of PPAR-γ agonists. **2011**, 20, 1005-1014	5
665	Phytoceramide and sphingoid bases derived from brewer's yeast Saccharomyces pastorianus activate peroxisome proliferator-activated receptors. **2011**, 10, 150	19
664	Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome. **2011**, 3, 562-87	46
663	A combined ligand- and structure-based virtual screening protocol identifies submicromolar PPARγ partial agonists. **2011**, 6, 94-103	24
662	Synthesis and pharmacological evaluation of novel benzoylazole-based PPAR α/γ activators. **2011**, 21, 1978-82	10
661	Design and synthesis of benzoxazole containing indole analogs as peroxisome proliferator-activated receptor-α/γ dual agonists. **2011**, 21, 3057-61	15
660	An arylidene-thiazolidinedione derivative, GPU-4, without PPARγ activation, reduces retinal neovascularization. **2011**, 8, 25-34	6
659	Rational targeting of peroxisome proliferating activated receptor subtypes. **2011**, 18, 5598-623	19

658	Induced fit simulations on nuclear receptors. **2011**, 11, 133-47	7
657	A mechanism for pituitary-resistance to thyroid hormone (PRTH) syndrome: a loss in cooperative coactivator contacts by thyroid hormone receptor (TR)beta2. **2011**, 25, 1111-25	27
656	The actin-binding protein, actinin alpha 4 (ACTN4), is a nuclear receptor coactivator that promotes proliferation of MCF-7 breast cancer cells. **2011**, 286, 1850-9	66
655	Additional sex comb-like (ASXL) proteins 1 and 2 play opposite roles in adipogenesis via reciprocal regulation of peroxisome proliferator-activated receptor {gamma}. **2011**, 286, 1354-63	52
654	Structural basis of digoxin that antagonizes RORgamma t receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production. **2011**, 286, 31409-17	105
653	Abscisic acid regulates inflammation via ligand-binding domain-independent activation of peroxisome proliferator-activated receptor gamma. **2011**, 286, 2504-16	78
652	Disorder-to-order transition underlies the structural basis for the assembly of a transcriptionally active PGC-1/ERR complex. **2011**, 108, 18678-83	49
651	Homeostatic levels of SRC-2 and SRC-3 promote early human adipogenesis. **2011**, 192, 55-67	32
650	The Ras inhibitors caveolin-1 and docking protein 1 activate peroxisome proliferator-activated receptor through spatial relocalization at helix 7 of its ligand-binding domain. **2011**, 31, 3497-510	35
649	Peroxisome proliferator-activated receptor is a target for halogenated analogs of bisphenol A. **2011**, 119, 1227-32	221
648	The Vitamin D Receptor: Biochemical, Molecular, Biological, and Genomic Era Investigations. **2011**, 97-135	6
647	Structural Basis for Ligand Activity in VDR. **2011**, 171-191	5
646	Coregulators of VDR-mediated Gene Expression. **2011**, 193-209	3
645	Solution Structures of PPAR/RXR Complexes. **2012**, 2012, 701412	17
644	The Role of PPAR in the Transcriptional Control by Agonists and Antagonists. **2012**, 2012, 362361	20
643	Effects of PPAR Ligands on Leukemia. **2012**, 2012, 483656	13
642	Glucocorticoid-dependent phosphorylation of the transcriptional coregulator GRIP1. **2012**, 32, 730-9	21
641	Identification of a novel LXXLL motif in actinin 4-spliced isoform that is critical for its interaction with estrogen receptor and co-activators. **2012**, 287, 35418-35429	21

640	Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor activation pathway in gastric cancer. **2012**, 287, 38028-40	106
639	Current status of vitamin D signaling and its therapeutic applications. **2012**, 12, 528-47	79
638	The p400/Brd8 chromatin remodeling complex promotes adipogenesis by incorporating histone variant H2A.Z at PPAR target genes. **2012**, 153, 5796-808	16
637	Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (agonist. **2012**, 12, 87-97	41
636	GQ-16, a novel peroxisome proliferator-activated receptor (PPAR) ligand, promotes insulin sensitization without weight gain. **2012**, 287, 28169-79	82
635	And in the end--Telmisartan directly binds to PPAR **2012**, 35, 704-5	2
634	POSITIONING OF Ftz-F1 DOMAIN AFFECTS ON THE ACTIVITY OF HUMAN LRH-1: MOLECULAR DYNAMICS STUDY ON HUMAN LRH-1-DNA COMPLEXES. **2012**, 11, 329-359	3
633	Regulation of androgen receptor-dependent transcription by coactivator MED1 is mediated through a newly discovered noncanonical binding motif. **2012**, 287, 858-70	21
632	Structural basis for a molecular allosteric control mechanism of cofactor binding to nuclear receptors. **2012**, 109, E588-94	62
631	PPAR Ligands Regulate Noncontractile and Contractile Functions of Airway Smooth Muscle: Implications for Asthma Therapy. **2012**, 2012, 809164	15
630	Familial focal segmental glomerulosclerosis (FSGS)-linked -actinin 4 (ACTN4) protein mutants lose ability to activate transcription by nuclear hormone receptors. **2012**, 287, 12027-35	31
629	Mode of peroxisome proliferator-activated receptor activation by luteolin. **2012**, 81, 788-99	73
628	Retinoids: novel immunomodulators and tumour-suppressive agents?. **2012**, 167, 483-92	18
627	Nitro-fatty acids as novel electrophilic ligands for peroxisome proliferator-activated receptors. **2012**, 53, 1654-63	14
626	Rifampicin-independent interactions between the pregnane X receptor ligand binding domain and peptide fragments of coactivator and corepressor proteins. **2012**, 51, 19-31	18
625	Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization. **2012**, 64, 161-71	32
624	Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Ppar **2012**, 150, 620-32	541
623	Crosstalk between the peroxisome proliferator-activated receptor (PPAR) and the vitamin D receptor (VDR) in human breast cancer cells: PPAR binds to VDR and inhibits 1 25-dihydroxyvitamin D3 mediated transactivation. **2012**, 318, 2490-7	28

622	Synthesis, radiolabeling and initial in vivo evaluation of [(11)C]KSM-01 for imaging PPAR- receptors. **2012**, 22, 6233-6	9
621	Noncanonical mechanisms to regulate nuclear receptor signaling. **2012**, 4, 1307-33	4
620	A scaffold-independent subcellular event-based analysis: characterization of significant structural modifications. **2012**, 52, 506-14	2
619	Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity. **2012**, 55, 37-54	44
618	Combination of fucoxanthin and conjugated linoleic acid attenuates body weight gain and improves lipid metabolism in high-fat diet-induced obese rats. **2012**, 519, 59-65	62
617	PPAR and NF-B regulate the gene promoter activity of their shared repressor, TNIP1. **2012**, 1819, 1-15	16
616	PPAR agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. **2012**, 15, 395-404	532
615	Structure and activation of rhodopsin. **2012**, 33, 291-9	42
614	Characterization of telmisartan-derived PPAR agonists: importance of moiety shift from position 6 to 5 on potency, efficacy and cofactor recruitment. **2012**, 7, 1935-42	6
613	Impact of X-Ray Structure on Predictivity of Scoring Functions: PPAR Case Study. **2012**, 31, 631-3	5
612	Amorfrutins are potent antidiabetic dietary natural products. **2012**, 109, 7257-62	140
611	Targeting alpha-helix based protein interactions; nuclear receptors as a case study. **2012**, 238-272	
610	Design and synthesis of marine fungal phthalide derivatives as PPAR- agonists. **2012**, 20, 4954-61	21
609	Expression of peroxisome proliferator activated receptor-gamma (PPAR- in human non-small cell lung carcinoma: correlation with clinicopathological parameters, proliferation and apoptosis related molecules and patients' survival. **2012**, 18, 875-83	21
608	A combination of chemical and mechanical stimuli enhances not only osteo- but also chondro-differentiation in adipose-derived stem cells. **2012**, 54, 188-195	7
607	Synthesis, characterization and biological evaluation of some novel 2,4-thiazolidinediones as potential cytotoxic, antimicrobial and antihyperglycemic agents. **2012**, 22, 6442-50	28
606	Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding. **2012**, 7, e33643	35
605	Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) activators and pan-PPAR partial agonists. **2012**, 7, e36297	121

604	Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach. **2012**, 7, e38546	81
603	Computational studies of LXR molecular interactions reveal an allosteric communication pathway. **2012**, 80, 294-306	14
602	Minimal ensembles of side chain conformers for modeling protein-protein interactions. **2012**, 80, 591-601	25
601	Nuclear hormone receptors enable macrophages and dendritic cells to sense their lipid environment and shape their immune response. **2012**, 92, 739-89	159
600	The application of comparative molecular field analysis for the design of -anilino substituted-3-phenyl propanoic acids as novel PPAR/ dual ligands. **2012**, 21, 2873-2884	8
599	Dietary modification of metabolic pathways via nuclear hormone receptors. **2012**, 30, 531-51	12
598	Structural basis for telmisartan-mediated partial activation of PPAR gamma. **2012**, 35, 715-9	41
597	Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. **2012**, 55, 4027-61	130
596	Rigid and flexible docking studies on PPAR- agonists: key interactions for a better antihyperglycemic activity and in silico pharmacodynamic activity versus experimental in vivo activity. **2012**, 21, 624-633	3
595	Peroxisome proliferator-activated receptor- cross-regulation of signaling events implicated in liver fibrogenesis. **2012**, 24, 596-605	51
594	COX-derived prostanoid pathways in gastrointestinal cancer development and progression: novel targets for prevention and intervention. **2012**, 1825, 49-63	28
593	Stereoisomers ginsenosides-20(S)-Rg and -20(R)-Rg differentially induce angiogenesis through peroxisome proliferator-activated receptor-gamma. **2012**, 83, 893-902	41
592	Photodynamic efficacy of photosensitizers under an attenuated light dose via lipid nano-carrier-mediated nuclear targeting. **2012**, 33, 5478-86	42
591	A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR) agonists: design and synthesis of benzylpyrazole acylsulfonamides. **2012**, 20, 714-33	27
590	Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors / dual agonists. **2012**, 20, 2141-51	21
589	Structure-activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR) Agonists. **2012**, 20, 3332-58	7
588	Substituents at the naphthalene C3 position of (-)-Cercosporamide derivatives significantly affect the maximal efficacy as PPAR partial agonists. **2012**, 22, 1348-51	14
587	Sesquiterpene lactones from Tithonia diversifolia act as peroxisome proliferator-activated receptor agonists. **2012**, 22, 2954-8	26

586	Obesogens, stem cells and the developmental programming of obesity. **2012**, 35, 437-48	106
585	Steroid receptor coactivators 1, 2, and 3: critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapy. **2012**, 348, 430-9	114
584	Androgen receptor coregulators: recruitment via the coactivator binding groove. **2012**, 352, 57-69	80
583	A conserved surface on the ligand binding domain of nuclear receptors for allosteric control. **2012**, 348, 394-402	70
582	Structural analysis of nuclear receptors: from isolated domains to integral proteins. **2012**, 348, 466-73	45
581	Nuclear hormone receptor co-repressors: structure and function. **2012**, 348, 440-9	112
580	Couple dynamics: PPAR and its ligand partners. **2012**, 20, 2-4	11
579	In vitro toxicological effects of estrogenic mycotoxins on human placental cells: structure activity relationships. **2012**, 259, 366-75	36
578	Molecular identification and tissue distribution of peroxisome proliferators activated receptor gamma transcript in cultured Thunnus orientalis. **2012**, 43, 1145-1158	8
577	Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor- **2012**, 9, 49	77
576	Quantitative assessment of protein structural models by comparison of H/D exchange MS data with exchange behavior accurately predicted by DXCOREX. **2012**, 23, 43-56	47
575	General and specific determinants of the selective interactions between SRC-1 NR box-2 and target nuclear receptors. **2012**, 39, 177-84	1
574	A tandem regression-outlier analysis of a ligand cellular system for key structural modifications around ligand binding. **2013**, 5, 21	
573	PPAR SUMOylation: some useful experimental tips. **2013**, 952, 145-61	1
572	Peroxisome Proliferator-Activated Receptors (PPARs). **2013**,	
571	Analysis of PPAR- Activity by Combining 2-D QSAR and Molecular Simulation. **2013**, 32, 431-45	7
570	Towards a humanized PPAR reporter system for in vivo screening of obesogens. **2013**, 374, 1-9	14
569	Identification of the antibiotic ionomycin as an unexpected peroxisome proliferator-activated receptor (PPAR) ligand with a unique binding mode and effective glucose-lowering activity in a mouse model of diabetes. **2013**, 56, 401-11	18

568	Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands. **2013**, 56, 4701-17	41
567	Peroxisome Proliferator-Activated Receptors. **2013**,	4
566	Assay validation for the assessment of adipogenesis of multipotential stromal cells--a direct comparison of four different methods. **2013**, 15, 89-101	44
565	Tocopherol from seeds of Cucurbita pepo against diabetes: validation by in vivo experiments supported by computational docking. **2013**, 112, 676-90	37
564	Dimerization of nuclear receptors. **2013**, 117, 21-41	17
563	Coffee component hydroxyl hydroquinone (HHQ) as a putative ligand for PPAR gamma and implications in breast cancer. **2013**, 14 Suppl 5, S6	14
562	Dynamics of nuclear receptor Helix-12 switch of transcription activation by modeling time-resolved fluorescence anisotropy decays. **2013**, 105, 1670-80	29
561	3D-QSAR study of tyrosine and propanoic acid derivatives as PPAR/ dual agonists using CoMSIA. **2013**, 22, 287-302	8
560	Thiazolidine-2,4-diones: progress towards multifarious applications. **2013**, 21, 1599-620	99
559	Expression patterns of peroxisome proliferator-activated receptor gamma 1 versus gamma 2, and their association with intramuscular fat in goat tissues. **2013**, 528, 195-200	15
558	Discovery of INT131: a selective PPAR modulator that enhances insulin sensitivity. **2013**, 21, 979-92	38
557	Design and synthesis of alkoxyindolyl-3-acetic acid analogs as peroxisome proliferator-activated receptor- agonists. **2013**, 23, 513-7	14
556	Allosteric controls of nuclear receptor function in the regulation of transcription. **2013**, 425, 2317-29	48
555	Regulation of the Nuclear Hormone Receptor Ppar by Endogenous Lysophosphatidic Acids (LPAS). **2013**, 349-372	
554	Structural characterization of amorfrutins bound to the peroxisome proliferator-activated receptor **2013**, 56, 1535-43	51
553	Discovery of a novel selective PPAR ligand with partial agonist binding properties by integrated in silico/in vitro work flow. **2013**, 53, 923-37	25
552	Design, development and evaluation of novel dual PPAR/PPAR agonists. **2013**, 23, 873-9	12
551	Peroxisome Proliferator-Activated Receptors. **2013**, 15-23	

550	Tissue Distribution and Versatile Functions of PPARs. **2013**, 33-69	
549	Molecular mechanism of peroxisome proliferator-activated receptor activation by WY14643: a new mode of ligand recognition and receptor stabilization. **2013**, 425, 2878-93	71
548	Signaling by nuclear receptors. **2013**, 5, a016709	157
547	The orphan nuclear receptors at their 25-year reunion. **2013**, 51, T115-40	66
546	Regulation of the structurally dynamic N-terminal domain of progesterone receptor by protein-induced folding. **2013**, 288, 30285-30299	34
545	An evolving understanding of nuclear receptor coregulator proteins. **2013**, 51, T23-36	63
544	Understanding nuclear receptor form and function using structural biology. **2013**, 51, T1-T21	122
543	Nuclear receptors and their selective pharmacologic modulators. **2013**, 65, 710-78	156
542	Divergent sequence tunes ligand sensitivity in phospholipid-regulated hormone receptors. **2013**, 288, 20702-12	12
541	Small molecule modulation of nuclear receptor conformational dynamics: implications for function and drug discovery. **2013**, 83, 1-8	78
540	Expression of the PXR gene in various types of cancer and drug resistance. **2013**, 5, 1093-1100	49
539	Phytol/Phytanic acid and insulin resistance: potential role of phytanic acid proven by docking simulation and modulation of biochemical alterations. **2013**, 8, e45638	65
538	Diverse coactivator recruitment through differential PPAR nuclear receptor agonism. **2013**, 36, 134-9	8
537	Modulation of the transcriptional activity of peroxisome proliferator-activated receptor gamma by protein-protein interactions and post-translational modifications. **2013**, 54, 545-59	19
536	The asymmetric binding of PGC-1 to the ERR and ERR nuclear receptor homodimers involves a similar recognition mechanism. **2013**, 8, e67810	27
535	SAR and Computer-Aided Drug Design Approaches in the Discovery of Peroxisome Proliferator-Activated Receptor Activators: A Perspective. **2013**, 2013, 1-38	20
534	Identification of novel multitargeted PPAR/ pan agonists by core hopping of rosiglitazone. **2014**, 8, 2255-62	10
533	Identification of novel peroxisome proliferator-activated receptor-gamma (PPAR) agonists using molecular modeling method. **2014**, 28, 1143-51	6

532	Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif. **2014**, 289, 8839-51	36
531	Molecular modelling study of the PPARγ receptor in relation to the mode of action/adverse outcome pathway framework for liver steatosis. **2014**, 15, 7651-66	34
530	Biased Signaling and Conformational Dynamics in Nuclear Hormone Receptors. **2014**, 103-135	
529	The roles of peroxisome proliferator-activated receptors in the metabolic syndrome. **2014**, 121, 217-66	55
528	The effect of peroxisome proliferator-activated receptor-γ ligands on in vitro and in vivo models of COPD. **2014**, 43, 409-20	66
527	Diosgenin relieves goiter via the inhibition of thyrocyte proliferation in a mouse model of Graves' disease. **2014**, 35, 65-73	22
526	Structural basis of the transactivation deficiency of the human PPARγ F360L mutant associated with familial partial lipodystrophy. **2014**, 70, 1965-76	9
525	The therapeutic potential of nuclear receptor modulators for treatment of metabolic disorders: PPARγ, RORs, and Rev-erbs. **2014**, 19, 193-208	87
524	Local motifs involved in the canonical structure of the ligand-binding domain in the nuclear receptor superfamily. **2014**, 185, 355-65	11
523	Role of histone acetyltransferases and histone deacetylases in adipocyte differentiation and adipogenesis. **2014**, 93, 170-7	45
522	Regulation of energy metabolism by long-chain fatty acids. **2014**, 53, 124-44	369
521	Immunological Mechanisms and Therapies in Brain Injuries and Stroke. **2014**,	2
520	Design and synthesis of non-TZD peroxisome proliferator-activated receptor γ (PPARγ) modulator. **2014**, 23, 2150-2159	4
519	Phenotypic screening to identify small-molecule enhancers for glucose uptake: target identification and rational optimization of their efficacy. **2014**, 53, 5102-6	16
518	Nuclear receptor profiling of bisphenol-A and its halogenated analogues. **2014**, 94, 229-51	47
517	Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers. **2014**, 40, 1137-52	23
516	Novel benzenesulfonylureas containing thiophenylpyrazoline moiety as potential antidiabetic and anticancer agents. **2014**, 24, 5298-303	11
515	Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats. **2014**, 221, 133-44	8

514	SEURAT-1 liver gold reference compounds: a mechanism-based review. **2014**, 88, 2099-133	17
513	Reinvestigations into synthesis of allyldithiocarbamates and their intramolecular cyclization: synthesis and antihyperglycemic activity of 2-thioxothiazolidine-4-alkanoates. **2014**, 70, 6841-6850	10
512	Charge clamps of lysines and hydrogen bonds play key roles in the mechanism to fix helix 12 in the agonist and antagonist positions of estrogen receptor intramolecular interactions studied by the ab initio fragment molecular orbital method. **2014**, 118, 4993-5008	18
511	Structure-dependent binding and activation of perfluorinated compounds on human peroxisome proliferator-activated receptor **2014**, 279, 275-283	59
510	Thrap3 docks on phosphoserine 273 of PPAR and controls diabetic gene programming. **2014**, 28, 2361-9	39
509	Unprecedented conformational flexibility revealed in the ligand-binding domains of the Bovicola ovis ecdysone receptor (EcR) and ultraspiracle (USP) subunits. **2014**, 70, 1954-64	13
508	Natural product agonists of peroxisome proliferator-activated receptor gamma (PPAR) a review. **2014**, 92, 73-89	389
507	Differential roles of PPAR vs TR4 in prostate cancer and metabolic diseases. **2014**, 21, R279-300	14
506	Physiological functions of peroxisome proliferator-activated receptor **2014**, 94, 795-858	104
505	An alternate binding site for PPAR ligands. **2014**, 5, 3571	123
504	7-ketocholesteryl-9-carboxynonanoate enhances ATP binding cassette transporter A1 expression mediated by PPAR in THP-1 macrophages. **2014**, 234, 461-8	5
503	Amorfrutins: A promising class of natural products that are beneficial to health. **2014**, 15, 1231-8	27
502	Understanding the variegation of fat: novel regulators of adipocyte differentiation and fat tissue biology. **2014**, 1842, 352-7	30
501	Targeting nuclear receptors with marine natural products. **2014**, 12, 601-35	8
500	Synthesis of PPAR- activators inspired by the marine natural product, paecilocin A. **2014**, 12, 926-39	10
499	St. John's wort promotes adipocyte differentiation and modulates NF-B activation in 3T3-L1 cells. **2014**, 37, 1132-8	13
498	Phenotypic Screening to Identify Small-Molecule Enhancers for Glucose Uptake: Target Identification and Rational Optimization of Their Efficacy. **2014**, 126, 5202-5206	4
497	Retinoid Receptors. **2015**, 131-149	1

496	Bongkrekic acid as a selective activator of the peroxisome proliferator-activated receptor (PPAR)isoform. **2015**, 40, 223-33	7
495	Involvement of covalent interactions in the mode of action of PPARantagonists. **2015**, 5, 76483-76490	4
494	Mechanisms of peroxisome proliferator activated receptor regulation by non-steroidal anti-inflammatory drugs. **2015**, 13, e004	47
493	Integrative and systemic approaches for evaluating PPAR(PPARD) function. **2015**, 13, e001	40
492	Structural and Dynamical Insight into PPARAntagonism: In Silico Study of the Ligand-Receptor Interactions of Non-Covalent Antagonists. **2015**, 16, 15405-24	13
491	Unlock the Thermogenic Potential of Adipose Tissue: Pharmacological Modulation and Implications for Treatment of Diabetes and Obesity. **2015**, 6, 174	39
490	Evolutionary Pattern and Regulation Analysis to Support Why Diversity Functions Existed within PPAR Gene Family Members. **2015**, 2015, 613910	10
489	Review of the Structural and Dynamic Mechanisms of PPARPartial Agonism. **2015**, 2015, 816856	112
488	Role of Peroxisome Proliferator-Activated Receptor In Ocular Diseases. **2015**, 2015, 275435	20
487	Nuclear Receptor Modulators Current Approaches and Future Perspectives. **2015**,	3
486	Sphingosine 1-phosphate is a ligand for peroxisome proliferator-activated receptor-that regulates neoangiogenesis. **2015**, 29, 3638-53	49
485	Peroxisome proliferator-activated receptor alpha1 in yellow catfish Pelteobagrus fulvidraco: molecular characterization, mRNA tissue expression and transcriptional regulation by insulin in vivo and in vitro. **2015**, 183, 58-66	14
484	Peroxisome proliferator-activated receptor gamma (PPAR)has multiple binding points that accommodate ligands in various conformations: Structurally similar PPARpartial agonists bind to PPARLBD in different conformations. **2015**, 25, 2758-62	11
483	Different structures of the two peroxisome proliferator-activated receptor gamma (PPAR) ligand-binding domains in homodimeric complex with partial agonist, but not full agonist. **2015**, 25, 2639-44	13
482	Conformational Diversity of the Helix 12 of the Ligand Binding Domain of PPARand Functional Implications. **2015**, 119, 15418-29	12
481	Developing Adnectins that target SRC co-activator binding to PXR: a structural approach toward understanding promiscuity of PXR. **2015**, 427, 924-942	17
480	Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia. **2015**, 360, 28-38	38
479	On the metabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal muscles. **2015**, 10, 555-65	22

478	Peroxisome proliferator-activated receptor gamma (PPARγ) in yellow catfish Pelteobagrus fulvidraco: molecular characterization, mRNA expression and transcriptional regulation by insulin in vivo and in vitro. **2015**, 212, 51-62	15
477	Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligands. **2015**, 29, 421-39	9
476	Activation of PPARγ from computer modelling to biological effects. **2015**, 172, 754-70	11
475	RXR agonist modulates TR: corepressor dissociation upon 9-cis retinoic acid treatment. **2015**, 29, 258-73	17
474	Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Ligand Choreography: Newcomers Take the Stage. **2015**, 58, 5381-94	61
473	Structure of a biologically active estrogen receptor-coactivator complex on DNA. **2015**, 57, 1047-1058	103
472	The optimal corepressor function of nuclear receptor corepressor (NCoR) for peroxisome proliferator-activated receptor γ requires G protein pathway suppressor 2. **2015**, 290, 3666-79	15
471	Two homoisoflavonoids act as peroxisome proliferator-activated receptor agonists. **2015**, 24, 2898-2905	2
470	Phosphorylation of PPARγ Affects the Collective Motions of the PPARγ-RXRα-DNA Complex. **2015**, 10, e0123984	11
469	Molecular Recognition of PPARγ by Kinase Cdk5/p25: Insights from a Combination of Protein-Protein Docking and Adaptive Biasing Force Simulations. **2015**, 119, 8330-9	9
468	Characterizing the peroxisome proliferator-activated receptor (PPARγ) ligand binding potential of several major flame retardants, their metabolites, and chemical mixtures in house dust. **2015**, 123, 166-72	80
467	Determinants of Receptor- and Tissue-Specific Actions in Androgen Signaling. **2015**, 36, 357-84	79
466	Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α/γ. **2015**, 191, 332-40	30
465	Selective targeting of PPARγ by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency. **2015**, 5, 12222	28
464	Structural basis for PPARγ transactivation by endocrine-disrupting organotin compounds. **2015**, 5, 8520	41
463	Mapping functional group free energy patterns at protein occluded sites: nuclear receptors and G-protein coupled receptors. **2015**, 55, 700-8	40
462	Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis. **2015**, 5, 9530	50
461	Neuroprotective and anti-inflammatory properties of a novel non-thiazolidinedione PPARγ agonist in vitro and in MPTP-treated mice. **2015**, 302, 23-35	34

460	Identification and characterisation of a prototype for a new class of competitive PPAR antagonists. **2015**, 755, 16-26	4
459	Characterization of covalent bond formation between PPAR and oxo-fatty acids. **2015**, 26, 690-8	16
458	High salt diet modulates vascular response in A2AAR (+/+) and A 2AAR (-/-) mice: role of sEH, PPAR and K ATP channels. **2015**, 404, 87-96	15
457	Activation helix orientation of the estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations. **2015**, 17, 13403-20	21
456	Thiazolidine-2,4-dione derivatives: programmed chemical weapons for key protein targets of various pathological conditions. **2015**, 23, 2953-74	52
455	Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma. **2015**, 36, 688-704	66
454	Nuclear Receptors: From Structure to the Clinic. **2015**,	1
453	Pro-inflammatory Macrophages suppress PPAR activity in Adipocytes via S-nitrosylation. **2015**, 89, 895-905	26
452	Cinnamaldehyde Contributes to Insulin Sensitivity by Activating PPAR PPAR and RXR. **2015**, 43, 879-92	18
451	Identification of a New Type of Covalent PPAR Agonist using a Ligand-Linking Strategy. **2015**, 10, 2794-804	25
450	Combining 'dry' co-crystallization and in situ diffraction to facilitate ligand screening by X-ray crystallography. **2015**, 71, 1777-87	36
449	A ligand-entry surface of the nuclear receptor superfamily consists of the helix H3 of the ligand-binding domain. **2015**, 62, 262-275	4
448	Molecular characterization, transcriptional activity and nutritional regulation of peroxisome proliferator activated receptor gamma in Nile tilapia (Oreochromis niloticus). **2015**, 223, 139-47	19
447	Nuclear receptor full-length architectures: confronting myth and illusion with high resolution. **2015**, 40, 16-24	52
446	A structural perspective on nuclear receptors as targets of environmental compounds. **2015**, 36, 88-101	68
445	Pleiotropic role of PPAR in intracerebral hemorrhage: an intricate system involving Nrf2, RXR, and NF-B. **2015**, 21, 357-66	73
444	Molecular modeling design, synthesis, and anti-hyprglycemic evaluation of certain 5-(aryl-alkoxy-benzylidine)-imidazolidine-2,4-dione derivatives as potential PPAR agonists. **2015**, 24, 2115-2126	1
443	Structural design and synthesis of arylalkynyl amide-type peroxisome proliferator-activated receptor (PPAR)-selective antagonists based on the helix12-folding inhibition hypothesis. **2015**, 90, 53-67	21

442	Design, synthesis and evaluation of PPAR gamma binding activity of 2-thioxo-4-thiazolidinone derivatives. **2015**, 26, 63-68	16
441	PPAR as a Metabolic Initiator of Mammary Neoplasia and Immune Tolerance. **2016**, 2016, 3082340	4
440	Principles of Hormone Action. **2016**, 18-48	3
439	Selective Inhibition of PTP1B by Vitalboside A from Syzygium cumini Enhances Insulin Sensitivity and Attenuates Lipid Accumulation Via Partial Agonism to PPARγ In Vitro and In Silico Investigation. **2016**, 88, 302-12	22
438	Sirtuin1 promotes osteogenic differentiation through downregulation of peroxisome proliferator-activated receptor γ in MC3T3-E1 cells. **2016**, 478, 439-445	14
437	A Novel Partial PPARγ/δ Dual Agonist SN159 Improves Insulin Sensitivity. **2016**, 37, 226-233	3
436	Allosteric Pathways in the PPARγ-RXRα nuclear receptor complex. **2016**, 6, 19940	31
435	Discovery of Isoquinolinoquinazolinones as a Novel Class of Potent PPARγ Antagonists with Anti-adipogenic Effects. **2016**, 6, 34661	9
434	Dietary component isorhamnetin is a PPARγ antagonist and ameliorates metabolic disorders induced by diet or leptin deficiency. **2016**, 6, 19288	42
433	Browning of White Adipose Tissue with Roscovitine Induces a Distinct Population of UCP1 Adipocytes. **2016**, 24, 835-847	80
432	Development of an ELISA for High-Throughput Screening of Inhibitors of Cdk5-Mediated PPARγ Phosphorylation. **2016**, 14, 261-72	2
431	Novel peroxisome proliferator-activated receptor gamma mutation in a family with familial partial lipodystrophy type 3. **2016**, 84, 141-8	7
430	The antiproliferative and proapoptotic effects of cladosporols A and B are related to their different binding mode as PPARγ ligands. **2016**, 108, 22-35	18
429	Mechanistic elucidation guided by covalent inhibitors for the development of anti-diabetic PPARγ ligands. **2016**, 7, 5523-5529	29
428	Discovery of N-(1-(3-(4-phenoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)acetamides as novel acetyl-CoA carboxylase 2 (ACC2) inhibitors with peroxisome proliferator-activated receptor α/γ (PPARα/γ) dual agonistic activity. **2016**, 24, 5258-5269	6
427	Apo- and Antagonist-Binding Structures of Vitamin D Receptor Ligand-Binding Domain Revealed by Hybrid Approach Combining Small-Angle X-ray Scattering and Molecular Dynamics. **2016**, 59, 7888-900	19
426	Peroxisome proliferator-activated receptor gamma (PPARγ) in brown trout: Interference of estrogenic and androgenic inputs in primary hepatocytes. **2016**, 46, 328-336	7
425	Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR) γ partial agonists. **2016**, 124, 49-62	12

424	Computational study of the binding orientation and affinity of PPARagonists: inclusion of ligand-induced fit by cross-docking. **2016**, 6, 64756-64768	18
423	Exploration of the conformational landscape in pregnane X receptor reveals a new binding pocket. **2016**, 25, 1989-2005	8
422	MiR-132 regulates osteogenic differentiation via downregulating Sirtuin1 in a peroxisome proliferator-activated receptor dependent manner. **2016**, 478, 260-267	31
421	arrestin-1 contributes to brown fat function and directly interacts with PPARand PPAR**2016**, 6, 26999	11
420	The effect of regulating molecules on the structure of the PPAR-RXR complex. **2016**, 1861, 1852-1863	21
419	The Perilipins: Major Cytosolic Lipid Droplet-Associated Proteins and Their Roles in Cellular Lipid Storage, Mobilization, and Systemic Homeostasis. **2016**, 36, 471-509	144
418	Identifying potential PPARagonist/partial agonist from plant molecules to control type 2 diabetes using in silico and in vivo models. **2016**, 25, 1980-1992	6
417	The Biochemistry of Retinoid Signaling II. **2016**,	10
416	Non-classical Transcriptional Activity of Retinoic Acid. **2016**, 81, 179-199	14
415	The conformational dynamics of H2-H3n and S2-H6 in gating ligand entry into the buried binding cavity of vitamin D receptor. **2016**, 6, 35937	2
414	N-palmitoylethanolamide in the anterior cingulate cortex attenuates inflammatory pain behaviour indirectly via a CB1 receptor-mediated mechanism. **2016**, 157, 2687-2696	24
413	Novel benzothiazole based sulfonylureas/sulfonylthioureas: design, synthesis and evaluation of their antidiabetic potential. **2016**, 40, 6777-6786	4
412	Using steric bulk for selective recognition; blocking the binding site to differentiate guests. **2016**, 52, 8719-21	7
411	Structural dataset for the PPARV290M mutant. **2016**, 7, 1430-1437	1
410	Role of co-regulators in metabolic and transcriptional actions of thyroid hormone. **2016**, 56, 73-97	23
409	SR2067 Reveals a Unique Kinetic and Structural Signature for PPARPartial Agonism. **2016**, 11, 273-83	30
408	Averrhoa carambola L. peel extract suppresses adipocyte differentiation in 3T3-L1 cells. **2016**, 7, 881-92	7
407	Fatty acids, eicosanoids and PPAR gamma. **2016**, 785, 44-49	127

406	Structural Studies of Vitamin D Nuclear Receptor Ligand-Binding Properties. **2016**, 100, 83-116	15
405	New PPAR partial agonist improves obesity-induced metabolic alterations and atherosclerosis in LDLr(-/-) mice. **2016**, 104, 49-60	23
404	The elusive endogenous adipogenic PPAR agonists: Lining up the suspects. **2016**, 61, 149-62	28
403	PPAR Antagonist Gleevec Improves Insulin Sensitivity and Promotes the Browning of White Adipose Tissue. **2016**, 65, 829-39	59
402	Structures and regulation of non-X orphan nuclear receptors: A retinoid hypothesis. **2016**, 157, 27-40	5
401	Design and synthesis of novel Y-shaped barbituric acid derivatives as PPAR activators. **2016**, 108, 423-435	17
400	Recent Developments on the Antidiabetic Sesquiterpene Lactones and Their Semisynthetic Analogues. **2017**, 185-207	3
399	Identification of a novel selective PPAR ligand with a unique binding mode and improved therapeutic profile in vitro. **2017**, 7, 41487	12
398	Activation of Peroxisome Proliferator-Activated Receptor Gamma and Disruption of Progesterone Synthesis of 2-Ethylhexyl Diphenyl Phosphate in Human Placental Choriocarcinoma Cells: Comparison with Triphenyl Phosphate. **2017**, 51, 4061-4068	46
397	Cloning and expression characterization of peroxisome proliferator-activated receptors (PPARs) with their agonists, dietary lipids, and ambient salinity in rabbitfish Siganus canaliculatus. **2017**, 206, 54-64	23
396	Highly Flexible Protein-Peptide Docking Using CABS-Dock. **2017**, 1561, 69-94	24
395	Structural aspects of Vitamin D endocrinology. **2017**, 453, 22-35	21
394	Endothelial LRP1 regulates metabolic responses by acting as a co-activator of PPAR **2017**, 8, 14960	34
393	Structure-based design, synthesis, PPAR- activation, and molecular docking of N-substituted phthalimides. **2017**, 26, 1628-1634	3
392	A network model predicts the intensity of residue-protein thermal coupling. **2017**, 33, 2106-2113	5
391	X-ray crystal structure of rivoglitazone bound to PPAR and PPAR subtype selectivity of TZDs. **2017** , 1861, 1981-1991	11
390	Role of Peroxisome Proliferator-Activated Receptors in Inflammation and Angiogenesis. **2017**, 417-456	
389	Structure-Activity Relationship of 2,4-Dichloro-N-(3,5-dichloro-4-(quinolin-3-yloxy)phenyl)benzenesulfonamide (INT131) Analogs for PPAR Targeted Antidiabetics. **2017**, 60, 4584-4593	14

388	Agonist-specific Protein Interactomes of Glucocorticoid and Androgen Receptor as Revealed by Proximity Mapping. **2017**, 16, 1462-1474	40
387	Structural studies unravel the active conformation of apo RORγ nuclear receptor and a common inverse agonism of two diverse classes of RORγ inhibitors. **2017**, 292, 11618-11630	31
386	Structural review of PPARγ in complex with ligands: Cartesian- and dihedral angle principal component analyses of X-ray crystallographic data. **2017**, 85, 1684-1698	4
385	Structural basis for specific ligation of the peroxisome proliferator-activated receptor γ **2017**, 114, E2563-E2570	38
384	How α-Helical Motifs Form Functionally Diverse Lipid-Binding Compartments. **2017**, 86, 609-636	15
383	Spectroscopic and molecular modeling approaches to investigate the interaction of bisphenol A, bisphenol F and their diglycidyl ethers with PPARγ **2017**, 180, 253-258	16
382	Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternate site. **2017**, 1865, 674-681	29
381	Roles of Peroxisome Proliferator-Activated Receptor β/δ in skeletal muscle physiology. **2017**, 136, 42-48	33
380	New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity. **2017**, 127, 379-397	14
379	Importance of 5/6-aryl substitution on the pharmacological profile of 4'-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid derived PPARγ agonists. **2017**, 126, 590-603	6
378	Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes. **2017**, 7, 14453	23
377	Comparing pharmacophore models derived from crystallography and NMR ensembles. **2017**, 31, 979-993	2
376	Study of new interactions of glitazone's stereoisomers and the endogenous ligand 15d-PGJ2 on six different PPAR gamma proteins. **2017**, 142, 168-193	13
375	Study of the interactions between Edaglitazone and Ciglitazone with PPARγ and their antiplatelet profile. **2017**, 186, 59-65	6
374	Identification of a New Zinc Binding Chemotype by Fragment Screening. **2017**, 60, 7333-7349	5
373	Characterization of alendronic- and undecylenic acid coated magnetic nanoparticles for the targeted delivery of rosiglitazone to subcutaneous adipose tissue. **2017**, 13, 559-568	11
372	Immunosenescence and the Ageing Lung. **2017**, 87-104	2
371	The Ageing Immune System and Health. **2017**,	1

370	Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs. **2017**, 7, 16837	33
369	MSDC-0160 and MSDC-0602 Binding with Human Mitochondrial Pyruvate Carrier (MPC) 1 and 2 Heterodimer. **2017**, 7, 43-67	7
368	Two Isomeric C16 Oxo-Fatty Acids from the Diatom Chaetoceros karianus Show Dual Agonist Activity towards Human Peroxisome Proliferator-Activated Receptors (PPARs) Α. **2017**, 15,	7
367	Discovery of Farnesoid X Receptor Antagonists Based on a Library of Oleanolic Acid 3-O-Esters through Diverse Substituent Design and Molecular Docking Methods. **2017**, 22,	2
366	CHARMM Force Field Parameterization of Peroxisome Proliferator-Activated Receptor γ Ligands. **2016**, 18,	2
365	Single-Nucleotide Polymorphism of PPARγ a Protein at the Crossroads of Physiological and Pathological Processes. **2017**, 18,	7
364	Treatment with a New Peroxisome Proliferator-Activated Receptor Gamma Agonist, Pyridinecarboxylic Acid Derivative, Increases Angiogenesis and Reduces Inflammatory Mediators in the Heart of -Infected Mice. **2017**, 8, 1738	6
363	Investigations on Binding Pattern of Kinase Inhibitors with PPAR: Molecular Docking, Molecular Dynamic Simulations, and Free Energy Calculation Studies. **2017**, 2017, 6397836	16
362	Flavonoids as Putative Inducers of the Transcription Factors Nrf2, FoxO, and PPAR. **2017**, 2017, 4397340	44
361	Cloning retinoid and peroxisome proliferator-activated nuclear receptors of the Pacific oyster and in silico binding to environmental chemicals. **2017**, 12, e0176024	24
360	Small leucine zipper protein functions as a negative regulator of estrogen receptor in breast cancer. **2017**, 12, e0180197	5
359	IN SILICO STUDIES ON FUNCTIONALIZED AZAGLYCINE DERIVATIVES CONTAINING 2, 4-THIAZOLIDINEDIONE SCAFFOLD ON MULTIPLE TARGETS. **2017**, 9, 209	4
358	Role of pregnane X-receptor in regulating bacterial translocation in chronic liver diseases. **2017**, 9, 1210-1226	11
357	Design, sythesis and evaluation of a series of 3- or 4-alkoxy substituted phenoxy derivatives as PPARs agonists. **2017**, 8, 20766-20783	1
356	Examination of VDR/RXR/DRIP205 Interaction, Intranuclear Localization, and DNA Binding in Ras-Transformed Keratinocytes and Its Implication for Designing Optimal Vitamin D Therapy in Cancer. **2018**, 159, 1303-1327	3
355	Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice. **2018**, 20, 1688-1701	6
354	Ginsenoside Rg3 stereoisomers differentially inhibit vascular smooth muscle cell proliferation and migration in diabetic atherosclerosis. **2018**, 22, 3202-3214	15
353	Deficiency Stimulates Thermogenic Beige Adipocytes Through Activation. **2018**, 67, 791-804	15

352	Thiazolidinediones as antidiabetic agents: A critical review. **2018**, 77, 548-567	136
351	Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPAR□**2018**, 8, 31	41
350	Defining a conformational ensemble that directs activation of PPAR□**2018**, 9, 1794	37
349	Researching the complexing conditions of residual boron in produced water from oil & gas fields. **2018**, 116, 254-261	6
348	Synthesis, biological evaluation, and molecular docking investigation of benzhydrol- and indole-based dual PPAR-/FFAR1 agonists. **2018**, 28, 1595-1602	13
347	A computational study to identify the key residues of peroxisome proliferator-activated receptor gamma in the interactions with its antagonists. **2018**, 36, 1822-1833	4
346	Virtual identification of novel PPAR/□dual agonists by scaffold hopping of saroglitazar. **2018**, 36, 3496-3512	8
345	5,4'-Dihydroxy-7,8-dimethoxyflavanone and Aliarin from Dodonaea viscosa Are Activators of PPAR□**2018**, 84, 500-506	
344	Identification of novel PPAR/□dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations. **2018**, 36, 2988-3002	7
343	"Multiple partial recognitions in dynamic equilibrium" in the binding sites of proteins form the molecular basis of promiscuous recognition of structurally diverse ligands. **2018**, 10, 421-433	11
342	In-silico Analysis of Phenyl Propanoic Acid Derivatives to Design Potent Peroxisome Proliferator-activated Receptor (PPAR) Dual Agonists for Type 2 Diabetes mellitus Therapy. **2018**, 34, 1400-1410	1
341	Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases. **2018**, 19,	23
340	A structural mechanism for directing corepressor-selective inverse agonism of PPAR□**2018**, 9, 4687	29
339	The Nuclear Receptor Field: A Historical Overview and Future Challenges. **2018**, 5,	38
338	Modulation of Soluble Receptor Signaling by Coregulators. **2018**, 55-75	
337	Peroxisome Proliferator-Activated Receptors: Biological and Toxicological Importance. **2018**, 161-179	
336	Identification of a Novel PPAR-□Agonist through a Scaffold Tuning Approach. **2018**, 19,	9
335	The mechanistic insight of a specific interaction between 15d-Prostaglandin-J2 and eIF4A suggests an evolutionary conserved role across species. **2018**, 7,	3

334	Glutaminase Affects the Transcriptional Activity of Peroxisome Proliferator-Activated Receptor (PPAR)via Direct Interaction. **2018**, 57, 6293-6307	6
333	The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond. **2018**, 9, 1093	16
332	Development of Dihydrodibenzooxepine Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Ligands of a Novel Binding Mode as Anticancer Agents: Effective Mimicry of Chiral Structures by Olefinic E/ Z-Isomers. **2018**, 61, 10067-10083	8
331	Signaling Mechanisms of Selective PPAR Modulators in Alzheimer's Disease. **2018**, 2018, 2010675	34
330	Proteomic Profiling of Native Unpassaged and Culture-Expanded Mesenchymal Stromal Cells (MSC). **2018**, 93, 894-904	16
329	Discovery of DS-6930, a potent selective PPAR modulator. Part I: Lead identification. **2018**, 26, 5079-5098	6
328	Design of PPAR-agonist based on algal metabolites and the endogenous ligand 15-deoxy-prostaglandin J. **2018**, 157, 1192-1201	5
327	Idebenone and coenzyme Q are novel PPARligands, with potential for treatment of fatty liver diseases. **2018**, 11,	13
326	Chemical Crosslinking Mass Spectrometry Reveals the Conformational Landscape of the Activation Helix of PPARa Model for Ligand-Dependent Antagonism. **2018**, 26, 1431-1439.e6	14
325	A current structural perspective on PXR and CAR in drug metabolism. **2018**, 14, 635-647	26
324	A molecular docking study of Rhizoma Atractylodis and Rhizoma Atractylodis Macrocephalae herbal pair with respect to type 2 diabetes mellitus. **2018**, 5, 185-198	5
323	Tributyltin induces a transcriptional response without a brite adipocyte signature in adipocyte models. **2018**, 92, 2859-2874	17
322	Screening for PPAR Non-Agonist Ligands Followed by Characterization of a Hit, AM-879, with Additional No-Adipogenic and cdk5-Mediated Phosphorylation Inhibition Properties. **2018**, 9, 11	13
321	Molecular dynamics simulation of human estrogen receptor free and bound to morpholine ether benzophenone inhibitor. **2018**, 137, 1	2
320	Insights into the Role of PPARin NAFLD. **2018**, 19,	29
319	Structural Basis for Ligand Activity in Vitamin D Receptor. **2018**, 189-209	1
318	Using bisphenol A and its analogs to address the feasibility and usefulness of the CALUX-PPAR assay to identify chemicals with obesogenic potential. **2018**, 53, 208-221	3
317	Indole and 2,4-Thiazolidinedione conjugates as potential anticancer modulators. **2018**, 6, e5386	19

316	The nuclear receptor superfamily: A structural perspective. **2018**, 27, 1876-1892	128
315	A bile acid derivative with PPAR-mediated anti-inflammatory activity. **2018**, 137, 40-46	2
314	Modulating Vitamin D Receptor-Coregulator Binding With Small Molecules. **2018**, 657-666	1
313	PPAR-In Complex with an Antagonist and Inverse Agonist: a Tumble and Trap Mechanism of the Activation Helix. **2018**, 5, 69-79	29
312	Modulation of Nuclear Receptor Function by Chromatin Modifying Factor TIP60. **2018**, 159, 2199-2215	8
311	Lanthionine synthetase C-like protein 2 (LanCL2) is important for adipogenic differentiation. **2018**, 59, 1433-1445	2
310	Degradation of selenoprotein S and selenoprotein K through PPAR-mediated ubiquitination is required for adipocyte differentiation. **2019**, 26, 1007-1023	12
309	Mono(2-ethylhexyl) phthalate (MEHP) and mono(2-ethyl-5-oxohexyl) phthalate (MEOHP) but not di(2-ethylhexyl) phthalate (DEHP) bind productively to the peroxisome proliferator-activated receptor -**2019**, 33 Suppl 1, 75-85	15
308	Hormone-Responsive Cancers. **2019**, 717-741.e8	1
307	Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPAR- phosphorylation. **2019**, 9, 11168	7
306	Structural development of 1H-pyrazolo-[3,4-b]pyridine-4-carboxylic acid derivatives as human peroxisome proliferator-activated receptor alpha (PPAR)-selective agonists. **2019**, 29, 2124-2128	7
305	Exploring the mechanism of PPAR-phosphorylation mediated by CDK5. **2019**, 207, 317-326	10
304	Cannabinoid Interactions with Proteins: Insights from Structural Studies. **2019**, 1162, 39-50	2
303	Polycerasoidol, a Natural Prenylated Benzopyran with a Dual PPAR/PPAR-Agonist Activity and Anti-inflammatory Effect. **2019**, 82, 1802-1812	8
302	Discovery of BR102375, a new class of non-TZD PPAR-full agonist for the treatment of type 2 diabetes. **2019**, 29, 2275-2282	1
301	Cigarette Smoke Extract Modulates Functions of Peroxisome Proliferator-Activated Receptors. **2019**, 42, 1628-1636	
300	Aryl hydrocarbon receptor (AhR) regulates adipocyte differentiation by assembling CRL4B ubiquitin ligase to target PPAR-for proteasomal degradation. **2019**, 294, 18504-18515	16
299	Flow cytometry-based FRET identifies binding intensities in PPAR- protein-protein interactions in living cells. **2019**, 9, 5444-5463	3

298	Type II diabetes mellitus and obesity: Common links, existing therapeutics and future developments. **2019**, 44, 1	8
297	Evaluating Chemicals for Thyroid Disruption: Opportunities and Challenges with in Vitro Testing and Adverse Outcome Pathway Approaches. **2019**, 127, 95001	44
296	Structural Basis for the Regulation of PPARActivity by Imatinib. **2019**, 24,	9
295	Utility of B-Factors in Protein Science: Interpreting Rigidity, Flexibility, and Internal Motion and Engineering Thermostability. **2019**, 119, 1626-1665	159
294	Allosteric small molecule modulators of nuclear receptors. **2019**, 485, 20-34	21
293	Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPARDrug Pioglitazone. **2019**, 62, 2008-2023	16
292	Adiponectin-Secretion-Promoting Phenylethylchromones from the Agarwood of Aquilaria malaccensis. **2019**, 82, 259-264	12
291	Understanding Peroxisome Proliferator-Activated Receptors: From the Structure to the Regulatory Actions on Metabolism. **2019**, 1127, 39-57	12
290	Early impairment of epigenetic pattern in neurodegeneration: Additional mechanisms behind pyrethroid toxicity. **2019**, 124, 110629	18
289	Importance of the Proximity and Orientation of Ligand-Linkage to the Design of Cinnamate-GW9662 Hybrid Compounds as Covalent PPARAgonists. **2019**, 24,	2
288	2-Phenyl-8-(1-phenylallyl)-chromenone compounds have a pan-PPAR modulator pharmacophore. **2019**, 27, 2948-2958	6
287	An update about the crucial role of stereochemistry on the effects of Peroxisome Proliferator-Activated Receptor ligands. **2019**, 176, 326-342	2
286	Molecular Modeling Approach to Study the PPARLigand Interactions. **2019**, 1966, 261-289	1
285	Phenolic Compounds Inhibit 3T3-L1 Adipogenesis Depending on the Stage of Differentiation and Their Binding Affinity to PPAR**2019**, 24,	35
284	Peptides and Peptidomimetics as Potential Antiobesity Agents: Overview of Current Status. **2019**, 6, 11	27
283	Bio-derived hydroxystearic acid ameliorates skin age spots and conspicuous pores. **2019**, 41, 240-256	14
282	Chiral phenoxyacetic acid analogues inhibit colon cancer cell proliferation acting as PPARpartial agonists. **2019**, 9, 5434	12
281	Structure-Based Stepwise Screening of PPARAntagonists as Potential Competitors with NCOA1 Coactivator Peptide for PPARCIS Site. **2019**, 25, 1369-1377	5

280	Adipogenic Activity of Oligomeric Hexafluoropropylene Oxide (Perfluorooctanoic Acid Alternative) through Peroxisome Proliferator-Activated Receptor Pathway. **2019**, 53, 3287-3295	23
279	Gene-gene and gene-environment interactions in lipodystrophy: Lessons learned from natural PPAR mutants. **2019**, 1864, 715-732	15
278	Definition of functionally and structurally distinct repressive states in the nuclear receptor PPAR **2019**, 10, 5825	12
277	(S)-1,2,3,4-Tetrahydroisoquinoline Derivatives Substituted with an Acidic Group at the 6-Position as a Selective Peroxisome Proliferator-Activated Receptor Partial Agonist. **2019**, 67, 1211-1224	2
276	Di-n-butyl phthalate modifies PMA-induced macrophage differentiation of THP-1 monocytes via PPAR **2019**, 54, 168-177	7
275	Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies. **2019**, 174, 53-89	137
274	Estrogen Receptor and Breast Cancer. **2019**,	3
273	Molecular characterization and tissue distribution of SREBP-1 and PPAR in Onychostoma macrolepis and their mRNA expressions in response to thermal exposure. **2019**, 230, 16-27	5
272	Recurrent activating mutations of PPAR associated with luminal bladder tumors. **2019**, 10, 253	26
271	Structural Studies with Coactivators for the Estrogen Receptor. **2019**, 71-93	
270	A comprehensive strategy for studying protein-metabolite interactions by metabolomics and native mass spectrometry. **2019**, 194, 63-72	12
269	Structure based docking and molecular dynamics studies: Peroxisome proliferator-activated receptors - dual agonists for treatment of metabolic disorders. **2020**, 38, 511-523	4
268	Bindings of PPAR ligand-binding domain with 5-cholesten-3 25-diol, 3-sulfate: accurate prediction by molecular simulation. **2020**, 38, 1918-1926	2
267	Agonism activities of lyso-phosphatidylcholines (LPC) Ligands binding to peroxisome proliferator-activated receptor gamma (PPAR) **2020**, 38, 398-409	3
266	Involvement of peroxisome proliferator-activated receptor in anticonvulsant activity of asaronol against pentylenetetrazole-induced seizures in zebrafish. **2020**, 162, 107760	12
265	Consumption of Terpenoids-Rich Extract Attenuates Hyperglycemia, Insulin Resistance and Oxidative Stress, and Upregulates PPAR in a Rat Model of Type 2 Diabetes. **2019**, 9,	12
264	Anti-diabetic drugs recent approaches and advancements. **2020**, 28, 115263	48
263	In search for potential antidiabetic compounds from natural sources: docking, synthesis and biological screening of small molecules from . (Goji). **2020**, 6, e02782	4

262	GQ-130, a novel analogue of thiazolidinedione, improves obesity-induced metabolic alterations in rats: Evidence for the involvement of PPAR pathway. **2020**, 47, 798-808	1
261	A FABP4-PPAR signaling axis regulates human monocyte responses to electrophilic fatty acid nitroalkenes. **2020**, 29, 101376	17
260	Novel linked butanolide dimer compounds increase adiponectin production during adipogenesis in human mesenchymal stem cells through peroxisome proliferator-activated receptor modulation. **2020**, 187, 111969	2
259	Strategies for developing pregnane X receptor antagonists: Implications from metabolism to cancer. **2020**, 40, 1061-1083	14
258	Computational investigation reveals Picrasidine C as selective PPAR lead: binding pattern, selectivity mechanism and ADME/tox profile. **2020**, 38, 5401-5418	5
257	Molecular determinants of MED1 interaction with the DNA bound VDR-RXR heterodimer. **2020**, 48, 11199-11213	13
256	The molecular mechanism involved in cardioprotection by the dietary flavonoid fisetin as an agonist of PPAR- in a murine model of myocardial infarction. **2020**, 694, 108572	9
255	PPAR Cistrome Repression during Activation of Lung Monocyte-Macrophages in Severe COVID-19. **2020**, 23, 101611	17
254	Computational analysis of single nucleotide polymorphisms (SNPs) in PPAR gamma associated with obesity, diabetes and cancer. **2020**, 1-15	6
253	Differential Effects of Cancer-Associated Mutations Enriched in Helix H3 of PPAR **2020**, 12,	2
252	The PPAR Pocket: Renewed Opportunities for Drug Development. **2020**, 2020, 9657380	5
251	Deoxynivalenol Exposure Suppresses Adipogenesis by Inhibiting the Expression of Peroxisome Proliferator-Activated Receptor Gamma 2 (PPAR) in 3T3-L1 Cells. **2020**, 21,	0
250	Photohormones Enable Optical Control of the Peroxisome Proliferator-Activated Receptor (PPAR) **2020**, 63, 10908-10920	16
249	In vitro dual-target activities and in vivo antidiabetic effect of 3-hydroxy-N-(p-hydroxy-phenethyl) phthalimide in high-fat diet and streptozotocin-induced diabetic golden hamsters. **2020**, 29, 2077-2088	1
248	targets gene networks that promote browning of human and mouse adipocytes. **2020**, 319, E667-E677	7
247	Protein-Protein Interaction Disruptors of the YAP/TAZ-TEAD Transcriptional Complex. **2020**, 25,	12
246	PPAR Ligand-Binding Domain Structures with Endogenous Fatty Acids and Fibrates. **2020**, 23, 101727	16
245	PPARs and Microbiota in Skeletal Muscle Health and Wasting. **2020**, 21,	18

244	Transcriptional Control of Circadian Rhythms and Metabolism: A Matter of Time and Space. **2020**, 41,	29
243	Delineation of the molecular determinants of the unique allosteric binding site of the orphan nuclear receptor RORγ. **2020**, 295, 9183-9191	3
242	ENDOCRINE-DISRUPTING CHEMICALS. **2020**, 535-554	0
241	Adipogenic commitment induced by green tea polyphenols remodel adipocytes to a thermogenic phenotype. **2020**, 83, 108429	7
240	Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-gamma. **2020**, 9, 59	1
239	Identification and structural insight of an effective PPARγ modulator with improved therapeutic index for anti-diabetic drug discovery. **2020**, 11, 2260-2268	5
238	Stirring rate affects thermodynamics and unfolding kinetics in isothermal titration calorimetry. **2020**, 168, 53-62	2
237	IDPs and their complexes in GPCR and nuclear receptor signaling. **2020**, 174, 105-155	3
236	A molecular switch regulating transcriptional repression and activation of PPARγ **2020**, 11, 956	19
235	Rumex dentatus L. phenolics ameliorate hyperglycemia by modulating hepatic key enzymes of carbohydrate metabolism, oxidative stress and PPARγ in diabetic rats. **2020**, 138, 111202	11
234	An In Silico Comparative Study of Anti-inflammatory Role of Biochanin A and Genistein with 9 Omega-3-Fatty Acids Using Complex Docking Analysis with PPARγ and GPR120. **2020**, 26, 2587-2602	2
233	Cyclin-Dependent Kinase 5 Inhibitor Butyrolactone I Elicits a Partial Agonist Activity of Peroxisome Proliferator-Activated Receptor γ **2020**, 10,	9
232	Anti-inflammatory effects of an optimized PPAR-γ agonist via NF-κB pathway inhibition. **2020**, 96, 103611	6
231	Synthesis and evaluation of novel peptidomimetics bearing -aminobenzoic acid moiety as potential antidiabetic agents. **2020**, 12, 991-1013	0
230	To Probe Full and Partial Activation of Human Peroxisome Proliferator-Activated Receptors by Pan-Agonist Chiglitazar Using Molecular Dynamics Simulations. **2020**, 2020, 5314187	5
229	Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment. **2020**, 197, 112311	4
228	Insights into PPARγ Phosphorylation and Its Inhibition Mechanism. **2020**, 63, 4811-4823	11
227	The quasi-irreversible inactivation of cytochrome P450 enzymes by paroxetine: a computational approach. **2020**, 18, 3334-3345	8

226	identification of peroxisome proliferator-activated receptor (PPAR) agonists from Ligand Expo Components database. **2021**, 39, 1853-1864	2
225	Characterization of local gut microbiome and intestinal transcriptome responses to rosiglitazone treatment in diabetic db/db mice. **2021**, 133, 110966	3
224	Inhibitory effect of PPAR on NLRP3 inflammasome activation. **2021**, 11, 2424-2441	16
223	Rapid Induction of the Unfolded Protein Response and Apoptosis by Estrogen Mimic TTC-352 for the Treatment of Endocrine-Resistant Breast Cancer. **2021**, 20, 11-25	6
222	PPAR LBD and its ligand specificity reveal a selection of potential partial agonist: Molecular dynamics based T2D drug discovery initiative. **2021**, 45, 953-961	
221	Ligand-Independent Coactivation of Peroxisome Proliferator-Activated Receptor Gamma. **2021**, 519-535	0
220	Pregnane X Receptor: Understanding Its Function and Activity at the Molecular Level. **2021**, 179-198	
219	MSDC-0160 and MSDC-0602 Binding with Human Mitochondrial Pyruvate Carrier (MPC) 1 and 2 Heterodimer. **2021**, 427-455	
218	Design of Novel PPAR Agonist for Neurodegenerative Disease. **2021**, 249-270	
217	PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action. **2021**, 12, 624112	41
216	Tetrazoles as PPAR ligands: A Structural and Computational Investigation.	
215	Characterization of an Agarophyton chilense oleoresin containing PPAR natural ligands with insulin-sensitizing effects in a C57BL/6J mouse model of diet-induced obesity and antioxidant activity in Caenorhabditis elegans.	0
214	Synthesis of a Coumarin-Based PPAR Fluorescence Probe for Competitive Binding Assay. **2021**, 22,	4
213	Nuclear Hormone Receptor Medicinal Chemistry. 1-117	
212	Structural Insights into the Interaction of the Intrinsically Disordered Co-activator TIF2 with Retinoic Acid Receptor Heterodimer (RXR/RAR). **2021**, 433, 166899	6
211	Thiazolidinedione "Magic Bullets" Simultaneously Targeting PPAR and HDACs: Design, Synthesis, and Investigations of their and Antitumor Effects. **2021**, 64, 6949-6971	9
210	Characterization of an Oleoresin Containing PPAR Natural Ligands with Insulin-Sensitizing Effects in a C57Bl/6J Mouse Model of Diet-Induced Obesity and Antioxidant Activity in. **2021**, 13,	2
209	Two Types of PPAR Ligands Identified in the Extract of Artemisia campestris. **2021**, 3, 647-657	

208	Role of Peroxisome Proliferator-Activated Receptor Gamma (PPAR)in Different Disease States: Recent Updates. **2021**, 28, 3193-3215	9
207	Bioactivity profiling of per- and polyfluoroalkyl substances (PFAS) identifies potential toxicity pathways related to molecular structure. **2021**, 457, 152789	17
206	Effect of Compounds from Moringa oleifera Lam. on in Vitro Non-Alcoholic Fatty Liver Disease (NAFLD) Model System. **2021**, 18, e2100243	
205	Targeting KEAP1/Nrf2, AKT, and PPAR-signals as a potential protective mechanism of diosmin against gentamicin-induced nephrotoxicity. **2021**, 275, 119349	4
204	Orphan nuclear receptor 4A1 (NR4A1) and novel ligands. **2021**, 65, 877-886	5
203	N-acylsphingosine amidohydrolase 1 promotes melanoma growth and metastasis by suppressing peroxisome biogenesis-induced ROS production. **2021**, 48, 101217	1
202	Binding of Per- and Polyfluoro-alkyl Substances to Peroxisome Proliferator-Activated Receptor Gamma. **2021**, 6, 15103-15114	1
201	A Mechanistic approach of Peroxisome Proliferator-Activated Receptors and its subtypes on Clinical and preclinical model of Neurodegenerative disorders. **2021**, 3967-3975	3
200	Neuroprotective Effect of Cyclo-(L-Pro-L-Phe) Isolated from the Jellyfish-Derived Fungus. **2021**, 19,	0
199	Benzosuberene-sulfone analogues synthesis from Cedrus deodara oil and their therapeutic evaluation by computational analysis to treat type 2 diabetes. **2021**, 112, 104860	2
198	Tetrazoles as PPARligands: A structural and computational investigation. **2021**, 106, 107932	
197	An Overview of Computer-aided Drug Design Tools and Recent Applications in Designing of Anti-diabetic Agents. **2021**, 22, 1158-1182	2
196	A New Symmetrical Thiazolidinedione Derivative: In Silico Design, Synthesis, and In Vivo Evaluation on a Streptozotocin-Induced Rat Model of Diabetes. **2021**, 9, 1294	2
195	Syntheses, biological evaluation of some novel substituted benzoic acid derivatives bearing hydrazone as linker. 1	1
194	Conformational Characterization of the Co-Activator Binding Site Revealed the Mechanism to Achieve the Bioactive State of FXR. **2021**, 8, 658312	0
193	Identification of an allosteric hotspot for additive activation of PPARin antidiabetic effects. **2021**, 66, 1559-1570	9
192	Helix 12 stabilization contributes to basal transcriptional activity of PXR. **2021**, 297, 100978	2
191	Structural mechanism underlying ligand binding and activation of PPAR**2021**, 29, 940-950.e4	7

190	Crystal Structures of the Human Peroxisome Proliferator-Activated Receptor (PPAR) Ligand-Binding Domain in Complexes with a Series of Phenylpropanoic Acid Derivatives Generated by a Ligand-Exchange Soaking Method. **2021**, 44, 1202-1209	5
189	Repurposing Small Molecules to Target PPAR- as New Therapies for Peripheral Nerve Injuries. **2021**, 11,	1
188	Cyclooxygenase-2 Inhibitor Parecoxib Was Disclosed as a PPAR- Agonist by and Assay. **2021**, 29, 519-526	0
187	Insights into Dynamic Mechanism of Ligand Binding to Peroxisome Proliferator-Activated Receptor oward Potential Pharmacological Applications. **2021**, 44, 1185-1195	3
186	Deciphering the competitive inhibition of dihydropteroate synthase by 8 marcaptoguanine analogs: enhanced potency in phenylsulfonyl fragments. **2021**, 1-20	0
185	Computational identification of potential chemoprophylactic agents according to dynamic behavior of peroxisome proliferator-activated receptor gamma.. **2020**, 11, 147-159	2
184	PPAR and Ligand Design: Honing the Traditional Empirical Method with a More Holistic Overview. **2021**, 111-178	
183	New Drugs for the Treatment of Diabetes Mellitus.	1
182	Insulin and Hypoglycemic Agents. **2003**, 1-33	2
181	Retinoid Receptors RAR and RXR: Structure and Function. 191	1
180	Phytochemical drug candidates for the modulation of peroxisome proliferator-activated receptor in inflammatory bowel diseases. **2020**, 34, 1530-1549	9
179	The Role of Environmental Obesogens in the Obesity Epidemic. **2011**, 383-399	6
178	The Role of PPAR n Stroke. **2014**, 301-320	2
177	Design, Structure, and Function of Novel PPAR Ligands. **2002**, 5-8	1
176	Signal Transduction and Structure of Nuclear Receptors. **2002**, 241-267	1
175	Androgen Receptor Biology in Prostate Cancer. **2010**, 61-70	1
174	Therapeutic role of peroxisome proliferator-activated receptors in obesity, diabetes and inflammation. **2003**, 60, 93-132	20
173	Peroxisome proliferator activated receptor agonists. **2000**, 89, 141-51	57

172	Transcription Factors That Regulate Macrophage Development and Function. **2003**, 11-40	3
171	Corepressors and nuclear hormone receptor function. **2001**, 254, 101-16	65
170	Regulation of SMRT and N-CoR corepressor function. **2001**, 254, 117-36	36
169	Architecture of DNA Bound RAR heterodimers. **2014**, 70, 21-36	6
168	Steroid Hormone Receptor Family: Mechanisms of Action. **2003**, 403-410	1
167	The Nuclear Receptor Superfamily. **2001**, 1-57	5
166	The Vitamin D Receptor. **2005**, 167-191	22
165	Comodulators of Vitamin D Receptor□Mediated Gene Expression. **2005**, 291-304	5
164	Exploring the Potential of ToxCast Data in Supporting Read-Across for Evaluation of Food Chemical Safety. **2021**, 34, 300-312	4
163	Androgen receptor.	1
162	Mass-spectrometric analysis of agonist-induced retinoic acid receptor gamma conformational change. **2002**, 362, 173-81	6
161	Comprehensive analysis of PPAR□agonist activities of stereo-, regio-, and enantio-isomers of hydroxyoctadecadienoic acids. **2020**, 40,	6
160	The structure of the ultraspiracle ligand-binding domain reveals a nuclear receptor locked in an inactive conformation. **2001**, 98, 1549-54	59
159	Pregnane X receptor polymorphism affects CYP3A4 induction via a ligand-dependent interaction with steroid receptor coactivator-1. **2007**, 17, 369-82	17
158	Cooperative Cobinding of Synthetic and Natural Ligands to the Nuclear Receptor PPAR□	1
157	Tributyltin induces a transcriptional response without a brite adipocyte signature in adipocyte models.	1
156	Molecular determinants of nuclear receptor-corepressor interaction. **1999**, 13, 3198-208	403
155	Mechanism of corepressor binding and release from nuclear hormone receptors. **1999**, 13, 3209-16	323

154	The coregulator exchange in transcriptional functions of nuclear receptors. **2000**, 14, 121-141	1060
153	Peroxisome Proliferator-Activated Receptors Features, Functions, and Future. **2015**, 2,	7
152	Structural and Dynamic Elucidation of a Non-acid PPAR Partial Agonist: SR1988. **2018**, 5,	3
151	Physiology and Pathophysiology of PPARs in the Eye. **2018**, 5,	2
150	Oxidized LDL reduces monocyte CCR2 expression through pathways involving peroxisome proliferator-activated receptor gamma. **2000**, 106, 793-802	140
149	What lipodystrophies teach us about the metabolic syndrome. **2019**, 129, 4009-4021	49
148	Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. **2001**, 108, 1667-75	85
147	Oligospermic infertility associated with an androgen receptor mutation that disrupts interdomain and coactivator (TIF2) interactions. **1999**, 103, 1517-25	56
146	Mitogen-activated protein kinase inhibits 1,25-dihydroxyvitamin D3-dependent signal transduction by phosphorylating human retinoid X receptor alpha. **1999**, 103, 1729-35	117
145	Modulating nuclear receptor function: may the phos be with you. **1999**, 103, 1617-8	88
144	Signaling and other functions of lipids in autophagy: a review. **2020**, 19, 214	10
143	Fatty Acids, White Adipose Tissue Development, and Adipocyte Differentiation. **2001**, 63-76	1
142	Correlation of Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) and Retinoid X Receptor-alpha (RXR-alpha) expression with clinical risk factors in patients with advanced carotid atherosclerosis. **2011**, 17, CR381-91	21
141	Recognition and accommodation at the androgen receptor coactivator binding interface. **2004**, 2, E274	176
140	Molecular evolution of ultraspiracle protein (USP/RXR) in insects. **2011**, 6, e23416	19
139	Dietary □eleostearic acid ameliorates experimental inflammatory bowel disease in mice by activating peroxisome proliferator-activated receptor-□**2011**, 6, e24031	32
138	A novel N-terminal domain may dictate the glucose response of Mondo proteins. **2012**, 7, e34803	33
137	GQ-16, a TZD-Derived Partial PPAR□Agonist, Induces the Expression of Thermogenesis-Related Genes in Brown Fat and Visceral White Fat and Decreases Visceral Adiposity in Obese and Hyperglycemic Mice. **2016**, 11, e0154310	18

136	Genetic predictors of obesity development. **2016**, 13, 7-13	9
135	Comparative Design, In Silico Dockingand Predictive ADME/ TOX Properties of Some Novel 2, 4-hydroxy Derivatives of Thiazolidine-2, 4-diones as PPAR Modulator. **2017**, 4, 11-19	2
134	Secondary Metabolites in the Treatment of Diabetes Mellitus: A Paradigm Shift. **2020**, 21, 493-511	3
133	PPAR Potential Therapeutic Target for Ailments Beyond Diabetes and its Natural Agonism. **2019**, 20, 1281-1294	12
132	Structural and Functional Diversity of Estrogen Receptor Ligands. **2015**, 15, 1372-84	44
131	Multi-Target Drugs Against Metabolic Disorders. **2019**, 19, 402-418	6
130	Novel Therapeutic Agents in Pediatric Sepsis: Peroxisome Proliferator Receptor (PPAR) Agonists. **2011**, 4, 120-124	9
129	New Development for Study of Oxidized Lipids Seeking for the Endogenous Ligands for PPAR.GAMMA.. **2005**, 37, 39-44	3
128	Ligand-Induced Allosteric Effects Governing SR Signaling. **2019**, 6,	7
127	Peroxisome proliferator-activated receptor-gamma is essential in the pathogenesis of gastric carcinoma. **2009**, 15, 3874-83	14
126	Clinical Significance of Peroxisome Proliferator-Activated Receptor and TRAP220 in Patients with Operable Colorectal Cancer. **2016**, 48, 198-207	7
125	Modulation of Transcription mediated by the Vitamin D Receptor and the Peroxisome Proliferator-Activated Receptor in the presence of GW0742 analogs. **2014**, 3,	3
124	Binding Model of Amentoflavone to Peroxisome Proliferator-Activated Receptor γ. **2012**, 33, 1475-1479	2
123	PPAR gamma agonist normalizes glomerular filtration rate, tissue levels of homocysteine, and attenuates endothelial-myocyte uncoupling in alloxan induced diabetic mice. **2008**, 4, 236-44	16
122	Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism could be a risk factor for gastric cancer. **2015**, 16, 2333-40	6
121	Cooperative cobinding of synthetic and natural ligands to the nuclear receptor PPAR **2018**, 7,	32
120	The effect of S427F mutation on RXR activity depends on its dimeric partner. **2021**, 12, 14700-14710	1
119	Repurposing Peroxisome Proliferator-Activated Receptor Agonists in Neurological and Psychiatric Disorders. **2021**, 14,	2

118 Recruitment of p160 Coactivators to Androgen Receptors. **2000**, 165-172

117 CREB Binding Protein Coactivator Complexes. **2000**, 395-403

116 The Androgen Receptor, Androgen Insensitivity, and Prostate Cancer. **2000**, 339-372

115 Therapeutic uses of retinoic acid receptor antagonists and inverse agonists. **2000**, 279-290

114 Retinoid Receptors. **2001**, 245-295 1

113 Peroxisome Proliferator-Activated Receptors. **2001**, 363-388

112 Structures and Functions of the Nuclear Receptor Family, PPAR. **2001**, 1, 1049-1056,1046

111 References. **2001**, 164-210

110 Peroxisome Proliferator-Activated Receptors (PPARs).

109 Androgen Receptor Interacting Proteins: Co-Activators And Co-Repressors. **2002**, 91-138

108 Antagonist action. **2002**, 64-68

107 Deregulation in disease and novel therapeutic targets. **2002**, 75-77

106 SERM Modulation of Gene Expression. **2002**, 57-76

105 Sensors for Metabolic Control. **2002**, 283-304

104 Chemical genomics of orphan nuclear receptors. **2003**, 29-42 4

103 The P160 Family of Steroid Hormone Receptor Coactivators. **2003**, 133-147 1

102 The Role of Nuclear Receptors in HDL Formation. **2003**, 83-95

101 Nuclear Receptor Coactivators. **2003**, 25-28

100	X-Ray Crystallography in Drug Discovery. **2003**, 611-632	
99	Structural Mechanisms of Ligand-Mediated Signaling by Nuclear Receptors. **2003**, 21-24	
98	Retinoids. **2003**, 316-348	
97	Role of the Adipocyte in Type 2 Diabetes.	
96	Molecular Recognition of Nuclear Hormone Receptor-Ligand Complexes. 1	
95	The Search for Potent Alpha-Lipoic Acid Derivatives. **2008**,	
94	Nuclear Receptors, Chemistry of. 1	
93	Steroid Hormones. 1	
92	The influence of dietary feeding type and acute exercise on gene expression of PPAR isoforms in skeletal muscle. **2008**, 17, 401-412	
91	Nuclear Receptor Coactivators. **2010**, 1999-2004	
90	Corepressors in Mediating Repression by Nuclear Receptors. **2010**, 2005-2014	
89	Nuclear Receptor-Mediated Gene Regulation in Drug Metabolism. 1	
88	Mechanism of Action of Hormones That Act on Nuclear Receptors. **2011**, 51-61	
87	[5-(3-Indol-1-ylpropoxy)-1H-indol-3-yl] Acetic Acid Enhances Adipocyte Differentiation and Glucose Uptake in 3T3-L1 Cells. **2011**, 7, 647-652	2
86	2-({1-[2-(Methyl-sulfan-yl)phen-yl]-1H-tetra-zol-5-yl}sulfan-yl)acetic acid. **2013**, 69, o759	1
85	The Role of Cyclooxygenases and Lipoxygenases in the Regulation of Tumor Angiogenesis. **2013**, 239-296	
84	4-{5-[(2-Bromo-benz-yl)sulfan-yl]-1H-tetra-zol-1-yl}benzoic acid. **2013**, 69, o1083-4	
83	The Liver in Metabolic Syndrome. **2014**, 27-61	0

82	Assembly and Regulation of Nuclear Receptor Corepressor Complexes. **2015**, 155-175	
81	Computational docking reveals evolutionary conservation of a specific interaction between 15d-Prostaglandin-J2 and eIF4A.	
80	A structural mechanism for directing inverse agonism of PPAR	1
79	Insights into the PPARR Phosphorylation and Its Inhibition Through Direct and Allosteric Mechanisms.	
78	Structural basis of altered potency and efficacy displayed by a major in vivo metabolite of the anti-diabetic PPAR drug pioglitazone.	
77	Quantitative Structural Assessment of Graded Receptor Agonism.	
76	Molecular determinants of MED1 interaction with the DNA bound VDR-RXR heterodimer.	0
75	Lipids in the transcriptional regulation of adipocyte differentiation and metabolism. **2020**, 81-98	
74	Targeting inflammation and redox aberrations by perindopril attenuates methotrexate-induced intestinal injury in rats: Role of TLR4/NF-B and c-Fos/c-Jun pro-inflammatory pathways and PPAR-/SIRT1 cytoprotective signals. **2021**, 351, 109732	2
73	Genetic exploration of a nuclear receptor transcriptional regulatory complex.	
72	Actions of Nuclear Receptors. **2006**, 273-292	
71	Rgulation de expression gique par les macronutriments. **2007**, 259-277	
70	Structural insights into the cooperative interaction of the intrinsically disordered co-activator TIF2 with retinoic acid receptor heterodimer (RXR/RAR).	
69	Structural Mechanism Underlying Ligand Binding and Activation of PPAR	1
68	A two-stage differential hydrogen deuterium exchange method for the rapid characterization of protein/ligand interactions. **2007**, 18, 194-204	43
67	The possible role of peroxisome proliferator-activated receptor gamma in heart failure. **2004**, 9, 169-73	2
66	Cystathionine beta synthase gene dose dependent vascular remodeling in murine model of hyperhomocysteinemia. **2011**, 3, 210-22	16
65	Nuclear receptor coactivator SRC-1 interacts with the Q-rich subdomain of the AhR and modulates its transactivation potential. **1999**, 8, 273-86	80

64	Galangin 3-benzyl-5-methylether derivatives function as an adiponectin synthesis-promoting peroxisome proliferator-activated receptor partial agonist.. **2021**, 54, 116564	2
63	Thiamine Is a Natural Peroxisome Proliferator Activated Receptor Gamma (PPAR- Activator. **2022**, 19,	
62	Cooperativity as quantification and optimization paradigm for nuclear receptor modulators.. **2022**, 13, 2744-2752	0
61	Type II diabetes mellitus and obesity: Common links, existing therapeutics and future developments. **2019**, 44,	5
60	Discovery by Virtual Screening of an Inhibitor of CDK5-Mediated PPAR Phosphorylation.. **2022**, 13, 681-686	1
59	Analyzing the Androgen Receptor Interactome in Prostate Cancer: Implications for Therapeutic Intervention.. **2022**, 11,	1
58	A New Fungal Triterpene from the Fungus Stimulates Glucose Uptake without Fat Accumulation.. **2022**, 20,	
57	Agonistic and potentiating effects of perfluoroalkyl substances (PFAS) on the Atlantic cod (Gadus morhua) peroxisome proliferator-activated receptors (Ppars).. **2022**, 163, 107203	0
56	Syzygium samarangense leaf extract exhibits distinct antidiabetic activities: Evidences from in silico and in vivo studies. **2022**, 15, 103822	1
55	Nuclear receptors in oral cancer-emerging players in tumorigenesis.. **2022**, 215666	2
54	Hepatoprotective effect of acetovanillone against methotrexate hepatotoxicity: Role of Keap-1/Nrf2/ARE, IL6/STAT-3, and NF- B/AP-1 signaling pathways.. **2021**,	0
53	Peroxisome proliferator-activated receptor- expression is associated with histological type in human gastric carcinoma.. **2022**, 16, 51	0
52	Structural overview and perspectives of the nuclear receptors, a major family as the direct targets for small-molecule drugs.. **2022**, 54, 1-13	0
51	Presentation_1.PDF. **2018**,	
50	Ethyl Gallate Dual-Targeting PTPN6 and PPAR Shows Anti-Diabetic and Anti-Obese Effects.. **2022**, 23,	0
49	Nuclear Receptor Coregulators in Hormone-Dependent Cancers. **2022**, 14, 2402	0
48	Peroxisome proliferator-activated receptor-gamma (PPAR and its immunomodulation function: current understanding and future therapeutic implications.. **2022**, 1-9	0
47	2,2',4,4'-Tetrabromodiphenyl Ether (PBDE 47) Selectively Stimulates Proatherogenic PPAR Signatures in Human THP-1 Macrophages to Contribute to Foam Cell Formation.. **2022**,	

46	A Narrative Review on Axonal Neuroprotection in Multiple Sclerosis.	0
45	How to tame your genes: mechanisms of inflammatory gene repression by glucocorticoids.	0
44	Targeting Nuclear Receptors in Lung Cancer: Novel Therapeutic Prospects. **2022**, 15, 624	1
43	Rational design, molecular docking, dynamic simulation, synthesis, PPAR-γ competitive binding and transcription analysis of novel glitazones. **2022**, 1265, 133354	0
42	Indazole MRL-871 interacts with PPARγ via a binding mode that induces partial agonism. **2022**, 68, 116877	
41	Vitamin D Resistance Genes- Promising Therapeutic Targets of chronic diseases.	0
40	Vitamin D and Its Receptor from a Structural Perspective. **2022**, 14, 2847	3
39	Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.	1
38	Peroxisome proliferator-activated receptor δ and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias. **2004**, 3, 1249-1262	25
37	Retinoid X receptor-α and peroxisome proliferator-activated receptor-γ expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. **2004**, 3, 1011-1020	10
36	AR Structural Variants and Prostate Cancer. **2022**, 195-211	1
35	Microsecond MD Simulations to Explore the Structural and Energetic Differences between the Human RXRα-PPARγ vs. RXRα-PPARβ DNA. **2022**, 27, 5778	0
34	Retinoic acid receptor structures: the journey from single domains to the full-length complex. **2022**,	0
33	Machine Learning and Computational Chemistry for the Endocannabinoid System. **2023**, 477-493	0
32	Biochemical and structural basis for the pharmacological inhibition of nuclear hormone receptor PPARβ by inverse agonists. **2022**, 102539	0
31	Structure-based screening and biological validation of the anti-thrombotic drug-dicoumarol as a novel and potent PPARγ modulating ligand. **2022**, 106191	0
30	A novel nuclear receptor subfamily enlightens the origin of heterodimerization. **2022**, 20,	2
29	Identification of Selective PPAR-γ Modulators by Combining Pharmacophore Modeling, Molecular Docking, and Adipogenesis Assay.	0

28	Molecular Modeling of Allosteric Site of Isoform-Specific Inhibition of the Peroxisome Proliferator-Activated Receptor PPAR **2022**, 12, 1614	1
27	Discovery of PPAR and glucocorticoid receptor dual agonists to promote the adiponectin and leptin biosynthesis in human bone marrow mesenchymal stem cells. **2023**, 245, 114927	0
26	Methylene Thiazolidinediones as Alkylation Reagents in Catalytic CH Functionalization: Rapid Access to Glitazones.	0
25	Cryo-EM reveals the architecture of the PELP1-WDR18 molecular scaffold. **2022**, 13,	1
24	Is the peroxisome proliferator-activated receptor gamma a putative target for epilepsy treatment? Current evidence and future perspectives. **2023**, 241, 108316	1
23	Molecular dynamics articulated multilevel virtual screening protocol to discover novel dual PPAR Agonists for anti-diabetic and metabolic applications.	0
22	Genome-wide identification and expression of the peroxisome proliferator-activated receptor gene family in the Tibetan highland fish Gymnocypris przewalskii. **2022**, 48, 1685-1699	0
21	Acetylation of nuclear receptors in health and disease: an update.	0
20	A Screening System for the Identification of Fragment Molecules toward the Creation of Nuclear Receptor Ligands. **2022**, 142, 1345-1351	0
19	DeepCubist: Molecular Generator for Designing Peptidomimetics based on Complex three-dimensional scaffolds.	0
18	Toward High-throughput Crystal Structure Determination of PPAR Ligand-binding Domains in Complexes with Less Soluble Ligands. **2022**, 142, 1353-1360	1
17	Valerenic Acid Promotes Adipocyte Differentiation, Adiponectin Production, and Glucose Uptake via Its PPAR Ligand Activity. **2022**, 7, 48113-48120	1
16	Atractylodin Ameliorates Colitis via PPAR Agonism. **2023**, 24, 802	0
15	The Role of PPARs in Breast Cancer. **2023**, 12, 130	1
14	Citrus nutraceutical eriocitrin and its metabolites are partial agonists of peroxisome proliferator-activated receptor gamma (PPAR) a molecular docking and molecular dynamics study. 1-21	0
13	A structural perspective of liver X receptors. **2023**,	0
12	Klotho, Oxidative Stress, and Mitochondrial Damage in Kidney Disease. **2023**, 12, 239	0
11	Computational studies, synthesis, in-vitro binding and transcription analysis of novel imidazolidine-2,4-dione and 2-thioxo thiazolidine-4-one based glitazones for central PPAR- agonism. **2023**, 1285, 135503	0

10	Research progress of PPARregulation of cholesterol and inflammation in Alzheimer's disease. **2023**, 38, 839-854	0
9	Structural Biology Inspired Development of a Series of Human Peroxisome Proliferator-Activated Receptor Gamma (PPAR)Ligands: From Agonist to Antagonist. **2023**, 24, 3940	0
8	The role of peroxisome proliferator-activated receptors in the modulation of hyperinflammation induced by SARS-CoV-2 infection: A perspective for COVID-19 therapy. 14,	0
7	Structural basis of the activation of PPARby the plasticizer metabolites MEHP and MINCH. **2023**, 173, 107822	0
6	Peroxisome Proliferator-Activated Receptor-Targeted Therapies: Challenges upon Infectious Diseases. **2023**, 12, 650	0
5	Appraisal of the Possible Role of PPARUpregulation by CLA of Probiotic Pediococcus pentosaceus GS4 in Colon Cancer Mitigation. **2023**, 2023, 1-15	0
4	Discovery of FXR/PPARdual partial agonist. **2023**, 85, 117238	0
3	Microfibrillar-associated protein 5 suppresses adipogenesis by inhibiting essential coactivator of PPAR**2023**, 13,	0
2	Biological Screening and Crystallographic Studies of Hydroxy Lactone Derivatives to Investigate PPARPhosphorylation Inhibition. **2023**, 13, 694	0
1	Want of Wnt in Parkinson disease: Could sFRP disrupt interplay between Nurr1 and Wnt signaling?. **2023**, 115566	0